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SUMMARY 
The enzymatic production of beta-lactam antibiotics can be simplified by integrating the 
synthesis and separation of the antibiotic within a single vessel. In situ crystallization 
during the synthesis of beta-lactam antibiotics improves yields by protecting the antibiotic, 
an intermediate in the enzyme catalyzed reaction pathway, from degradation by the 
enzyme. The design of a continuous synthesis, crystallization, and isolation (CSCI) process 
follows naturally because the reaction and crystallization kinetics are already coupled in 
the batch process. Rather than individually design and size several unit operations for use 
in series, a single unit that performs several operations at once was developed. The benefits 
of continuous reactive crystallization include simplified process control, improved 
environmental sustainability, and increased process performance. Enzyme catalysis 
decreases process mass intensity and increases reaction selectivity compared to chemical 
routes to beta-lactams. Use of process analytical technology (PAT) enables real time 
monitoring of critical process parameters (CPPs) to ensure production of pharmaceutical 
quality material. The kinetics of the enzyme reactions and antibiotic crystallization were 
determined in batch for ampicillin and cephalexin. A model of reactive crystallization was 
built and used to determine the optimal process configuration for continuous production of 
amoxicillin and cephalexin. Finally, implementation of the continuous process in the lab 
was begun. This process will enable more sustainable production of beta-lactam antibiotics 
with potential for on-demand production, especially important in light of recent drug 
shortages due to the 2020 SARS-CoV-2 pandemic. 
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CHAPTER 1. INTRODUCTION 
Amoxicillin ranks as the most prevalent antibiotic, with cephalexin not far behind. 
Amoxicillin alone has a market of 4.4B USD and is the most prescribed antimicrobial in 
60 out of 65 countries for which recent World Health Organization data are available.1 
Demand for beta-lactam medicines such as amoxicillin and cephalexin is also increasing 
rapidly, particularly in lower and middle income countries where demand has more than 
doubled since the year 2000.2 Supply of these drugs is incredibly geographically 
concentrated; at the outset of the COVID-19 pandemic in February 2020, when China 
halted manufacturing, immediate worldwide shortages of amoxicillin and cephalexin 
followed.3 A scalable, lower-cost, on-demand manufacturing platform for these two 
antibiotics would directly address issues of increased demand and supply chain fragility. 
Ideally, such a platform would leverage recent technologies and design principles to 
minimize cost, environmental impact, contamination, waste, and more. 
Enter Continuous Synthesis, Crystallization, and Isolation (CSCI) of beta-lactam 
antibiotics. The CSCI process developed in this thesis combines the agility of continuous 
manufacturing with the sustainability of biocatalytic antibiotic synthesis by a reactive 
crystallization mechanism. Continuous manufacturing (CM) can increase efficiency, 
improve product quality, decrease costs, and shrink environmental footprints associated 
with pharmaceutical manufacturing.4 Biocatalytic synthesis of beta-lactams is transitioning 
production of amoxicillin and cephalexin away from traditional chemical routes in favor 
of a greener alternative; however, the transition is not complete and legacy plants continue 
to produce large amounts of waste alongside antibiotics. Reactive crystallization couples 
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the driving force for product separation to that for product synthesis, improving efficiency 
and overcoming some limitations of the biocatalytic routes to amoxicillin and cephalexin.5  
Furthermore, beta-lactam antibiotics are potent allergens, requiring strict 
containment for safe manufacturing. One study found that up to 0.5% of those exposed to 
penicillins became anaphylactic, requiring hospitalization to treat the severe allergic 
reaction.6 The FDA requires that penicillins, like amoxicillin, be produced in standalone 
facilities and recommends that similar precautions be taken for cephalosporins, like 
cephalexin.7, 8 Continuous manufacturing inherently reduces the risk of contamination as 
it avoids shared equipment and charging/discharging of batch vessels. Reactive 
crystallization further reduces this risk by combining two operations in one vessel. End-to-
end CM has already been demonstrated as a containment strategy at the pilot plant scale in 
the production of highly potent anti-cancer drugs and could benefit beta-lactam 
manufacturing as well.9-11  
The remainder of the introduction will detail continuous manufacturing, synthesis of 
beta-lactams by the enzyme penicillin G acylase, and reactive crystallization of selected 
beta-lactams. 
1.1 Continuous manufacturing 
Presently, most pharmaceutical production relies on large batches being stockpiled 
and slowly dispensed, but this method cannot meet real-time demand; e.g. in response to a 
disease outbreak or supply disruption. Continuous manufacturing constantly feeds 
precursors to a unit operation and the unit constantly outputs products. End-to-end CM 
involves stringing multiple CM unit operations together, such that the products of one unit 
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operation serve as the precursors for the next one, with minimal holdup in between.12 
Continuous manufacturing is strongly encouraged by the US Food and Drug 
Administration for the reasons enumerated in the following paragraphs.13 
Supply flexibility is built into CM. If the process is designed to be run without 
interruption, production can be scaled up or down by increasing or decreasing the 
throughput of the process.14 If startup and shutdown are not complex, a simpler way to 
adjust production according to demand is to change the length of time the process operates, 
all while operating at an optimized throughput. Batch manufacturing requires periods of 
storage interspersed between batches. Responding to a change in demand may require 
larger equipment or challenging recycling of supplies. Flexibility of supply makes 
continuous manufacturing especially attractive for markets with inconsistent demand, such 
as low to middle income countries. 
A validated continuous process is more amenable to automated quality control.15, 16 
Online monitoring, by process analytical technology (PAT), is simpler for CM than for 
batch as the process is ideally operated in a well-controlled state, often at a steady state. 
PAT only needs to confirm that the process is at the expected state, rather than check that 
the batch is following the expected trajectory.17 When it comes to process control, a 
stability analysis of the CM steady state can determine whether a perturbation, detected 
with PAT, will derail the process. In process control for batch manufacturing, it is 
necessary to know how a perturbation will propagate during the batch time course, a far 
more complicated analysis than a steady state stability analysis, to make meaningful 
corrections. Automated PAT reduces the likelihood of human errors. Finally, batches are 
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typically tested at the end of the batch, and should it fail to meet specifications the batch 
may be lost.13  
Continuous manufacturing has the added bonus of improved tracking and tracing. As 
the entire process is monitored online, as soon as a quality defect is detected, the production 
line can be diverted, and the material possibly reprocessed, until the process returns to the 
quality steady state. In a batch process, a representative sample must be tested after each 
batch, and should it fail to meet quality specifications the entire batch is discarded, resulting 
in the loss of a much greater quantity of material. Additionally, in some discrete continuous 
processes, such as tableting, each and every tablet is tested by the online PAT, providing 
more robust quality than taking representative samples from a batch of material.18, 19 
1.2 Enzymatic beta-lactam synthesis 
Synthesis of semisynthetic beta-lactams, such as amoxicillin and cephalexin, is 
typically catalyzed by the enzyme penicillin G acylase (PGA). A key obstacle to more 
efficient beta-lactam production is poor selectivity, as enzyme-catalyzed synthesis 
competes with enzyme-catalyzed primary and secondary hydrolysis (see Figure 1.1).20 
Amoxicillin is produced from the condensation of 6-aminopenicillanic acid (6-APA) with 
4-hydroxy phenylglycine methyl ester (HPGME) and cephalexin is produced by the 
condensation of 7-aminodesacetoxycephalosporanic acid (7-ADCA) with phenylglycine 
methyl ester (PGME).21 While amoxicillin and cephalexin are the targets of the continuous 
manufacturing campaign, much of the work in this thesis is focused on ampicillin, 
produced by the condensation of 6-APA with PGME. Ampicillin is a particularly good 
model compound for a new process because phenylglycine, the byproduct of ampicillin 
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and PGME hydrolysis, is only sparingly soluble, rendering selectivity a greater challenge 
than with some other beta-lactams including cephalexin. The insolubility of phenylglycine 
elevates the problem of selectivity since excessive byproduct formation results in 
contaminated solid product. Solid product purity is a strict constraint throughout this thesis. 
The byproducts from amoxicillin hydrolysis, 4-hydroxy phenylglycine, is much more 
soluble, so lower selectivity interferes less with product purity. 22, 23  The phenylglycine 




Figure 1.1. Overview of PGA catalyzed reactions and reactive crystallization. Top: synthesis reaction 
and crystallization of amoxicillin (horizontal arrows) with enzyme catalyzed primary and secondary 
hydrolysis reactions (vertical arrows). Bottom: synthesis and hydrolysis of cephalexin and reactant 
PGME with subsequent crystallization of cephalexin and phenylglycine 
The first industrial use of PGA was to catalyze the hydrolysis of penicillin G, 
produced by fermentation, into phenylacetic acid and 6-APA, with 6-APA being the 
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starting point for other beta-lactams. PGA is found in the genome of over 40 
microorganisms; recombinant E. coli PGA has always dominated production.24 Early 
engineering of the enzyme focused on stability for reuse in 6-APA production. Being a 
heterodimeric enzyme, one focus was to covalently link the monomers to prevent 
dissociation and loss of activity,25, 26 or to mutate PGA to be produced as a monomer.27 
Immobilization has also been the subject of many studies, as it can covalently link the two 
monomers and improve reusability; Kallenberg et al. give a thorough review of PGA 
immobilization.28 Other means of increasing stability include genome analysis of 
thermophiles,29 use of ionic liquids,30 and PEGylation.31 
It was soon realized that PGA could catalyze the reverse reaction, but with a synthetic 
side chain rather than phenylacetic acid. Use of an activated side chain, such as the ester or 
amide of phenylglycine, enables approximately 50% yield of the semi-synthetic beta-
lactam ampicillin, compared to nearly 100% yield for the less sustainable chemical route.32, 
33 Many researchers have developed methods to push the reaction towards synthesis and 
away from hydrolysis, such as using supersaturated 6-APA or 7-ADCA concentrations,34 
mutant PGA variants,35 and fed-batch reactors.36 Since the antibiotic is ultimately an 
intermediate in the enzyme-catalyzed reaction pathway, several different strategies have 
been used to isolate the antibiotic in situ and prevent subsequent hydrolysis, such as 
aqueous two phase extraction,37 nanofiltration,38 and complexation.39 In this thesis a highly 
engineered PGA variant of unknown amino acid sequence, produced by DSM-Sinochem, 
Assemblase®, is used alongside reactive crystallization to isolate the antibiotic in situ.  
1.3 Reactive crystallization of amoxicillin and cephalexin 
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Reactive crystallization, where a desired compound is driven to supersaturation by a 
chemical reaction, often enhances a reaction by pulling the equilibrium towards the 
products or isolating an intermediate from further reaction. Beta-lactams fall into the latter 
category. In the case of ampicillin, the equilibrium of secondary hydrolysis favors 6-APA 
and D-phenylglycine over ampicillin by about 100-fold while the equilibrium of the 
synthesis reaction was not determinable because no ampicillin was detected at 
equilibrium.40 Work performed in this lab prior to this thesis has shown that simultaneous 
synthesis and crystallization of pure ampicillin is possible and feasible.41 This thesis has 
shown that the principles used for the reactive crystallization of ampicillin are also feasible 
for amoxicillin and cephalexin, with similar expected performance improvements. 
Like all crystallization, reactive crystallization is governed by the concurrent 
phenomena of nucleation and growth.5 Nucleation is the appearance of new crystals while 
growth is the enlargement of existing crystals. Both phenomena are driven by 
supersaturation, which has many practical definitions that are all derived from the ratio of 
the chemical potential of the solute to its chemical potential at equilibrium.42, 43 Equilibrium 
is determined from the solute solubility, which may be a function of temperature, pH, 
solvent composition, and co-solute concentration.44 One of the author’s major undertakings 
during the course of this thesis was the preparation of a comprehensive review of reactive 
crystallization, with coauthors including three members of the doctoral advisory 
committee, and it is the best resource for more information on reactive.5 Relevant details 
of the beta-lactams studied, such as solubility and shape, follow, with specifics on kinetics, 
nucleation, growth, purity, and modeling in CHAPTER 4, CHAPTER 5, and CHAPTER 
6. 
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The solubility of the antibiotics studied increases from amoxicillin to ampicillin to 
cephalexin. The solubility of each is also highly dependent on the pH value of the 
solution.45 As PGA has a narrow range of operating temperatures the solubility of these 
antibiotics as a function of temperature was not studied. It was also observed that the 
solubility of these antibiotics may be affected by the presence of the reactants used in their 
synthesis. The solubility of the key byproduct of cephalexin (and ampicillin) synthesis is 
similar to that of cephalexin, creating the risk of a contaminated solid phase. 
Both amoxicillin and cephalexin crystallize as needles, creating several challenges. 
First, needles can be difficult to handle, they do not filter quickly nor flow easily, making 
transfer of materials, even suspended in a slurry, a potential failure point.46, 47 Second, 
crystallization of needle-shaped particles can be difficult to monitor; common PAT often 
fail to capture a meaningful representation of the crystal size distribution because even low 
suspension density slurries can be quite dense optically.48, 49 Third, modeling crystallization 
of needle-shaped particles can be difficult because phenomena such as breakage and 
agglomeration are more common than for prismatic crystals.50-53 Adding controls to 
optimize particle size and shape during the process can be especially challenging as most 
crystallization control schemes have been developed around cooling crystallization and 
anti-solvent crystallization, not reactive crystallization, where several degrees of freedom 
may be lost in maintaining suitable reaction conditions.14, 54-56  
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All of the nuances of beta-lactam antibiotics, continuous manufacturing, biocatalysis, 
and crystallization create a unique set of challenges and opportunities, to be explored in 
detail in the forthcoming chapters and future work beyond these pages. 
 
Figure 1.2. Graphical abstract depicting the results from each chapter as they build towards the CM 
process for beta-lactams, center. 
  
 10 
CHAPTER 2. STABILITY OF PENICILLIN G ACYLASE1 
2.1 Introduction and motivation 
The most important prerequisite for implementing a continuous manufacturing 
process is stability. If the catalyst to be used deactivates in less than a single residence time, 
such as in catalytic cracking during petroleum refining, much effort must be expended 
engineering a regeneration mechanism. If on the other hand the catalyst retains its activity 
for thousands of residence times the process may be run without regard to catalyst 
deactivation. Additionally, as process controllers may manipulate reactor or crystallizer 
temperature as a means of reaching the set point faster, the effect of temperature excursions 
on the catalyst should be known to limit unintentional deactivation. Like many chemical 
processes, the rate of an enzyme-catalyzed reaction typically increases with temperature; 
however, enzymes are less stable than non-biologic catalysts, permanently deactivating 
with mild temperature (T > 60 °C) and prolonged use. If deactivation of the enzyme is 
understood, a process can be designed that minimizes deactivation, rendering continuous 
operation feasible.26, 30, 31, 57, 58 
In this chapter, the deactivation of PGA is examined. Deactivation of PGA is 
probed by non-isothermal continuous activity measurement with a novel temperature 
profile, developed during the course of this thesis, as well as a conventional discrete 
residual activity assay.59 The two activity measurement methods are compared and the 
 
1 Adapted from “Chemical Engineering Science, 187, McDonald, M.A.; Bromig, L.; Grover, M.A.; 
Rousseau, R.W.; Bommarius, A.S. Kinetic model discrimination of penicillin G acylase thermal deactivation 
by non-isothermal continuous activity assay, 79-86.” Copyright (2018), with permission from Elsevier. 
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ability of the non-isothermal assay to more effectively discriminate between models of 
deactivation is demonstrated. The free energy of deactivation (ΔGdeact = 98.70 ± 0.05 
kJ/mol) and the heat of reversible unfolding (ΔH1 = 236.1 ± 0.9 kJ/mol) of PGA are 
reported for the first time. The Akaike information criterion (AIC) is used to discriminate 
between proposed models fit to the non-isothermal assay. 
2.2 Materials and methods 
A new assay for model discrimination is presented. The activity of an enzyme 
confined in an enzyme membrane reactor (EMR) is continuously and indirectly measured 
as reaction conversion. The temperature of the EMR is varied, affecting both activity and 
enzyme deactivation rate. Different models can be fit to the activity measurements during 
the temperature scan to determine the kinetics and thermodynamics of enzyme 
deactivation.  Typical experiments used to probe enzyme deactivation were used to validate 
the new assay.  Experiments included residual activity assays (measuring the activity after 
incubating the enzyme at a set temperature for a set time) and reaction temperature 
dependence experiments (measuring the instantaneous reaction rate at elevated 
temperature before the enzyme has a chance to unfold).60, 61 
2.2.1 Chemicals 
 Ampicillin sodium salt was purchased from Fischer Scientific (Fair Lawn, NJ).  6-
APA and D-phenylglycine were purchased from Alfa Aesar (Heysham, UK) and were used 
to construct polarimetry standard conversion curves. Optical rotation varies linearly with 
concentration and is additive between species. Specific optical rotations are summarized 
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in Table 2.1.  Assemblase®, a highly engineered variant of PGA, was obtained from DSM-
Sinochem (Delft, Netherlands). 
2.2.2 Enzyme Membrane Reactor 
The reactor from EDS Maschinenbau GmbH (Linnich, Germany) consists of a 
jacketed stainless-steel vessel with a PTFE stir bar, a 10-kDa polyethersulfone membrane 
from EMD Millipore, and a working volume of 10.0 mL. The temperature of the reactor is 
controlled with a PolyTemp programmable water bath and measured with a thermocouple 
incorporated into the reactor body. Good mixing is maintained by constant stirring at 150 





=  ranging from 1.1×104 to 2.2×104 
over the temperature range of interest (N is the number of rotations per second, D is the 
impeller diameter, ρ is the solution density, and μ is the solution viscosity). A Reynolds 
number above 1×104 implies turbulent flow and good mixing. The reactor feed consisted 
of 20 mmol/L ampicillin in 50 mmol/L sodium phosphate buffer at pH 7.0 stored at 5 °C. 
The ampicillin solution was fed to the reactor at a constant volumetric flow rate by an 
ISMATEC IPC (Munich, Germany) peristaltic pump. The flow rate was 1.0 mL/min for 
all experiments, giving a residence time of 10.0 minutes. The enzyme was added last at a 
concentration of 0.5 μmol/L. Once the reactor reached steady state at 20.0 ± 0.1 °C, the 
temperature manipulation was begun. A schematic of the setup is shown in Figure 2.1. 
 13 
 
Figure 2.1.  Schematic of experimental setup.  The reactor volume is the region to which the enzyme 
is confined by the ultrafiltration membrane.  Mixing is maintained by a PTFE coated magnetic stir-
bar and reactor temperature is manipulated by water bath 1 and monitored via an online 
thermocouple. 
2.2.3 Non-isothermal continuous activity assay 
 The concentration of ampicillin (and 6-APA and phenylglycine) was determined 
via polarimetry. The optical rotation was measured with a Rudolph Autopol IV polarimeter 
(Hackettstown, NJ, USA). The optical rotation, along with the measured reactor 
temperature, was exported in real time to a PC approximately once per second. The 
polarimeter flow cell has a volume of 1 mL and an optical path length of 100 mm and was 
maintained at 20.0 °C. All three species have distinct specific optical rotations (θcomponent, 
[degrees/mol/L]), rendering the concentration of ampicillin a function of observed optical 
rotation (Θobs, [degrees]) as well as feed ampicillin concentration (CA0) and reaction 
stoichiometry. Stoichiometry is indicated in equation 2.5 where the subscripts A, B, and C 
refer to ampicillin, 6-APA, and D-phenylglycine, respectively.32 The observed rotation was 
converted to concentration by equation 2.1. θcomponent values are summarized in Table 2.1. 
 










  (2.1) 
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Table 2.1. Specific optical rotation of key species.  Measured in 250 mM pH 7 sodium phosphate 
buffer at 20 °C.  Measured at a wavelength of 589 nm along a path length of 10 cm.  Under 20 mM 
the concentration dependence is linear.    
Species Ampicillin 6-APA D-phenylglycine 
Measured specific optical rotation (°/mol/L) 96.9 61.6 -13.9 
 
2.2.4 Residual activity experiments 
 Residual activity experiments were performed by incubating 1.0 mL of 5.0 μmol/L 
PGA in 50 mmol/L sodium phosphate buffered at pH 7.0 at a constant elevated temperature 
for a fixed amount of time.  The PGA solution was then added to 4.0 mL of 25.0 mmol/L 
ampicillin in 50 mmol/L sodium phosphate buffered at pH 7.0, giving a final concentration 
of 1.0 μmol/L PGA and 20.0 mmol/L ampicillin.  The solution was prepared in a single-
sample polarimeter cell maintained at 20 °C. The optical rotation was measured for 3 
minutes, during which the rotation decreased linearly.  The residual activity was calculated 
as the rate of change in optical rotation divided by the rate of change in optical rotation for 
a sample that had not been incubated at elevated temperature.  By this method, the time-
temperature space was discretized, and individual measurements were taken in triplicate at 
each point. 
2.2.5 Reaction temperature dependence  
 Concentrations of reactants and products were measured as a function of 
temperature by polarimetry. The single-sample cell, loaded with 5.0 mL of 20.0 mmol/L 
ampicillin solution in 50 mmol/L sodium phosphate buffered at pH 7.0, was allowed to 
equilibrate at the desired temperature. Once at the desired temperature, 25.0 μL of 200 
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μmol/L PGA solution was added, giving a final PGA concentration of 1.0 μmol/L. The rate 
was measured in the same manner as for the residual activity experiments.   
2.3 Theory 
 Enzymes deactivate after long times or at (moderately) high temperatures or both.  
Typical stability assays require two sets of experiments, one examining time dependence 
and another probing temperature dependence. Manipulating EMR temperature (T) as a 
function of time (t) allows enzyme deactivation to be described as a function of only one 
variable (time or temperature).   
   (2.2) 
A simple model for the EMR is a well-stirred constant volume reactor, for which 
the non-steady-state concentration can be described by the equation   
   (2.3) 
where CA is the reactant concentration, CA0 is the feed reactant concentration, τ is the EMR 
residence time, and rA is the reaction rate (for the system of interest) as a function of 
natively folded enzyme concentration, [N], reactant concentration, CA, and temperature, T. 
Previous non-isothermal EMR experiments have limited the rate of temperature 
change to about 1 Kelvin per reactor residence time.  With this constraint the left hand side 
of equation 2.3 becomes negligible by the pseudo-steady-state-hypothesis.62 However, by 
directly solving the ordinary differential equation in equation 2.3, the pseudo-steady-state 
condition is not required and the rate of change of temperature is limited only by 
( )T f t=
 ( )0 , ,A AA A A
C CdC





practicalities such as experiment duration and heat transfer. Temperature profiles that 
maximize discrimination between deactivation models can be examined by considering 
transient concentrations.   
For direct comparison between experiments of different feed concentrations (or 
substrates), conversion, X, can be used.  Measuring the conversion allows determination of 
the concentration, through the relation below. 
   (2.4) 
The reaction probed in this study was the hydrolysis of ampicillin to 6-
aminopenicillanic acid (6-APA) and D-phenylglycine.  The mechanism by which PGA 
catalyzes this reaction is complex but has been previously explained.63, 64 The kinetic 
scheme and resulting rate equation are shown in equations 2.5 and 2.6 respectively. 
   (2.5) 
 
  (2.6) 
E represents PGA, A is ampicillin, E●A is ampicillin bound PGA, EC is D-phenylglycyl-
PGA complex, EC●B is 6-APA bound D-phenylglycyl-PGA complex, B is 6-APA, and C 
is D-phenylglycine.  6-APA may also bind to free PGA, forming E●B and causing product 
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enzyme, KA,B,C are equilibrium constants, and CB is the product (6-APA) concentration. 
Values of the equilibrium constants are summarized in Table 2.2.32   
Table 2.2. Reaction rate parameter values for equations 2.5 and 2.6, measured at 25 °C. 
Reaction rate parameter values 
KA  (mol/L) 0.095  
KB  (unit less) 1.083  
KC  (mol/L) 0.080  
 
The Eyring-Polanyi equation, which describes the variance of reaction rate with 
temperature through transition state theory, is only applied to kcat.  kcat represents the rate-
limiting hydrolysis step, therefore the equilibrium constants’ dependence on temperature 
is assumed to be negligible compared to that for kcat. 
The Eyring-Polanyi equation is given by    
   (2.7) 
where kB is the Boltzmann constant, h is Planck’s constant, R is the gas constant, and ΔG‡ 
is the free energy barrier of the hydrolysis reaction.   
 Several models of deactivation are found to describe the change in concentration of 
native enzyme, [N], for various enzymes. These models include the two-state first-order 
irreversible model, the three-state Lumry-Eyring model, and the four-state molten-globule 
model.65-67 These are referred to as Model 1, 2, and 3, respectively, and are represented in 










others are empirical; Models 1, 2, and 3 were chosen to demonstrate the non-isothermal 
continuous activity assay.  Model 1 represents the simplest case where an enzyme decays 
irreversibly and with no detectable intermediates.  Model 2 adds an unfolded intermediate 
to account for the time required for the enzyme to unfold and the observation that most 
enzymes exposed to high heat for a short period do not lose as much activity as Model 1 
predicts.68  Model 3 builds on Model 2 by introducing a second unfolded intermediate to 
explain the observation of multiple distinct transitions in differential scanning calorimetry 
(DSC).67, 69 
 
Figure 2.2.  The three models explored in this study.  N is the natively folded, active enzyme, Uj is an 
unfolded intermediate, and D is deactivated enzyme. 
In all models, N represents natively folded enzyme, Uj represents the jth reversibly 
unfolded and inactive intermediate, and D represents permanently deactivated enzyme.  
The deactivation rate constants (kd) are presumed to follow the Eyring-Polanyi equation 
where the free energy of deactivation ΔGdeact = ΔHdeact -T ΔSdeact, so that 
   (2.8) 
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   (2.9) 
where ΔHj is the change of enthalpy between enzyme conformations j-1 and j (i.e. between 
N and U1 or between U1 and U2) and is assumed to be constant.  Tm,j is the temperature at 
which Kj is equal to unity. 
The fraction of native enzyme depends on the current distribution of enzyme states; 
therefore, the relation between [N] and time (or temperature) is formulated as an initial 
value problem that can be numerically integrated.  Equation 2.10 gives the expression for 
Model 1, 2, and 3 when n = 0, 1, and 2, respectively:  
   (2.10) 
Equation 2.10, being independent of reactant concentration (CA), is solved first and 
then substituted into equation 2.3 to find the reactant concentration exiting the reactor as a 
function of time (or temperature). With the definitions of Kj and kd (eqns. 2.8 and 2.9) the 
model can be fit to experimental concentration data. The addition of more enzyme states 
in Model 2 and Model 3 increases the number of parameters compared to Model 1. More 
parameters enable these models to over fit data that would more appropriately be fit by a 
simpler model. Care must be taken to ensure that the selected model of deactivation is the 
best representation of the underlying mechanism of deactivation. 







































 All modeling was done in MATLAB.  Model parameters were fit by iterative least 
squares with the MATLAB function nlinfit. 95% confidence intervals were generated using 
the MATLAB function nlparci.  The differential equation solvers ode45 and ode15s were 
used to integrate equation 2.3 and 2.10, respectively (equation 9 becomes stiff under certain 
parameter values).   
The Akaike Information Criterion (AIC) was used to assist model selection.  AIC 
is an estimator of model quality; however, AIC does not test the absolute quality of a model 
in the same sense that null hypothesis testing does.  When comparing models, the model 
with the lowest AIC value (regardless of sign) is the best quality.  When using least squares 
estimation with normally distributed errors, the AIC may be calculated by  
   (2.11) 
where n is the number of independent measurements, ,  are the estimated 
residuals from the fitted model, and P is the number of parameters.70, 71  AIC provides an 
easily computed and easily interpreted evaluation of tradeoff between goodness of fit 
(captured by the logarithm term) and model complexity (captured by the 2P term). 
2.5 Results and discussion 
2.5.1 Linear temperature scans 
 The simplest temperature profile is a linear increase, as defined in equation 
2.12.  The results of three linear temperature scans are shown in Figure 2.3. 
 
  (2.12) 
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Figure 2.3.  (A) The measured conversion versus time (dashed line) at three different temperature 
scan rates and Model 1 fits (solid lines) used to produce the data shown in (A) and (B).  (B) The 
predicted ampicillin hydrolysis reaction rate as a function of time at the three temperature scan 
rates. (C) The fraction of active enzyme as a function of time at the three scan rates.  Yellow: 10.92 
K/h, red: 8.24 K/h, and blue: 5.42 K/h.   
Figure 2.3.A shows conversion versus time for a linear increase in temperature with 
three different rates, m = 5.42 K/h (blue), m = 8.24 K/h (red), and m = 10.92 K/h (yellow) 
and b = 293.2 K for all three. The data show an increase in enzyme activity with increasing 
temperature followed by a steep decline as the enzyme rapidly unfolds beyond 
approximately 54 °C, corresponding to a conversion of 0.37 (at 3 hours, 4 hours, and 6 
hours for the yellow, red, and blue lines, respectively).  Figure 2.3.B shows the hypothetical 
reaction rate without enzyme deactivation. As the temperature increases the conversion 
increases leading to product inhibition. Product inhibition causes the reaction rate 
temperature dependence, shown in Figure 2.3.B, to deviate from an exponential increase, 
as would be expected from the Eyring-Polanyi equation. The fraction of active enzyme, 
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Data
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shown in Figure 2.3.C, combined with the reaction rate from Figure 2.3.B, leads to the 
observed conversion versus time shown in Figure 2.3.A. Model 1 is used to fit the three 
scan rates. In each case Model 1 sufficiently describes observed conversion, but Figure 2.4 
shows how all three models can fit the data. 
 
Figure 2.4.  All three models are fit to the 5.42 K/h linear data.  The solid yellow, blue, and red lines 
represent Model 1, Model 2, and Model 3, respectively.  The dashed black line is the measured 
conversion, the green line is the observed temperature. 
Models 2 and 3, in addition to Model 1, also describe the results observed when the 
temperature profile follows equation 2.12. Figure 2.4 shows the m = 5.42 K/h (blue) data 
set from Figure 2.3.A fit by all three models. Based on AIC values (AIC1 = 10.3, AIC2 = 
10.7, and AIC3 = 37.9), Model 1 is the best candidate for the process that generated the 
data. However, the AIC values of Model 1 and 2 are similar and it has previously been 
shown that most enzyme deactivation cannot be adequately described by Model 1.72, 73 To 
confirm that Model 1 is representative of the true deactivation process, additional 
experiments are needed that attempt to falsify Model 1 based on the underlying mechanistic 
differences between Models 1, 2, and 3.  A single linear temperature profile for the non-
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isothermal continuous activity assay is not sufficient to discriminate between the three 
models. 
Changing the linear scan rate should differentiate semi-reversible mechanisms 
(Models 2 and 3) and irreversible mechanisms (Model 1), but in practice this is not the 
case.  From equation 2.10, Models 2 and 3 are dependent on the scan rate (dT/dt) while 
Model 1 is independent of the scan rate.  Equation 2.10 suggests that faster scan rates 
should give larger maximum conversions, however, Figure 2.3 shows that Model 1 fits the 
data at three different scan rates and there is no appreciable difference in maximum 
conversion.  The parameters from fitting the data in Figure 2.3 also predicted the observed 
conversion when the scan rate was increased by an order of magnitude (m = 54.9 K/h); see 
Figure 2.5.  Faster scan rates are hard to achieve employing a water bath and slower scan 
rates become impractically slow. 
 
Figure 2.5. Model 1 fit to the 54.9 K/h linear temperature ramp conversion data. 
2.5.2 Simulated experiments 
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 To maximize differences between the models, experiments with TEM-1 β-
lactamase, previously shown to follow Model 3, were simulated and the simulated data 
were refit with Models 1 and 2. The values of the parameters used in the simulation are 
given in Table 2.3.62 Noise, corresponding to a maximum 3% random error in the measured 
variable (approximately 0.05° optical rotation), was added to the simulated data before 
fitting the models. The simulation temperature profile was then changed, and new data 
were generated from the simulated model (Model 3) as well as from the fit models (Models 
1 and 2). A temperature profile was then generated that would increase the experimentally 
observable difference between the models.  
Table 2.3. Values used in TEM-1 beta-lactamase simulated deactivation experiments. The value of 
ΔG‡ is only dependent on the reaction, not the enzyme deactivation model, therefore the value for 
TEM-1 beta-lactamase was set to be the same as was measured for PGA for similarity of scale (actual 
value 54.2 kJ/mol). 
ΔG‡ (kJ/mol) ΔH1 (kJ/mol) Tm,1 (K) ΔH2 (kJ/mol) Tm,2 (K) ΔGdeact (kJ/mol) 
67.4 74.9 309.2 699.7 324.7 100.6 
 
 The novel temperature profile is motivated by differential scanning calorimetry 
(DSC), a popular method to observe protein unfolding. DSC can be used to observe 
conformational changes upon heating and cooling to test models of denaturation. Similar 
temperature increases and decreases can be implemented with the continuous activity 
assay. However, DSC detects all conformational changes that alter the protein heat 
capacity, whereas the continuous activity assay only observes changes in activity. The 
specificity for activity is especially useful when probing enzymes because, as Rodriguez-
Larrea et al. showed, enzymes may refold into non-functional conformations that produce 
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DSC thermograms indistinguishable from the functional conformation.74 It is possible that 
many enzymes that are believed to have functional reversibility also refold to an inactive 
form. 
   
Figure 2.6.  Results of the simulated TEM-1 deactivation experiment.62 The reaction conditions are 
similar to those used for the non-isothermal continuous activity assay: the substrate is penicillin G 
and the product is penicilloic acid, the substrate feed concentration is 20 mM, the enzyme 
concentration is 5 μM, and the reactor residence time is 8 minutes. (A) Simulated TEM-1 (Model 3) 
non-isothermal continuous assay and fit with Model 1 and Model 2.  (B) Simulated data based on 
TEM-1 (Model 3) and simulated data based on Model 1 and Model 2 fits at slower temperature scan 
rate.  (C) Simulated data based on TEM-1 (Model 3) and simulated data based on Model 1 and 
Model 2 fits with saw-tooth temperature profile.  
The temperature profile is most effective when it probes the main differences 
between models, namely functional reversibility. Figure 2.6 illustrates the process 
described above for a saw-tooth temperature profile. The saw-toothed profile in this 
example was designed to deactivate approximately equal amounts of enzyme with each 
temperature oscillation. Figure 2.6.A shows a simulated TEM-1 beta-lactamase experiment 
with a linear scan rate of 10 K/h and the corresponding Model 1 and Model 2 fits. Figure 
2.6.B shows three simulated TEM-1 beta-lactamase experiments with a linear scan rate of 
5 K/h. One experiment was generated with the true model (Model 3) from (A) and two 
other experiments were generated from the results of the fits with Models 1 and 2 from 
(A). With a 3% random error it is nearly impossible to differentiate the three sets of data, 
confirming that practical changes to a linear scan rate do not provide observable changes 
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in the conversion profile. Figure 2.6.C is the same as (B) but with a saw-tooth temperature 
profile (at 10 K/h) that makes clear the differences between the models even with 3% 
measurement error. While Models 1 and 2 can approximate data produced by Model 3 with 
a linear temperature profile, the saw-tooth profile effectively differentiates Models 1 and 2 
from the true model (Model 3) by the third temperature oscillation.  
The same simulation procedure used for TEM-1 beta-lactamase was used on 
lysozyme, an enzyme whose deactivation was previously shown to follow Model 2.69 The 
simulation showed that a saw-tooth temperature profile considerably differentiates Model 
2 from Model 1.  
2.5.3 PGA deactivation model discrimination  
The temperature profile from the simulated experiment in Figure 2.6.C was 
implemented for PGA and shows Model 2 best describes PGA deactivation. Figure 2.7.A 
shows the observed ampicillin conversion along with the fit for each Model. Figure 2.7.B-
D shows the distribution of enzyme in each state (native, unfolded, deactivated) obtained 
when each model is fit to the data in panel A. The irreversibility of Model 1 manifests in 
the overshoot when fitting the peaks in conversion; the lack of unfolded intermediate 
results in harder transitions between heating and cooling (deactivating and stabilizing 
conditions). Model 2 is better able to fit the data by using the unfolded intermediate as a 
buffer to soften the transition from heating to cooling; the maxima in unfolded population 
align with the peaks in the temperature in Figure 2.7.C. The unfolded intermediates in 
Model 3 also give a better fit than Model 1, however, as shown in Figure 2.7.D, the relative 
proportion of enzyme in the first unfolded state is nearly zero at all times, indicating only 
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one unfolded state is important. A second solution to fitting the data with Model 3 results 
in the population of the first unfolded state being substantial and the population in the 
second unfolded state being nearly zero, however the goodness of fit was equal to that 
shown in Figure 2.7. This is interpreted to mean only one intermediate is important, which 
is the mechanism captured by Model 2. 
 
Figure 2.7  (A) The observed conversion of ampicillin and the fit of Model 1 (solid yellow), Model 2 
(solid red), and Model 3 (solid blue) to the data (black dashed).  (B) The fractions of active (solid) and 
deactivated (dashed) enzyme when the data in (A) are fit with Model 1.  (C) The fractions of active 
(solid), reversibly unfolded (dotted), and deactivated (dashed) enzyme when the data in (A) are fit 
with Model 2.  (D) The fractions of active (solid), 1st reversibly unfolded (dotted), 2nd reversibly 
unfolded (dash-dot), and deactivated (dashed) enzyme when the data in (A) are fit with Model 3. (E) 
The temperature as a function of time. 
The residual sum of squares (RSS) and AIC values, shown in Table 2.4, support 
Model 2 as best representing the underlying deactivation process. The parameters from 
fitting the saw-tooth profile are given in Table 2.5. The melting temperature of PGA 
measured by differential scanning fluorimetry (DSF) is 332±4.9 K, which is consistent 
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with the fit value of Tm,1 of 328.4±0.1 K. Only one transition was observed with DSF, 
which also supports Model 2 over Model 3. Figure 2.8 shows the onset of melting and 
melting temperature as measured by DSF for PGA at two different concentrations and six 
pH values. No variation was found with concentration, indicating that aggregation is not a 
primary driver of deactivation. DSF also suggests that PGA is more stable in slightly acidic 
solution compared to neutral conditions, however other factors, such as solubility and PGA 
activity, have greater influence on choice of operating pH for the continuous process, and 
so the non-isothermal continuous activity measurement was only conducted at pH 7. 
Table 2.4.  The number of parameters, P, residual sum of squares, RSS, and Akaike information 
criterion, AIC, for each model fit to the data generated from the saw-tooth temperature profile. 
Model P RSS AIC 
Model 1 3 0.0022 -447 
Model 2 4 0.0009 -661 
Model 3 6 0.0014 -545 
 
Table 2.5. Parameter values resulting from fitting Model 2 to the saw-tooth temperature profile given 
as 95% confidence intervals.  ΔGdeact (kJ/mol) is given at 25 °C. 
 Model 1 Model 2 Model 3 
ΔG‡ (kJ/mol) 67.40 ± 0.02 67.38 ± 0.01 67.41 ± 0.02 
ΔGdeact (kJ/mol) 121.2 ± 2.4 98.70 ± 0.05 100.17 ± 0.04 
ΔH1 (kJ/mol)  236.1 ± 0.9 219.8 ± 0.04 
Tm,1 (K)  328.4 ± 0.1 362.9 ± 0.1 
ΔH2 (kJ/mol)   203.85 ± 0.18 




Figure 2.8.  The melting temperature, Tm, and unfolding onset temperature, Tonset, of Assemblase 
PGA are shown as a function of pH value at two protein concentrations.  The melting was measured 
by differential scanning fluorimetry (DSF).  Tm is interpreted as the temperature where the DSF 
curve is at a maximum and Tonset is the temperature at which the DSF curve increases 5% above the 
baseline. 
From the simulations in Figure 2.7.C, it is clear that PGA deactivation is not strongly 
reversible, as indicated by the low fraction of PGA in the reversibly unfolded state (U1), 
which reaches a maximum of about 20%. The low reversibility may be because PGA is a 
heterodimer formed from a single precursor sequence. Proteins activated by proteolytic 
processing often unfold irreversibly because the mature amino acid sequence does not 
encode the same folding as the precursor sequence.75 PGA likely refolds up to the point 
when the two monomers dissociate, at which point proper refolding is less likely. Grinberg 
et al. employed DSC to deduce that the α subunit of PGA unfolds reversibly while the β 
subunit aggregates upon dissociation of the heterodimer.76 While aggregation was not 
observed in this study, their results are consistent with the observed limited reversibility 
found for PGA. Their results, combined with the results of this study, may suggest the 
structure of the α subunit is less critical than that of the β subunit, on which the active site 
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serine resides. This limited reversibility still informs process design of beta-lactam 
synthesis by PGA because the catalyst has some resilience to temperature fluctuations in 
the reactor, which could enable operation closer to stability limits.  
2.5.4 PGA deactivation by batch assay 
In addition to the continuous non-isothermal activity measurements, the residual 
activity was also assayed by the conventional batch isothermal method for PGA.  Both the 
reaction rate and the fraction of active enzyme as a function of temperature are needed for 
comparison to the non-isothermal assay.  The results of these experiments are shown in 
Figure 2.9. The reaction rate is presented as an Eyring-Polanyi plot in Figure 2.9 (left), the 
residual enzyme activity at six different temperatures is shown with exponential decay fits 
(equivalent batch-wise to Model 1) to the data in Figure 2.9 (middle), and the decay 
constants are plotted in Eyring-Polanyi linearized space in Figure 2.9 (right).  The decay 
constants are also listed in Table 2.6.  Enthalpy and entropy can be determined from Eyring 
plots. The free energy of the reaction determined by this method agrees well with that found 
by fitting the non-isothermal experiments and is relatively constant over the temperature 
range of interest (indicated by the small entropy of reaction).  A comparison between these 
methods is summarized in Table 2.7. 
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Figure 2.9.  Results of batch deactivation assay of PGA.  (Left) Ampicillin hydrolysis rate as a 
function of temperature.  (Middle) Residual enzyme activity as a function of time and temperature.  
(Right) Model 1 deactivation constant as a function of temperature. 
Table 2.6. Enzyme decay constants measured by batch residual rate experiments (Figure 2.9 middle 
and right) 
Temperature (K) Decay Constant (standard deviation) [s-1] 
310 1.15×10-5   (0.2×10-6) 
318 0.00030     (0.00008) 
322 0.00329     (0.00212) 
325 0.00426     (0.00016) 
327 0.01039     (0.00094) 
329 0.02570     (0.00113) 
 
As the batch method relies on discrete measurements it does not provide the same 
resolution as the continuous method, therefore, model discrimination is much more 
difficult. It does, however, provide estimates of the enthalpy and entropy of deactivation 
for Model 1. The confidence intervals from the isothermal batch assay are much wider than 
those from the non-isothermal continuous assay, for both the linear and saw-tooth 
temperature scans (shown in Table 2.7); however, the results are consistent with those from 
the Model 1 fits. The disagreement between the values determined from the linear and saw-
tooth temperature profiles is expected because it was previously shown that Model 1 does 
not represent the data-generating process. However, the congruence of the isothermal batch 
ΔHrxn = 36±7 kJ/mol 
ΔSrxn = -100±23 J/mol/K 
ΔHdeact =  
370±35 kJ/mol 
ΔSdeact =  
870±110 J/mol/K 
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results with both continuous results gives additional validation of the continuous non-
isothermal activity assay; when an incorrect model (Model 1) is fit to both data sets the 
same result is produced by the continuous and batch methods.  
Table 2.7.  Comparison of results from non-isothermal continuous assay with linear and saw-tooth 
temperature profiles analyzed with Model 1 and isothermal batch assay.  Values are 95% confidence 
intervals. 
 Linear temperature scan Saw-tooth temperature scan Isothermal batch 
ΔG‡ (kJ/mol) 68.9 ± 0.1 67.40 ± 0.02 67 ± 14 
ΔHdeact (kJ/mol) 355 ± 2 350.7 ± 0.6 370 ± 35 
ΔSdeact (J/mol/K) 771 ± 5 770 ± 2 870 ± 110 
 
2.6 Conclusion 
Determination of the mechanism of enzyme deactivation is not always possible with 
a linear temperature scan when the enzyme activity is observed continuously.  The 
theoretical framework for the continuous non-isothermal assay has been expanded to 
enable a larger range of experiments for better differentiation of deactivation models.  The 
technique is explored in depth for three models and experimental data from PGA is 
examined with each model.  However, the assay is generalizable to any deactivation model.  
The results indicate model discrimination is most effective with temperature profiles that 
include heating and cooling.  Compared to batch-wise enzyme activity measurement, the 
non-isothermal continuous assay provides more data faster to enable discrimination with 
single experiments.  
PGA and TEM-1 beta-lactamase were examined in real and simulated experiments, 
respectively. Linear temperature scans suggested that PGA deactivates according to Model 
 33 
1. However, in a simulated linear scan experiment, TEM-1 beta-lactamase, which is known 
to deactivate according to Model 3,62 could be better fit by Models 1 and 2. Novel 
temperature profiles were simulated for TEM-1 beta-lactamase and designed to maximize 
the experimentally observable difference between the models. A saw-tooth profile proved 
to be the simplest sufficient profile, demonstrating that TEM-1 beta-lactamase deactivation 
is indeed captured best with Model 3. Next, PGA deactivation was probed with the saw-
tooth temperature profile, which showed that PGA deactivation is slightly reversible. 
Batch-wise experiments, commonly used to probe enzyme activity during thermal 
deactivation, were not able to discriminate between any of the models but are consistent 
with the results from the non-isothermal continuous assay. Applying the saw-tooth 
temperature profile in combination with the Akaike information criterion for model 
discrimination not only pointed to Model 2 as the best fit for PGA deactivation but yielded 
activation and deactivation Gibbs Free enthalpies, enthalpies, and entropies with 




CHAPTER 3. KINETICS OF PGA-CATALYZED SYNTHESIS OF 
AMPCILLIN AND CEPHALEXIN2 
3.1 Introduction 
To design the physical pilot plant for a CM reactive crystallization process for beta-
lactams one needs to know that rates at which the reaction proceeds under different process 
conditions. The kinetics of PGA synthesis (and hydrolysis) of beta-lactams has been 
published by many,63, 77-83 including those in our lab.41, 84 This thesis builds on the work of 
the aforementioned citations to examine reactive crystallization and CM; this chapter 
specifically improves on those previously cited by expanding the mechanistic 
understanding of PGA catalyzed bate-lactam production to include pH-specific behavior 
and substrate inhibition, two formerly unreported facets of PGA catalysis. 
The primary obstacle to more highly efficient β-lactam production by PGA is poor 
selectivity, as kinetically controlled synthesis competes with both primary and secondary 
hydrolysis (Figure 3.1). Ampicillin, produced by the condensation of 6-aminopenicillanic 
acid (6-APA) with D-phenylglycine methyl ester (PGME) and the subject of this chapter, 
is a particularly good model compound for this process. Phenylglycine, the byproduct of 
ampicillin (and cephalexin) secondary hydrolysis, is only sparingly soluble, rendering 
selectivity a greater challenge than with amoxicillin. Ampicillin is also less soluble and 
more easily available than cephalexin (and its precursor 7-ADCA) and is therefore favored 
 
2 Adapted from “Chemical Engineering Science, 165, McDonald, M.A.; Bommarius, A.S.; Rousseau, R.W. 
Enzymatic reactive crystallization for improving ampicillin synthesis, 81-88.” Copyright (2017), with 
permission from Elsevier. 
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for reactive crystallization experiments over cephalexin.  The insolubility of phenylglycine 
elevates the problem of selectivity since excessive byproduct formation results in 
contaminated solid product.   
Selectivity is affected by both the rate of PGME hydrolysis and ampicillin 
hydrolysis. The ratio of rates of synthesis and hydrolysis (VS/VH) is used to characterize the 
differential selectivity; it is a property of the enzyme at the specified conditions and is 
therefore denoted Senz. The value of this ratio at zero conversion (the initial ratio, [VS/VH]0), 
often also denoted as the synthesis-to-hydrolysis ratio (S/H), captures the enzyme 
specificity for ampicillin synthesis over primary hydrolysis, and has been the subject of 
several studies regarding enzyme and reaction engineering.64, 85-87 The ratio of total 
ampicillin and phenylglycine produced up to a specified time—the integral selectivity 
(Sprocess), which is the quantity that captures the behavior of real reactors—depends on both 
primary and secondary hydrolysis, and has seen far less investigation because of the 
challenges posed by secondary hydrolysis. 
 
 
Figure 3.1 The overall reaction and crystallization scheme for the PGA-catalyzed synthesis of 
ampicillin, with crystallization of ampicillin and possible precipitation of phenylglycine. Synthesis is 
shown in blue, primary hydrolysis in yellow, secondary hydrolysis in orange, ampicillin trihydrate 
crystallization in green, and phenylglycine crystallization in red. 
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Reactive crystallization, where a desired compound is driven into supersaturation 
by a chemical reaction, is typically used to push the reaction equilibrium to the right (i.e. 
towards a desired product). However, Figure 3.1 shows that ampicillin is not the 
equilibrium product but rather is an intermediate; the equilibrium of secondary hydrolysis 
favors 6-APA and D-phenylglycine over ampicillin by about 100-fold while the 
equilibrium of the synthesis reaction was not determinable because no ampicillin was 
detected at equilibrium.40 In the present work we develop a crystallization-based process 
that isolates the intermediate and therefore increases the integral selectivity without the 
enzyme engineering required to affect the differential selectivity. Our own previous work 
has shown that simultaneous synthesis and crystallization of pure ampicillin is possible.41 
In the following sections we demonstrate that the crystallization of ampicillin is 
advantageous and can be optimized for selectivity and productivity. 
3.2 Materials and methods 
3.2.1 Materials 
PGME was from Sigma-Aldrich (St. Louis, MO). Phenylglycine, ampicillin 
sodium salt, and anhydrous ampicillin powder were from Alfa Aesar (Willard Hill, MA).  
6-APA and ampicillin trihydrate were from TCI America (Portland, OR). DSM-Sinochem 
(Delft, The Netherlands) kindly supplied the enzyme Assemblase®, with a protein 
concentration of 17 mg/mL and a specific activity for ampicillin hydrolysis of 1600 U/mg 
protein at pH 7.8 and 25 °C.  All materials were used as received. 
3.2.2 Determination of initial reaction rates 
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The reaction of 6-APA and PGME was performed in an Anton-Paar MCP 500 
polarimeter thermostated at 298 K. The contents were constantly mixed via circulation 
through the flow-cell by a peristaltic pump. The working volume was 5.0 mL. Samples of 
50.0 μL were periodically withdrawn for analysis by high-performance liquid 
chromatography (HPLC). The concentration of reactants varied from 5.0 mM to 80 mM.  
The concentration of enzyme was 1.25 μM and was added after the temperature in the cell 
had equilibrated. The pH value was maintained at the desired level by 100 mM phosphate 
buffer. The pH value was measured before and after the reaction and changed by less than 
a tenth of a pH-unit between the start and end of the reaction.  
The rates of both primary and secondary hydrolysis were measured individually by 
polarimetry.  PGME, 6-APA, ampicillin, and phenylglycine are all optically active, and 
specific rotations as determined in this study are summarized in Table 3.1. By measuring 
change in optical rotation with time, combined with knowledge of the reaction 
stoichiometry, the rate of either PGME hydrolysis or ampicillin hydrolysis could be 
determined in real time.   
The rate of ampicillin synthesis was measured by a Shimadzu Prominence HPLC 
with a 4.6 x 100 mm Phenomenex C18 reverse-phase column. The eluent consisted of 
30:70 v/v acetonitrile and water with 0.69 g/L SDS and 0.69 g/L NaH2PO4.  The flowrate 
was 0.75 mL/min. The initial synthesis to hydrolysis ratio was determined by comparing 
accumulation of ampicillin and phenylglycine directly. 
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Table 3.1. Summary of the optical rotation of the optically active species in ampicillin synthesis; 10 
cm path-length at 589 nm.  The specific rotation was measured at 298 K in 250 mM pH 7-phosphate 
buffer. 
Species D-PGME 6-APA Ampicillin D-phenylglycine 
Specific Optical Rotation (°/mol/L) -23.6 61.6 96.9 -13.9 
 
3.2.3 Determination of solubilities 
The solubility of each species as a function of pH was determined with the 
saturation approach.45 The pH value of a saturated suspension was adjusted by titration 
with 2 M HCl or NaOH while the temperature was held steady at 298 K and the vessel was 
stirred constantly. After equilibrium was reached (as indicated by unchanging pH value, 
typically over 1 hour) samples were withdrawn through a 0.45-μm filter and diluted, either 
1:200 for analysis by HPLC or 1:10 for examination by polarimetry.  The results of HPLC 
and polarimetry vary by less than 5% and the average of the two values was used for the 
purposes of modeling the system. 
3.2.4 Modelling 
The reaction kinetics were determined experimentally and modelled in MATLAB.  
The crystallization kinetics have previously been determined and were also modelled in 
MATLAB.88, 89 The pH value was calculated via a charge balance and species balance.90 
Since the reaction kinetics were found to be rate-limiting, the system was regarded as 
consisting of two time scales, with the transition between the two scales determined by 
thermodynamics rather than kinetics for computational simplicity. The pairing of these two 
kinetic processes along with separation into different scales and pH changes necessitated 
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construction of a purpose-built semi-implicit Euler integrator to determine concentration 
trajectories.  
3.2.5 Reactive crystallization experiments 
To seed the reactive crystallizer, 14.1 mg/mL of ampicillin trihydrate were added 
to a solution of PGME and 6-APA in equimolar amounts. The solubility of ampicillin 
trihydrate is less than 14.1 mg/mL (see Figure 3.2, equivalent to 35 mM dissolved 
ampicillin), which means that, at equilibrium and before the reaction is started, the resulting 
mixture is a suspension of dissolved and solid phase ampicillin (5-15% seed crystals, 
depending on pH value). To simulate the homogeneous (non-crystallizing) process, 13.0 
mg/mL of ampicillin sodium salt (equivalent to 35 mM dissolved ampicillin) was added to 
the reaction solution. The solubility of ampicillin sodium salt is greater than 13.0 mg/mL, 
resulting in complete dissolution of the ampicillin and a solution slightly supersaturated 
with respect to ampicillin trihydrate (see Figure 3.2, solid versus dashed ampicillin curves).  
The solutions were titrated to the same initial pH value with 2 M NaOH.  The reaction was 
initiated by the addition of the enzyme. At the highest reactant concentrations crystal 
formation through primary nucleation was sometimes observed in the homogeneous 
experiments; in such cases, these data were not used to compare the process with and 
without crystallization.  The reactive crystallization experiments were conducted at 
constant stirring in a 298 K water bath.  Aliquots of 50.0 μL were periodically withdrawn 
for analysis by HPLC using the same HPLC procedure described above. 
3.2.6 Process Characterization 
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 Previous studies of enzymatic ampicillin synthesis define process metrics, such as 
selectivity or conversion, in many different ways. We have chosen to define process 
selectivity as the total ampicillin produced divided by the total phenylglycine produced (see 
equation 3.1) while enzymatic selectivity is defined as the instantaneous synthesis to 
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We define conversion with respect to PGME since 6-APA is both consumed by synthesis 
and produced by secondary hydrolysis. 
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The yield is defined with respect to 6-APA because it captures aspects of synthesis, primary 
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3.3 Results and discussion 
 41 
3.3.1 Solubility experiments 
 The reaction scheme (Figure 3.1) shows sequestering the ampicillin in a solid phase 
can compete with secondary hydrolysis. Since the solid phase must be relatively pure in 
ampicillin to avoid subsequent purification steps, the solubilities of species other than 
ampicillin should not be exceeded.  The measured solubilities of the relevant compounds 
are shown in Figure 3.2. The low solubility of ampicillin trihydrate relative to 6-APA and 
PGME points toward implementation of a practical reactive crystallization process; 
nevertheless, the low phenylglycine solubility significantly limits the operating range that 
results in high-purity ampicillin. Figure 3.2 shows that at pH values up to 7 the solubility 
of ampicillin and phenylglycine are very similar, however, in slightly basic conditions (pH 
7-8), ampicillin is significantly more soluble than phenylglycine, rendering operation in 
basic conditions unfavorable because of the large amount of product that will remain in 
solution. The decrease in solubility of ampicillin above pH values of 8 (dashed line) is the 
result of crystallization of ampicillin sodium salt as opposed to ampicillin trihydrate. We 
aim to only produce ampicillin trihydrate and therefore will not operate above a pH value 
of 8.  
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3.3.2 Initial rate experiments 
 The change in solubility with pH value has been previously documented,22, 45, 91 but 
the enzyme activity as a function of pH value is poorly characterized.  Previous studies of 
the effect of pH value on ampicillin synthesis have reported trends, sometimes conflicting, 
regarding specific reaction rates and yields.87, 92, 93 In the present work, the pH dependence 
of enzyme activity towards primary hydrolysis and synthesis was found to be very similar.  
Figure 3.3 shows that in three equimolar mixtures of 6-APA and PGME, each at a different 
concentration, the maximum activity of the enzyme occurred at around pH 8 for both 
synthesis and primary hydrolysis.  From this result it was determined that two significant 
protonation/deprotonation equilibria exist and likely affect a common intermediate through 































Figure 3.2. The solubility of 6-APA (◼), ampicillin (◆), and phenylglycine () as functions of 
pH value.  Lines indicate modeled fit based on the Henderson-Hasselbalch equation with ionic 
strength correction.  The solid ampicillin line represents ampicillin trihydrate while the 
dashed ampicillin line represents ampicillin sodium salt.  PGME is not shown because it is 
highly soluble. 
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observed at a pH value of 7.1 and the higher pKa was observed at a pH value of 8.5. Figure 
3.3 also shows that synthesis of ampicillin increases with higher reactant concentrations, 
but hydrolysis activity decreases as the reactant concentrations are raised. The decrease in 
hydrolysis suggests competition between 6-APA and water; increasing the amount of 6-
APA decreases the relative frequency at which hydrolysis can occur.  
 
 From the initial-rate experiments, the PGA used in this study (commercially 
available Assemblase® from DSM-Sinochem) was characterized in the framework 
established by Svedas et al. for α-chymotrypsin and later applied to PGA (and other serine 
and cysteine proteases).63 The proposed mechanism involves the binding of an acyl-donor 
(PGME) to the enzyme and subsequent formation of a covalent adduct between the acyl-
donor and the active site serine of PGA. This adduct, the acyl-enzyme complex, is likely 
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Figure 3.3. Synthesis (left) and hydrolysis (right) activity of Assemblase® as functions of pH at three 
different equimolar reactant concentrations. The activity is determined from the initial rate. Curves 
are to guide the eye. 
 44 
susceptible to a nucleophilic attack either by a desired nucleophile or water. Once formed, 
the acyl-enzyme complex binds a nucleophile (6-APA in the case of ampicillin) which then 
reacts with the acyl-enzyme complex and breaks the covalent bond to the critical serine 
residue.  The nucleophilic attack produces enzyme-bound ampicillin, which is then 
released to solution, or, if water attacks the acyl-enzyme complex, phenylglycine.  Binding 
of 6-APA does not prevent hydrolysis, but it significantly reduces it, as can be seen in 
Figure 3.4 below. 
 
Figure 3.4. The initial rate of ampicillin hydrolysis at different initial ampicillin concentrations and 
6-APA concentrations. 
 Svedas et al. used three parameters to evaluate enzymes that fit this mechanism, , 
0, and  where  describes the enzyme specificity for the acyl-donor over the desired 
product (PGME over ampicillin), 0 describes the reactivity of the nucleophile (6-APA) in 
the hypothetical situation of near-zero nucleophile concentration, and γ describes the 
fraction of acyl-enzyme complex hydrolyzed after binding the nucleophile.63 These three 
parameters are composites of parameters derived from the rate constants and equilibrium 
constants in the kinetic scheme described by Svedas et al.63 In fitting our initial rate 
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experiments, only 0 was found to be a function of pH value. Of , 0, and , only 0 
depends on the binding of 6-APA, which Figure 3.5a shows is a function of pH value. The 
parameter values we determined for Assemblase® and those Svedas et al. determined for 
PGA from E. coli are summarized in Table 3.2.77 Our enzyme has better affinity for PGME 
over ampicillin (captured by ; high  values desirable), which will slow secondary 
hydrolysis compared to primary hydrolysis and synthesis, it more strongly binds 6-APA at 
comparable pH values (captured by 0, high 0 values desirable), which will decrease rates 
of primary hydrolysis, and it is slightly less likely to hydrolyze the acyl-enzyme complex 
once 6-APA binds (captured by , low  values desirable), which will slow hydrolysis.  
Table 3.2 Comparison of Assemblase® and the E. coli PGA used by Svedas et al. (pH 6.4 only) at 298 
K.77 Assemblase with the other antibiotics studied in the course of this thesis are also reported with 
discussion at the end of the chapter. 
Enzyme Antibiotic  [-] 0 [M-1] γ [-] 
Assemblase ampicillin 3.9 
pH: 5.7 6.4 7.1 7.8 8.5 9.2 
0.038 
 160 120 62 38 27 18 
E. coli PGA ampicillin 2.3   60     0.056 
Assemblase amoxicillin 4.6  210 140 94 63 41 27 0.122 
Assemblase cephalexin 8.9  370 240 160 110 71 47 0.020 
 
Additionally, Figure 3.5b shows that the initial synthesis-to-hydrolysis ratio also 
depends on pH value, with slightly acidic conditions favoring synthesis.  Higher 
concentrations of reactants in equimolar amounts also resulted in higher initial synthesis-
to-hydrolysis ratios [Vs/Vh]0.  However, a more basic pH value does not hamper the 
secondary hydrolysis of ampicillin, indicating the nucleophilic attack by 6-APA on the 
acyl-enzyme complex is not pH-dependent.  These results reaffirm the trend in Figure 3.5a, 
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that the binding of 6-APA to the acyl-enzyme complex (but not the nucleophilic attack 
itself) is pH-dependent, with more basic conditions discouraging binding of 6-APA.  The 
selectivity of the initial reaction is therefore improved in slightly acidic conditions, 
however, since synthesis and secondary hydrolysis both scale similarly with pH value, the 
issue of integral selectivity goes unaddressed by pH modulation.  
 
3.3.3 Improved process model 
As expected from the stoichiometry (formation of an acid, phenylglycine, from an 
ester, PGME), the pH value of the reactor dropped during the course of the reaction. 
Because the activity of the enzyme decreases as the pH value decreases in the range of pH 
7.8 to 5.7, the pH value of the three different initial conditions decreased by different 
amounts, with the highest initial pH decreasing the most. This drop in pH value appears to 






































20 mM PGME and 6-
APA
Figure 3.5. The 6-APA dissociation constant at three different reactant concentrations (left) and 
the initial synthesis-to-hydrolysis ratio at three different reactant concentrations (right).  The 
dissociation constant should not be concentration dependent, but it is confounded by the 
competing and binding of 6-APA to free enzyme and 6-APA to acyl-enzyme complex. 
a b 
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increases. A representative pH profile is shown in Figure 3.6. Here, the reactant 
concentrations were increased to 160 mM and the reaction time was extended to better 
illustrate the pH change behavior. The initial increase in pH value corresponds to the 
consumption of 6-APA, an acid, but is quickly overtaken by the production of 
phenylglycine. The small disturbance at approximately 180 minutes is the result of 
crystallization of ampicillin (this system was initially unseeded) and the sudden depletion 
of ampicillin supersaturation slightly increased the pH value. This behavior was predicted 
by the model but is only found at concentrations high enough to spur primary nucleation; 
we mainly worked below these concentrations to avoid issues with 6-APA solubility. 
 
The strong influence of pH on synthesis and hydrolysis reaction rates has not been 
quantified nor modelled in previous work. The strength of the Svedas et al. model lies in 
its ability to describe the selectivity of the system accurately using only three fitted 
parameters, , 0, and , as defined above.94 Integrating this model to determine 
concentrations as a function of time, which is necessary for predicting crystallization, 
requires fitting eight parameters: KS, KP, KN, k2, k3, k4, k-4, and k5.  The significance of each 












Figure 3.6. The pH profile of a typical 
reaction is illustrated in a system at 
equimolar initial concentrations of 160 
mM to highlight the decrease in pH 
value with increasing conversion.  
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describing this system based on known mechanism and first principles (as opposed to 
bypassing mechanistic arguments with computational methods such as neural networks),83, 
95 requires refitting the kinetic parameters for every pH value. Since the reaction causes a 
change in pH (unless sufficiently buffered), the Svedas et al. model is only applicable to 
pH-stated systems. Operating at constant pH, however,  may not provide the best yield and 
results in the additional formation of salts that need to be discarded.87   
We have found that two protonation/deprotonation reaction equilibria are necessary 
to describe the enzyme activity towards synthesis, primary, and secondary hydrolysis and 
that 6-APA binding (and therefore 0) is a strong function of pH value. In Figure 3.7 we 
show the reformulated model. We introduced acidic and basic reactions between the acyl-
enzyme complex (EAH) and protonated and deprotonated forms of the acyl-enzyme 
complex (EAH2+ and EA-). The reaction cannot move forward from the protonated and 
deprotonated forms. While there may exist several additional pH-dependent protonation 
and deprotonation reactions, these two were sufficient to describe the experimental system. 
The relationship between the 6-APA dissociation constant (KN) and pH value could be 
approximated as exponential in slightly acidic conditions that solubility already dictates 
we operate in. The model therefore defined 0 as a function of pH in accordance with the 
exponential estimate.  
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Additionally, secondary hydrolysis by the enzyme was competitively inhibited by 
6-APA (see Figure 3.4), motivating the addition of another equilibrium between free 
enzyme and 6-APA bound acyl-enzyme complex (not to be confused with the desired 
binding of 6-APA and acyl-enzyme complex).  This addition has been proposed previously 
but lack of data and a small perceived influence had led to its elimination by previous 
authors in favor of a computationally simpler model.80 
Ampicillin crystallization kinetics from previous studies indicate that 
crystallization is significantly faster than the reactions when the enzyme is sufficiently 
dilute.88, 89 With the assumption that ampicillin crystallization is much faster than 
ampicillin synthesis, our model partitions the system into a solution phase and solid phase 
and assumes that significant supersaturation is never generated. This assumption negates 
the occurrence of primary nucleation; Encarnación-Gómez et al. showed that large 
supersaturation is needed for primary nucleation, especially in the presence of 6-APA.41 
However, when seed crystals are present, as in our study, they can grow and participate in 
secondary nucleation.  
3.3.4 Reactive crystallization experiments 
Figure 3.7. The improved kinetic 
scheme for DSM-Sinochem 
Assemblase®. Two pH-dependent 
equilibria have been added to the EAH 
form of PGA (top right).  
Abbreviations: E is free enzyme, EAH is 
acyl-enzyme complex, EAH2
+ and EA- 
are inactive forms of the acyl-enzyme 
complex, E•PGME, E•APA, EAH•APA, 
and E•Amp are enzyme bound PGME, 
enzyme bound 6-APA, acyl-enzyme 
complex bound 6-APA, and enzyme 
bound ampicillin, respectively.  PG is 
phenylglycine 
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Ampicillin was synthesized at 298 K and three different initial pH values: 6.00, 
6.35, and 6.75.  Experiments were initiated with equimolar amounts of PGME and 6-APA.  
The concentration of each reactant for all experiments was chosen to be 85 mM, the 
saturation concentration of 6-APA at pH 6.  The initial concentration of ampicillin was 
chosen to be 35 mM to simulate an initial conversion of 30% (from an initial concentration 
of 120 mM).  At this conversion solid ampicillin is present and thus the need for crystal 
seeding is avoided.  The initial addition of ampicillin is justified because at low conversions 
the ampicillin has not yet reached saturation and therefore, in a batch process, both the 
reactive crystallizer and homogeneous reactor follow the same dynamics.  In the reactive 
crystallizer, solid ampicillin represents approximately 13%, 7%, and 2% of the initial 
ampicillin present at pH 6.00, pH 6.35, and pH 6.75, respectively.  These correspond to 
initial supersaturations (S = C/C*) of 1.15, 1.07, and 1.02 in the homogeneous reactor.   
Figure 3.8 shows the course of ampicillin production for the control reactor and 
reactive crystallizer. The data begin at 25 minutes because the results of the first 25 minutes 
are simulated by the initial ampicillin addition. The reactive crystallizer shows higher final 
concentration of ampicillin and lower final concentration of phenylglycine. Figure 3.8 also 
demonstrates the robustness of our model; the solid curves represent predictions based on 
integrating initial rate data and they match the observed concentrations remarkably well. 
The increased conversion (see equation 3.3) of reactive crystallization can be seen in the 
steeper PGME consumption curve at longer times. The enhanced process selectivity of 
reactive crystallization can also be seen in the relative final ampicillin and phenylglycine 
concentrations.   
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The overall process selectivity is increased by reactive crystallization. Figure 3.9 
shows how the process selectivity is increased by nearly 50% at all three initial pH values 
tested.  Additionally, the solid lines, again representing the model predicitions based on 
initial rate data, predict the increase in selectivity relatively well.  The increase in selectivity 
in the reactive crystallizer over the homogeneous reactor is due to the reduction in 
secondary hydrolysis—which both degrades ampicillin and forms phenylglycine—by 
crystallization.  These data support our hypothesis that crystallization can be used to isolate 
the reactive intermediate in the enzymatic reaction pathway.  The increasing selectivity 
with decreasing pH value matches what is expected from the increased enzymatic 
selectivity, which is enhanced by slightly acidic conditions, a consequence of the acidity 
dependence of enzyme-6-APA binding. 
Figure 3.8. The reaction course for the control reactor (left) and reactive crystallization scheme 
(right) at a pH value of 6.75. Error bars are one standard deviation, n = 5.  Lines represent 
model predictions based on initial rate data.  PGME concentration was not directly measured 
but can be determined via a mass balance.  These profiles are representative of the 






















































   
The yield (see equation 3.4) is maximized (Ymax) when the ampicillin concentration 
is highest which occurs when the rates of synthesis and secondary hydrolysis are equal.  It 
would not be desirable to operate the process to reach Ymax because of diminishing returns 
of ampicillin with respect to the amount of phenylglycine being produced.  However, Ymax 
is still a valuable means to evaluate the process, especially because there exists a theoretical 
maximum determinable using the parameters , 0, and  previously discussed.  Gololobov 
et al. derived the following expression for Ymax and determined it was valid for papain (a 
cysteine protease with a similar mechanism to PGA) when the initial amount of acyl-donor 





















  (3.6) 
Figure 3.9. The selectivity of the reactive crystallization process is compared to the 
homogeneous reactor.  The selectivity is defined as the total amount of ampicillin 
formed over the total amount of phenylglycine formed.  The solid lines represent 













































  (3.7) 
Applying the relation above to our system yielded good agreement between the 
homogeneous control experiments and the theoretical maximum (the center two columns 
in Table 3.3).  Reactive crystallization broke the theoretical maximum, increasing the 
maximum yield by nearly 10% at lower 6-APA concentrations and more than 20% at the 
higher 6-APA concentration (both with initial pH value of 6.75).  The increase over the 
theoretical maximum is caused by the decreased rate of secondary hydrolysis. 
Table 3.3.  The maximum yield of ampicillin compared between the theoretical maximum, the 
control homogeneous experiment, and the reactive crystallization setup.  The initial pH value is 6.75 
and the reactants are equimolar. 
Conditions Ymax theoretical (eqn. 6) Ymax control experiment Ymax reactive crystallization 
n0 = 120 mM 0.449 0.451 0.486 
n0 = 240 mM 0.540 0.500 0.665 
 
Aside from the limits of reactant solubility at lower pH value, operating below 
neutral conditions seems to be highly favorable.  However, there is a tradeoff with 
productivity as the pH value decreases.  The activity of the enzyme, towards both synthesis 
and hydrolysis, decreases considerably below pH value 5.5.  Figure 3.10 shows that the 
productivity has a maximum around pH value 6.5.  This is the consequence of not tolerating 
phenylglycine supersaturation to guarantee product purity.  We have defined the 
characteristic time for the productivity as the time until phenylglycine reaches saturation.  
Therefore, the optimal productivity balances the lower enzyme activity at low pH value 
with the lower selectivity at high pH value. As the plots in Figure 3.10 reveals, the model 
 54 
appears to underpredict the productivity of the homogeneous system.  One possible 
explanation is that the model in fact underpredicts the productivity (τ) of both systems, but 
only appears to underpredict the homogeneous system because in measuring the 
concentration of the reactive crystallization system a well-mixed, representative sample 
must be withdrawn for HPLC, and it is possible that crystals have settled despite mixing 
with a magnetic stir-bar.  The data appear to follow the same trend as the model; however, 
the large error bars prevent us from confirming this finding.  We can conclude that reactive 
crystallization slightly boosts the productivity at these reaction conditions.   
 
We have already shown that increasing reactant concentration can increase the 
synthesis to hydrolysis ratio. However, there is also evidence that increasing the reactant 
concentrations will increase the benefit of reactive crystallization since increasing the 
concentrations speeds-up the reaction but leaves solubility unchanged. This results in the 
same amount of ampicillin being subject to secondary hydrolysis regardless of initial 
Figure 3.10. Productivity of the reactive crystallization process is compared to 
the homogeneous reactor.  The solid lines represent model predictions.  The 































conditions. The effect of this can already be seen in Ymax. The benefit of increasing 
concentration of PGME and/or 6-APA is expected to be seen in both selectivity and 
productivity as well. 
3.4 Ampicillin summary 
 Reactive crystallization can be employed to increase the selectivity of ampicillin.  
The increased selectivity for ampicillin results from the decreased secondary hydrolysis of 
ampicillin because the enzyme cannot degrade the solid ampicillin.  Different enzymes also 
have different propensities for synthesis versus hydrolysis; Assemblase® from DSM-
Sinochem, compared to previous studies of PGA from E. coli, has greater 
PGME/Ampicillin affinity by approximately 70%, stronger nucleophile binding by 100%, 
and lower acyl-enzyme bound 6-APA hydrolysis by 60%.  Using Assemblase® for both 
reactive crystallization and homogeneous reaction, the selectivity is increased by 
approximately 50% in the reactive crystallization scheme over the conventional liquid-
phase-only reactor.  The yield with reactive crystallization is also improved by more than 
20% over the theoretical maximum that does not consider isolating the product from 
secondary hydrolysis. The productivity is also higher with reactive crystallization, although 
only by 10-20% at our reaction conditions. The selectivity is highest at initial pH value 6.0, 
the lowest pH value tested, however, the productivity peaks around initial pH value 6.5. 
The pH sensitive model, regressed only with initial rate data, is capable of accurately 
predicting concentration profiles for non-pH-stat batch reactions at any degree of 
conversion. By separating the reaction into a solid and dissolved phase the model also 
accurately predicts the behavior of reactive crystallization of ampicillin, including the 
increase in selectivity. The pH value is shown to influence the activity of the enzyme as 
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well as the binding of the β-lactam 6-APA to the acyl-enzyme complex. Our model predicts 
and the experiments confirm that reactive crystallization presents a more efficient means 
than reaction in liquid-phase-only to produce ampicillin and possibly other β-lactams. 
3.5 Other beta-lactams 
So far, this chapter has focused on elucidating the mechanisms of PGA and the 
interplay of the enzyme-catalyzed reaction with the sequestration of ampicillin in the solid 
phase. Parameters to model the reaction were determined for the ampicillin system. Later 
the same parameters were determined for cephalexin by the same techniques, and for 
amoxicillin by analyzing published data with this new model. Figure 3.11 shows the 
inhibition of cephalexin hydrolysis by 7-ADCA, in the same fashion as Figure 3.4 showed 
ampicillin hydrolysis inhibited by 6-APA. Comparing the two figures shows that this 
variant of PGA has a stronger affinity for 7-ADCA than 6-APA, as the reaction is arrested 
more by 7-ADCA than 6-APA. Using the same techniques as described for ampicillin the 
α, β0, and γ grouped parameters were determined for cephalexin and are reported alongside 
those for ampicillin in Table 3.2. 
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Figure 3.11. The initial rate of cephalexin hydrolysis at different initial antibiotic concentrations and 
7-ADCA concentrations. 
For amoxicillin, sufficient published synthesis data exist for Assemblase® to 
determine parameter values. It helps that amoxicillin and ampicillin use the same 
nucleophile, 6-APA, and therefore have considerable overlap in their respective parameter 




CHAPTER 4. KINETICS OF CEPHALEXIN 
CRYSTALLIZATION WITH CO-SOLUTES3 
4.1 Introduction 
Scale-up of end-to-end CM in the pharmaceutical industry requires detailed 
knowledge of the mechanism and kinetics of each phenomenon in the process.  
Crystallization has been used to purify the active pharmaceutical ingredient (API) in most 
published end-to-end CM studies.9, 12, 21, 97, 98 So far, published end-to-end CM 
crystallization studies have been at the lab scale, where space-time yield is a low priority. 
Sustainable production of large-scale APIs such as amoxicillin and cephalexin requires 
optimization of space-time yield while maintaining product attributes such as crystal size 
and shape, which necessitates comprehensive understanding of crystallization kinetics. 
Cephalexin crystallization kinetics were determined before amoxicillin, as cephalexin 
enzymatic reactive crystallization is especially challenging due to the potential for 
phenylglycine precipitation. Amoxicillin on the other hand does not have to be as 
exactingly optimized, as 4-hydroxy phenylglycine is unlikely to contaminate the product, 
and therefore estimates of the crystallization kinetics, based on similar molecules, should 
be sufficient for the CM pilot plant.89, 99 While there are few data on cephalexin 
crystallization in the literature, studies published on similar β-lactams, such as ampicillin, 
 
3 Adapted with permission from “McDonald, M.A.; Marshall, G.D.; Bommarius, A.S.; Grover, M.A.; 
Rousseau, R.W. Crystallization Kinetics of Cephalexin Monohydrate in the Presence of Cephalexin 
Precursors. Crystal Growth & Design 2019, 19, 5065-5074.” Copyright 2019 American Chemical Society. 
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have focused on kinetics in pure systems that do not reflect the purification needed in real 
crystallization processes.88, 89 
Crystallization kinetics depend on the presence of other species as well as the process 
conditions.100-102  To address this issue, in this study cephalexin monohydrate is crystallized 
in the presence of two other species found in the enzymatic synthesis of cephalexin: the 
reactants 7-aminodesacetoxycephalosporanic acid (7-ADCA) and D-phenylglycine methyl 
ester (PGME).21, 32, 63 Based on the chemistry of cephalexin, 7-ADCA, and PGME, this 
research provides insights into the mechanism of crystallization and the incorporation of 
impurities. The mechanistic understanding of crystal growth inhibition could simplify the 
evaluation of other co-solutes on the crystallization of cephalexin or other β-lactam 
antibiotics. Online process analytical technologies (PAT) are employed to monitor and help 
determine crystallization kinetics.89, 103, 104  Use of extensive PAT in a batch experiment 
can simplify the translation of PAT tools to a continuous process.105, 106 Additionally, the 
impact of mixing intensity is explored to inform decisions on how a continuous operation 
could be implemented.  
4.2 Materials and Methods 
4.2.1 Nucleation and growth of crystals 
Experiments began with 75 mL of deionized water in a Mettler-Toledo OptiMax 
1001 workstation with a 250-mL capacity vessel (inner diameter 62 mm, liquid height 
approximately 45 mm) controlled to 25.0 °C. A 40-mm diameter, 9.0 mm high, 4-blade 
stainless-steel impeller with blades inclined at 45° was suspended 8 mm above the reactor 
bottom. A temperature probe, pH meter, Mettler-Toledo G400 focused beam reflectance 
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measurement (FBRM) probe, and Mettler-Toledo ReactIR iC10 attenuated total 
reflectance Fourier transform infrared (ATR-FTIR) probe, created significant baffles in the 
reactor and recorded their respective measurements. The stir rate was varied from 200 to 
800 rpm, resulting in Reynolds numbers, Re, ranging from 5,000 to 21,000. Background 
spectra of water were collected for 10 minutes, then the non-crystallizing co-solutes, either 
7-ADCA (TCI America, Portland OR) or PGME (Sigma-Aldrich, St. Louis MO), were 
added at the desired concentration and dissolved, and a second background was collected 
for 10 minutes. Cephalexin monohydrate (TCI America, Portland OR) was dissolved in 
known increments, to create a new ATR-FTIR concentration calibration curve at the start 
of each experiment. The solubility of cephalexin, a zwitterion, depends on pH; sodium 
hydroxide (Sigma-Aldrich, St. Louis MO) was used to adjust the pH to 7.6±0.2 to dissolve 
the cephalexin. Complete dissolution was verified online with FBRM. Supersaturation was 
generated by adjusting the pH by dosing 2 M hydrochloric acid (Ricca Chemical, Arlington 
TX) at a rate of 0.3 pH units per minute with a Mettler-Toledo SP-50 Dosing Unit. 
Crystallization occurred under isothermal and constant volume conditions (primary 
nucleation occurred after addition of acid) and was observed for 2-6 hours, depending on 
the primary nucleation induction time (which is stochastic).  
4.2.2 Process analytical technology 
Infrared spectroscopy data were used to measure the concentration of cephalexin 
present in solution during the experiment. The difference in peak height between 1369 cm-
1 and 1305 cm-1 (see supplemental Figure S1 for cephalexin IR spectrum) was found to 
correlate linearly with the dissolved cephalexin concentration, as shown in Figure 4.1. This 
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concentration measurement was independent of the PGME and 7-ADCA concentration 
after applying a baseline correction to remove the co-solute spectrum. 
 
Figure 4.1. (Left) Calibration of cephalexin solute concentration with ATR-FTIR. The difference in 
IR intensity between the 1369 cm-1 and 1305 cm-1 is correlated with the molar concentration.  Points 
represent measurements and the shaded region shows the 95% prediction interval based on the 
linear best fit. 
FBRM data were used to measure crystal chord counts per second (‘counts’) and 
crystal chord length distributions (CLDs). In contrast to the robust concentration 
measurements, see Figure 4.1, previous studies have found counts and CLDs to be 
qualitative, which makes them useful for detecting nucleation and observing trends in 
suspension density but ill-suited to determining a true crystal size distribution (CSD).107, 
108 To determine the efficacy of FBRM for this system, a simulated crystallization 
experiment was used to map crystal counts to the number density of crystals in 
suspension.109, 110 The details of the simulated crystallization are as follows; a suspension 
of crystals produced by the method previously described was incrementally added to a 
saturated solution of cephalexin and the resulting increase in FBRM counts was observed. 
The counts and suspension density do not linearly correlate, the counts saturate as the 
suspension density increases (see Figure 4.2, left). This observation has previously been 
termed the snowstorm effect where a flurry of small particles obscures the FBRM from 
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accurately sampling the crystal population. The rapid onset of the snowstorm effect at low 
weight fraction of solids was likely due to the needle-like morphology and small average 
size of the cephalexin crystals. A linear approximation of the count-suspension density 
relationship could be made below approximately 40,000 counts (2 g/L, approximately 10% 
of the final suspension density), where each count per second corresponded to 
approximately 1.5 ± 0.2 million crystals per liter. The FBRM was only used qualitatively 
because increases in crystallization extent did not result in significant increases in counts. 
The number density of crystals in suspension was estimated by image analysis with a 
hemocytometer counting chamber, Figure 4.2, right.  
 
Figure 4.2. (Left) The number of crystals in suspension, as measured by extent of crystallization 
(bottom axis) and offline microscopy (top axis), was correlated with the number of chord counts 
observed online by FBRM.  The FBRM counts were fit with a hyperbolic trend (solid curve) and 
initial linear trend (dashed line). Note the break in the axis for the final measured point. (Right) A 
1/100 slurry dilution (in saturated solution) is shown. The area inside the red square has a volume of 
6.25 nL and contains 51 crystals (counting those on the left and top borders but discounting those on 
the right and bottom borders). Using several images and randomly sampling different squares in the 
same image the total number density was determined to be 890 ± 89 billion crystals per liter for this 
sample.  This image was sampled from the end of a batch of cephalexin with no co-solute and an 
initial supersaturation of 2.56. 
 The solids were best characterized by offline microscopy, using image analysis to 
directly measure a CSD. At the end of each experiment, samples of the suspension were 
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diluted in saturated cephalexin solution at the same pH and temperature and several 
microscope images were collected, giving the dimensions of thousands of individual 
crystals. A counting chamber with demarcated volumes was used to estimate the number 
suspension density, see Figure 4.2 for details. Image processing for CSD construction was 
conducted in MATLAB; Figure 4.3 shows an optical micrograph (left) and processed 
image (right). Objects with an aspect ratio greater than 3.5 (shown in green) were counted 
as single crystals and used to construct a number based CSD. Objects with an aspect ratio 
less than 3.5 (red) were assumed to be overlapping or clumped crystals and were therefore 
excluded from the CSD; individual crystals with an aspect ratio less than 3.5 may exist but 
must have formed by breaking of a larger crystal, a phenomenon not considered in this 
study. Objects on the border of the frame (blue) were discounted because their true size is 
unknown.  
 
Figure 4.3. An optical micrograph of product cephalexin crystals (left) and the result of processing 
that image (right). Counted crystals in green, discounted overlapping crystals in red, and discounted 
cutoff crystals in blue. 
 High performance liquid chromatography (HPLC) was used to analyze samples 
offline. A gradient of 10 mM pH 7 sodium phosphate buffer and acetonitrile, starting at 
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100:0 buffer: acetonitrile and linearly decreasing to 40:60 buffer: acetonitrile over 10 
minutes baseline separated 7-ADCA, cephalexin, and PGME in a 150 mm C18 reverse 
phase column.  
4.2.3 Computational methods 
The rate of primary nucleation was determined independent of secondary 
nucleation and growth. Being a stochastic process, primary nucleation was assumed to 
follow a Poisson distribution111, where the rate of primary nucleation, J, was determined 
from the induction time distribution, F (equation 4.1). Here F is the cumulative fraction of 
experiments where primary nucleation occurred, V is the system volume, t is the induction 
time (time at which a crystal is detected), and tG is the time required for a crystal nucleus 
to grow to a detectable size.112 
 ( )1 exp GF JV t t= − − −    (4.1) 
The primary nucleation rate, J, depends on the supersaturation, *S c c= , 
according to equation 4.2, with a rate constant, kJ.  The Bo term is related to the energy 










   (4.2) 
After the induction time had elapsed the concentration was fit to a one-dimensional 
population balance model (PBM), shown in Equation 4.3, where n is the crystal population 
as a function of length, L, and time, t. The PBM was solved with the method of moments 
defined in equations 4.4 and 4.5, where μi is the ith moment of the population, n.21 Crystal 
growth (G, equation 4.6) was assumed to be independent of size and unaffected by growth-
rate dispersion. Dependence of growth rate on supersaturation was assumed to follow a 
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power law where the exponent, g, was constrained to be between 1 and 2, in accordance 
with the crystal growth theory of Burton, Frank and Cabrera.113  Secondary nucleation (B, 
equation 4.7) was modeled as a power law with respect to the growth rate, suspension 
density (MT), and specific power input divided by kinematic viscosity (ε/ν); b, m, and p are 
the exponents on the growth, suspension density, and power input terms, respectively. A 
solute balance constructed within the method of moments framework and defined by 
equation 4.8 was used to couple cephalexin solute concentration and crystal growth.  
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The kinetic parameters were constrained to give physically meaningful values, 
summarized in Table 4.1. 
Table 4.1. Parameter bounds used in constrained parameter fitting. 
Parameter Symbol Lower bound Upper bound 
Growth rate pre-exponential kG 0 ∞ 
Growth rate exponent g 1 2 
Secondary nucleation pre-exponential kB 0 ∞ 
Secondary nucleation exponent b 0 1 
Suspension density exponent m 0 2 
Mixing power exponent p 0 2 
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At the end of the crystallization, samples of the product crystals were taken and 
analyzed under a microscope. The number based CSD measured via image analysis was 















  (4.9) 
with parameters m  and σ. 
Figure 4.4 shows the CSD calculated from the image in Figure 4.3. The gamma 
distribution114 and Weibull distribution115 were also investigated, however, the lognormal 
distribution provided the best fit (the residual sum of squares, RSS, was smallest for the 
lognormal, the values computed for the data in Figure 4.4 were RSSlognormal = 6.6, RSSgamma 
= 18.9, RSSWeibull = 53.2). For determination of kinetic parameters, data from dozens of 
images were combined to produce a more robust CSD. The moments of the CSD were 
approximated from the lognormal distribution by the following equation. 
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Figure 4.4. The number based CSD calculated from Figure 4.3. The CSD histogram was fit to a 
lognormal distribution (green solid curve), gamma distribution (pink dashed curve), and Weibull 
distribution (brown dotted curve). 
The RSS was computed with Equation 4.11 where Nμ is the number of moments 
and Ny is the number of concentration measurements. The moments of the CSD, μi, were 
calculated from the lognormal fit of the CSD, and were compared to the moments fit with 
equations 4.4 and 4.5, ˆ i .  The measured concentration, yj, was compared to the fit 
concentration ŷj. The logarithm rectified the difference in scale between moments and 
concentration.116 Fitting the CSD moments simultaneously with the concentration 
information, by minimizing RSS with the MATLAB function fmincon, proved to be more 
effective than using the FBRM counts in determining kinetic parameters.107 
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4.3 Results and Discussion 
4.3.1 Cephalexin monohydrate solubility 
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Solubility as a function of pH must be determined to develop a model of the 
nucleation and growth kinetics and the effects of additional solutes on crystallization. 
Figure 4.5 presents data showing the solubility, defined in this study as moles of cephalexin 
per liter of solution, over the pH range for which cephalexin is anionic and zwitterionic. 
Since enzymatic cephalexin synthesis is adversely affected by a low pH, solubility at more 
acidic pH conditions was not examined; nevertheless, the solubility is expected to increase 
as the solute takes on a positive charge. The solubility is a minimum at the isoelectric point, 
pI, and increases with increasing pH in proportion with the amount of anionic cephalexin, 
according to equation 4.12.91 The minimum solubility does not depend strongly on 
temperature, but the pKa is a function of temperature leading to a solubility-temperature 
relationship captured empirically by equation 4.13.117 










  (4.12) 
 14.6 1703 0.018apK T T= − −    (4.13) 
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Figure 4.5. Solubility of cephalexin, in moles of cephalexin per liter of solution, as a function of pH at 
5.0 °C (blue) and 25.0 °C (red) with 95% confidence regions based on fitting the data to Equations 
4.12 and 4.13. 
The solubilities in Figure 4.5 were obtained by crystallizing cephalexin as described 
in the methods, and then adding base to increase the pH and dissolve the product crystals. 
Once equilibrated (indicated by stable FBRM counts, temperature, and pH), the 
concentration was measured with ATR-FTIR. Dissolving the cephalexin as received by 
adding base in a controlled fashion produced an ATR-FTIR concentration curve that 
appeared to show solubility decreasing as the pH increased; however, decreasing FBRM 
counts showed that the crystals were in fact dissolving. As shown in Figure 4.6, powder x-
ray diffraction (PXRD) confirmed that both the cephalexin as received and as crystallized 
are the same crystal form. The hydrophobic nature of the crystals, and their resulting 
tendency to collect at air-water interfaces, could explain the discrepancy between ATR-
FTIR and FBRM data. The cephalexin as received initially adhered to the dry ATR-FTIR 
probe window, giving anomalous concentration measurements, while cephalexin 
crystallized in-situ did not adhere to or nucleate on the submerged probe. 
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Interestingly, 7-ADCA did nucleate on the ATR-FTIR probe window, which placed 
an upper bound on the 7-ADCA co-solute concentration. The solubility of 7-ADCA is also 
a function of pH and, at 50 mM and above, it crystallized concurrently with cephalexin. 
PXRD showed that crystals produced with 50 mM 7-ADCA had the same pattern as 
cephalexin but with two additional broad peaks at 6° and 13° corresponding to crystalline 
7-ADCA. The peaks in the pattern did not shift, which suggested that the cephalexin did 
not contain a stoichiometric amount of 7-ADCA (i.e. formed a different crystal phase) but 
may have contained trace 7-ADCA impurities. The breadth of two 7-ADCA peaks could 
indicate the solid 7-ADCA phase has poor crystallinity or is present in small quantities. 
The simplest interpretation of these data is a physical mixture of two distinct solid phases; 
the desired cephalexin monohydrate and 7-ADCA.  The solubility of PGME is at least two 
orders of magnitude greater than cephalexin or 7-ADCA and therefore it did not appear in 
the solids analyzed by PXRD. 
 
Figure 4.6. PXRD patterns for cephalexin as received (blue), crystallized without a co-solute (red), 
with PGME co-solute (yellow), with 7-ADCA co-solute (green), and PXRD pattern of 7-ADCA 
(purple).  
4.3.2 Primary nucleation kinetics 
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Figure 4.7 shows the course of a typical experiment, which was comprised of three 
stages: the preparation stage (before time zero), the primary nucleation stage (from zero to 
the time at which crystals were detected by the FBRM), and the growth and secondary 
nucleation stage (after the detection time). During the preparation stage the solution was 
undersaturated and the FBRM confirmed a clear solution. The zero time point, t = 0, was 
the time at which the solution becomes saturated by the addition of acid. The primary 
nucleation phase began at t = 0 and continued until an inflection in the FBRM counts, 
shown in the inset in Figure 4.7, indicated that nucleation had occurred. Prior to nucleation, 
the FBRM counts were steady around zero; after nucleation detection, counts rapidly 
increased, followed after several minutes by a significant drop in supersaturation (as 
measured by ATR-FTIR).  Shortly after nucleation detection, the counts saturated and 




Figure 4.7. An example of pH trend (green dashed curve), saturation (blue dotted curve), and counts 
(red solid curve) during a typical batch cephalexin crystallization experiment. The inset shows 
FBRM nucleation detection in detail. 
The primary nucleation detection time was independently measured 47 times, 
divided into three sets of experiments with different supersaturation: S = 1.98 (nexp = 13), 
S = 2.27 (nexp = 11), and S = 2.56 (nexp = 23) where *S c c= .118 All primary nucleation 
experiments were conducted at 25 °C. Crystallization of cephalexin in the presence of 7-
ADCA and PGME was conducted at a cephalexin supersaturation of S = 2.56, leading to a 
larger set for S = 2.56.  The detection times at each supersaturation were sorted to create a 
cumulative distribution function and were fit to a Poisson distribution, from which the 
nucleation rate, J, at that value of S could be determined using equation 4.1. The time for 
a nucleus to grow to a detectable size, tG, was fit simultaneously with J. Figure 4.8 shows 
the detection times for cephalexin crystallization without a co-solute (●) and cephalexin 
crystallization with 7-ADCA and PGME co-solutes (×). The fit to the Poisson distribution 
did not include experiments with co-solutes present. However, a Kolmogorov-Smirnov test 
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failed to reject the null hypothesis that the detection time distributions with and without the 
co-solute experiments sampled different underlying phenomena at the 95% confidence 
level. This finding, made visual by the fact that the detection times with co-solute were 
well interspersed within the pure cephalexin detection times in Figure 4.8, led to the 
conclusion that the co-solutes did not impact primary nucleation.  
 
Figure 4.8. Experimental cumulative distribution functions of stochastic detection times, F, at three 
supersaturations: S = 1.98 (in red), S = 2.27 (in yellow), and S = 2.56 (in blue), were fit to Poisson 
distributions (curves) according to equation 4.1. The black points are experiments without a co-solute 
(squares S = 1.98, diamonds S = 2.27, and circles S = 2.56) and the red ×’s represent experiments with 
a co-solute (S = 2.56). The shaded regions are the 95% confidence regions based on the fit to equation 
4.1. 
The nucleation rates from Figure 4.8 were used to determine the primary nucleation 
prefactor (kJ) and exponential (Bo) by fitting the rates to equation 4.2. The exponential 
factor (Bo) is related to the energy required to create the new particle surface (γ) and the 
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The molecular volume is v = 4.32×10-28 m3, computed from the density (1.403 g/cm3)119 
and molecular weight (365.4 g/mol) of cephalexin monohydrate. The value of the energy 
required to create new surface area (determined from the value of Bo) can lend insight into 
growth and inhibition mechanisms (see below). Bootstrapping was used to construct 
confidence intervals from the small experimental sample set (nexp = 38, with three different 
values of S); four experiments were randomly sampled at each supersaturation, and 
equation 4.2 was refit 200 times. Based on this analysis, the value of kJ (with 95% 
confidence interval) is 2.54 (1.39 9.00) and the value of Bo is 1.79 (1.28 2.88). The 
confidence intervals are asymmetric because the data are not normally distributed, instead 
the confidence interval was bound by the 2.5th and 97.5th percentiles (corresponding to α = 
0.05) of the bootstrap values of kJ and Bo, see Figure 4.9.120 Based on this analysis, a 
cephalexin monohydrate nucleus has surface energy of γ = 3.41 (3.05 4.00) mJ/m2 which 
indicates heterogeneous primary nucleation (i.e. on the crystallizer surface).121  
 
Figure 4.9. Bootstrapping was used to determine the primary nucleation parameters. In this figure 
the parameters that gave the best fit to equation 4.2 (for data randomly generated by taking four 
samples from each of three data sets at different supersaturation values) are sorted and plotted for 
200 bootstrap trials. The confidence interval lies between the 2.5th and 97.5th percentile. 
4.3.3 Secondary nucleation and mixing 
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Secondary nucleation, unlike primary nucleation, is assumed to be a deterministic 
phenomenon that can be empirically modeled with the power law in equation 4.7. The 
suspension density is related to the third moment of the crystal size distribution by equation 
4.15, with crystal density ρc and crystal volume shape factor kV, or can be calculated with 
a material balance for a batch crystallization, with molecular weight MW = 365.4 g/mol, to 
avoid the need to determine a value for the shape factor.  
 ( )3 0T c V WM k M c c = = −   (4.15) 
The specific power input, the (ε/ν) term in equation 4.7, can be estimated from the 
Power Number (NP), the slurry density (ρs), impeller rotational velocity (ω), diameter (D), 
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The Power Number for a 45° pitched four-bladed impeller in this reactor geometry 
and range of rotational velocities is 1.74.122 The values of m and p, the exponents on the 
suspension density term and specific power input term in equation 4.7, respectively, are 
related to the source of secondary nuclei: m = 1 implies secondary nucleation is 
predominately the result of crystal-impeller collisions or fluid shearing while m = 2 implies 
crystal-crystal collisions are most important. When m = 1, a value of p = 1 indicates crystal-
impeller collisions contribute most to secondary nucleation while p = 2 indicates inertial 
eddies shear nuclei from existing crystals.123 The stir rate was to be varied to determine the 
principal mechanism by which cephalexin secondary nuclei are bred, informing scale-up 
and adaptation to different reactor geometries, as well as strategies to manipulate the CSD. 
However, as will be discussed later, unique properties of cephalexin monohydrate 
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prevented investigation of a wide enough range of stir rates to determine the mechanism of 
crystal breeding. 
Figure 4.10 is an optical photomicrograph of cephalexin monohydrate crystallized 
with 7-ADCA as a co-solute. It shows a population of cephalexin monohydrate crystals, 
all of which have a needle-like aspect ratio, but three have exceedingly high aspect ratios. 
A reasonable explanation for their size is they were formed from primary nucleation and, 
therefore, had significantly more time at an elevated supersaturation than those formed 
later in the process. Another hypothesis is that crystal breakage may play a role in reducing 
the population of large crystals; it is rational to assume that needle-like crystals are prone 
to breakage and that exceedingly long crystals should break more readily.52 This image, 
along with the fit values for the primary and secondary nucleation rates aligned with 
previous findings that secondary nucleation breeds several orders of magnitude more 
crystals than primary nucleation (Figure 4.10 right).107   
 
Figure 4.10. An optical micrograph of cephalexin monohydrate crystals formed in the presence of 7-
ADCA co-solute (left) and a comparison of the number of nuclei created by primary nucleation and 
secondary nucleation based on fit parameters (right). 
In the present work, secondary nucleation kinetics could be accurately determined 
only over a narrow range of stirrer speeds. At low rpm, crystals formed on probe surfaces 
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and then grew into the less turbulent regions surrounding the probe/baffle, creating a dead 
(poorly mixed) zone. The zone spread until only the region in immediate contact with the 
impeller was being mixed. The dead zones were detected by anomalous FBRM readings 
(see Figure 4.11) and were confirmed visually and with a tracer experiment that showed 
reduced volume. At high stir rates, the crystallizer also exhibited poor mixing due to the 
formation of stable foam on top of the slurry. These two phenomena limited the range of 
stir rates where crystallization kinetics could be precisely observed to the yellow region in 
Figure 4.12. 
 
Figure 4.11. Three examples of anomalous FRBR readings suggesting that a dead zone had formed in 
front of the FBRM probe window at (from left to right) 140 minutes, 70 minutes, and 100 minutes. In 
all experiments, the counts followed an s-shape curve in time, eventually saturating when the 
snowstorm effect prevents the FBRM from detecting all crystals. In the experiments where a dead 
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zone formed, the counts rapidly drop, suggesting crystals had stopped moving in front of the probe 
window. 
 
Figure 4.12. A mixing diagram for the crystallizer geometry used to determine cephalexin 
crystallization kinetics.  Experiments marked with an open circle (○) were well mixed and were used 
to fit the kinetic model. Experiments marked with a cross (×) showed poor mixing and experiments 
marked with a plus (+) showed significant foaming. 
In Figure 4.12, the boundary between the poorly mixed (orange) and well mixed 
(yellow) regions was linearly regressed with the cross (×) points; the boundary compares 
favorably with the theoretical boundary based on transition to turbulent flow as determined 
by the measured (solid red line) and extrapolated (dashed red line) Reynolds Number, Re, 






=   (4.17) 
At suspension densities as low as 1.5%, crystallization in a quiescent vessel led to 
a “sherbet-like” slurry that would not flow under force of gravity. Similar non-flowability 
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is observed in the non-mixed regions in low-rpm experiments. The non-flowability can be 
explained through the lens of yield stress; below a critical mixing intensity the slurry 
behaves as a solid, however above a certain stress the material yields and flows as a slurry. 
Formation of dead zones is a function of both rpm and solids concentration. Dead zones, 
where the stress due to mixing is below the yield stress, may be expected when the 
Reynolds number indicates predominately laminar flow (Re < 3,000);124 however, the red 
line in Figure 4.12 shows the observed sherbet behavior occurred at Reynolds numbers 
greater than 3,000. The density used in equation 4.17 was calculated with the known solids 
fraction, using a measured liquid density of 1.005 g/mL for a saturated solution at pH 4.5 
and a solid density of 1.403 g/mL. The viscosity was measured with a capillary viscometer, 
which was not practical for solids fraction greater than 1%. Measuring the viscosity of 
suspensions is difficult; the measured viscosity is an estimate useful for qualitative 
interpretation of the mixing results. A linear relation between solids fraction and viscosity 
was measured (kinematic viscosity, 43 94TM = + , measured in St and g/L) and used to 
construct the solid portion of the red line in Figure 4.12 and then extrapolated to higher 
solids fractions (dashed red line). Dead zones were accompanied by a decrease in the 
observed rate of desupersaturation, and experiments showing poor mixing behavior were 
excluded from the parameter fitting routine. 
The boundary of the foaming (blue) region is the convex hull of the experiments 
that generated foam, with the zero suspension density point being determined with the 
Froude number, Fr. The foam generated at high stirrer speeds consisted of air bubbles and 
entrained mother liquor stabilized by the needle-shaped crystals.  Engineered needle-
shaped particles have been used to stabilize surfactant foams,125 and the presence of the 
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crystals in the cephalexin system is critical to the foam stability.  Foaming was only 
observed once crystallization began, and foam accumulated and did not collapse when 
mixing ceased; FBRM results showed a reduction in counts of nearly 30% which 
qualitatively indicated a significant amount of solids was sequestered in the foam, see 
Figure 4.13. The Froude number indicates formation of aerating surface vortices when Fr 
is of order unity; in Figure 4.12, Fr = 1 is indicated at ω = 930, however the real transition 
is less well-defined than the abrupt change at ω = 930. Fr, defined in equation 4.18 (where 
gr is the acceleration due to gravity), predicted significant aeration at greater than 900 rpm, 
however Figure 4.12 shows significant foaming occurred at stir rates as low as 650 rpm 
(blue region). Foam forming experiments were also excluded in the parameter fitting 






=   (4.18)  
 
Figure 4.13. The stir rate (blue) was increased from 400 to 900 RPM for 5 minutes to generate a 
stable foam. The counts measured by FBRM (red) decreased during foam generation and did not 
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return after the stir rate was dropped back to 400 RPM, indicating crystals had been permanently 
sequestered in the foam. 
 Equation 4.7 assumes a power law relationship between stirring energy input ε and 
secondary nucleation rate, B, hence the need to examine a range of stirring rpm. Within the 
narrow range of well-mixed ω there was no obvious correlation between ε (as calculated 
with equation 4.16) and B. Therefore, the stir power input exponent, p, was set to zero to 
avoid overfitting the limited data. All further experiments were conducted at 400 rpm for 
consistency.  
With p = 0 and no co-solute present, the secondary nucleation rate and growth rate 
were simultaneously fit (see the next section for discussion of growth rate). The secondary 
nucleation prefactor, kB, had a value 2.98 × 105 min-1 L-1 (95% C.I: 1.01 × 105 4.95 × 105). 
The secondary nucleation exponent, b, had a fit value of 0.99, which was not statistically 
different from b = 1. Since there is a theoretical justification for b to be unity,123 b was set 
to 1 and a confidence interval was not calculated. The suspension density exponent, m, was 
found to be 0.46 (0.30 0.62). A value of m < 1 suggests secondary nuclei form from crystal-
impeller collisions, but not all crystals breed nuclei upon impeller impact; perhaps only 
crystals of a certain size breed secondary nuclei in such events.  
Since secondary nucleation is defined in terms of the growth rate (see equation 4.7), 
the effect of co-solutes on secondary nucleation was mathematically captured by the effect 
of co-solutes on growth rate, which are discussed in the next section. That the growth rate 
equation completely captured the co-solute dependence may indicate that secondary 
nucleation occurs by attrition of larger crystals,126 however these data are too sparse to 
exclude other, less pronounced, effects of co-solutes on secondary nucleation, e.g. surface 
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nucleation.127 In any case, the functional dependence of secondary nucleation and growth 
on supersaturation is empirical and appears to be the same.  
In Figure 4.14 (left), the CSD is shown for pure cephalexin, with PGME (30 mM) 
as co-solute, and with 7-ADCA (30 mM) as co-solute. A Kolmogorov-Smirnov test (which 
is agnostic to the underlying distribution) failed to reject the null hypothesis that the 
measured CSD for pure cephalexin and measured CSD for PGME co-solute sampled 
different underlying distributions at the 95% confidence level.  However, as is apparent 
from the yellow bars at long crystal lengths in Figure 4.14 (left), a Kolmogorov-Smirnov 
test rejected the null hypothesis (at the 95% confidence level) that the pure CSD and 7-
ADCA co-solute CSD came from the same distribution. This result was repeated in several 
data sets. When fitting the experiments with 7-ADCA co-solute, the value of m (the 
suspension density exponent in equation 4.7) was consistently at the high end of the 
confidence interval determined for pure cephalexin monohydrate (0.30 0.62). Simulated 
experiments in silico showed that larger values of m result in wider spread CSDs. It is 
possible that the presence of 7-ADCA increased the sensitivity of secondary nucleation to 
the suspension density (i.e. increased m), however, there was no statistically significant 
difference between the values of m determined from fitting pure experiments and co-solute 
containing experiments. Therefore, it was concluded that co-solutes did not have a 
substantial impact on the kinetics of secondary nucleation (beyond the proportionality 
between B and G established in equation 4.7), especially when compared to the impact of 
co-solutes on the kinetics of crystal growth. 
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Figure 4.14. Left, the final CSD of cephalexin monohydrate without co-solute (blue), with 30 mM 
PGME co-solute (red), and 30 mM 7-ADCA co-solute (yellow). Right, the desupersaturation of 
cephalexin without co-solute (blue circle), with 30 mM PGME co-solute (red diamond), and 30 mM 
7-ADCA co-solute (yellow square). 
4.3.4 Growth kinetics 
The different co-solutes had different impacts on crystal growth. Having 
determined that the co-solute impact on nucleation was negligible compared to the impact 
on growth (these two phenomena were determined simultaneously while fitting 
crystallization experiments with the PBM), the decrease in desupersaturation rate observed 
in the presence of co-solutes, particularly 7-ADCA, was the result of growth inhibition by 
the co-solutes. Two models of growth inhibition were considered, a competitive model 
based on co-solute and solute competing for surface adsorption sites,128, 129 and a step-
pinning model based on adsorbed co-solutes impeding advancing growth steps.130 Both 
models captured the decreased rate of desupersaturation, however only the step-pinning 
model accounts for the observed incomplete desupersaturation seen in the presence of co-
solutes. In Figure 4.14 (right) the cephalexin supersaturation stopped decreasing at long 
times in the presence of PGME (red diamonds) or 7-ADCA (yellow squares), a behavior 










k S S S S S
G
S S
− − − 
= 

  (4.19) 
 In the step-pinning mechanism of crystal growth inhibition, a modified growth rate, 
defined in equation 4.19, is used when the supersaturation is above a critical 
supersaturation, Scr, and zero growth rate is used when the supersaturation is below Scr. The 
critical supersaturation prevents the solution from completely desupersaturating. Figure 
4.15 shows how the critical supersaturation increased as the concentration of each co-solute 
increased. 
 
Figure 4.15. The critical supersaturation, Scr, as a function of co-solute concentration. The lines are 
best fits of equation 4.20. The error bars are 95% confidence intervals. 
 The Langmuir adsorption isotherm was used to fit the dependence of the critical 
supersaturation on co-solute concentration because the step-pinning mechanism is based 
on co-solutes adsorbing onto the growing surface. The critical supersaturation depends on 
the energy required to create new cephalexin monohydrate surface, γ, the area of the growth 
unit, a, the average spacing between adsorption sites, l, the Langmuir equilibrium 
coefficient, K, and the concentration of co-solute, ccs according to equation 4.20. Using the 
value of γ calculated from primary nucleation and the fit of Scr in Figure 4.15, the ratio a l  
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evaluated to approximately 1 (fit value of 1.15) for 7-ADCA and 0.5 (fit value of 0.61) for 
PGME, suggesting that 7-ADCA adsorption sites and cephalexin monohydrate growth 
units are equally spaced but PGME adsorption sites are spaced over every two growth units. 
7-ADCA, containing both an acid and an amine group may be able to form hydrogen bonds 
with the cephalexin monohydrate crystal in two locations, while PGME, containing only 
an amine group, may only form a hydrogen bond with the growing crystal in one location. 
However this interpretation is not definite as there is substantial uncertainty surrounding 
the values of a l , especially for PGME where the fit to equation 4.20 is poor (see Figure 














  (4.20) 
The needle-like morphology causes a small crystal surface area (the faces on the 
ends) to account for the majority of desupersaturation. At high supersaturation, the strong 
adsorption of 7-ADCA onto the fast-growing faces suggests the possibility that 7-ADCA 
would be incorporated into the cephalexin monohydrate crystal; PGME on the other hand 
would not be expected to incorporate into the crystal to the same extent. PXRD did not 
show any peak shifts in the pattern for cephalexin crystallized with the 7-ADCA co-solute, 
indicating the 7-ADCA and cephalexin are not crystallizing together (as a co-crystal) in a 
distinct crystal lattice. HPLC analysis, shown in Figure 4.16, demonstrated that crystals 
produced with 7-ADCA co-solute contained 7-ADCA in proportion with the amount of 
initial 7-ADCA, even after washing with cold water. However, the amount of 7-ADCA 
was always less than 0.2% by weight of the final product after washing, indicating washed 
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crystals were of pharmaceutical quality. PGME was not detected in washed crystals 
produced with PGME co-solute. 
 
Figure 4.16. HPLC analysis of purity of unwashed (light hue) and washed (dark hue) cephalexin 
monohydrate crystals formed in the presence of a co-solute at different concentrations. The 50 mM 
7-ADCA point was excluded because 7-ADCA also crystallized giving a physical mixture of solid 7-
ADCA and cephalexin monohydrate (consisting of roughly 30% 7-ADCA). Washing consisted of 
suspending 250 mg of product cephalexin in 5 mL of cold water (<5 °C) and stirring for 15 minutes 
under chilled conditions. 
4.3.5 Discussion of continuous manufacturing 
All aspects of the design of an end-to-end CM process for cephalexin need to 
consider the crystallization kinetics of cephalexin monohydrate. The rate of primary 
nucleation is slow, even at considerable supersaturation, therefore the process should rely 
on secondary nucleation, either by recycling product crystals or using a well-mixed 
crystallizer. Secondary nucleation did not depend on the mixing intensity within the range 
of mixing intensities that were feasible for the studied crystallizer geometry. However, the 
stir rate was important because cephalexin monohydrate suspensions have a propensity to 
form poorly mixed “sherbets” with insufficient agitation and difficult-to-handle foams with 
excess agitation.  
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In the enzymatic synthesis of cephalexin, one of the parameters than can be used to 
optimize the process is the reactant concentration ratio of PGME and 7-ADCA.21 This work 
suggests that, from the viewpoint of crystallization, it is best to run the reaction lean in 7-
ADCA. Complete consumption of 7-ADCA in the reaction will lead to lower crystal 
growth inhibition, rendering more of the cephalexin recoverable (by crystallization) in a 
shorter time. A 7-ADCA lean process is further supported by the finding that 7-ADCA is 
more likely than PGME to incorporate into the cephalexin monohydrate crystal, albeit at 
part per thousand concentrations, and that 7-ADCA is more valuable than PGME. 
4.4 Conclusion 
The crystallization kinetics of cephalexin monohydrate are reported for the first time 
in an aqueous environment, summarized in Table 4.2, and the effect of co-solutes that 
would be found in the enzymatic synthesis of cephalexin were investigated. The solubility 
was determined over a range of pH values (4 to 8) and at two temperatures (5.0 °C and 
25.0 °C), crystallization kinetics were explored only at 25.0 °C. Primary nucleation of 
cephalexin monohydrate occurred slowly, even at high supersaturation (S > 2), and was not 
impacted by the presence of PGME or 7-ADCA co-solutes.  The secondary nucleation of 
cephalexin birthed many more crystals than primary nucleation (see Figure 4.10) and 
depended on the growth rate and suspension density, but did not appear to depend on the 
mixing power in the regime accessible in this crystallizer geometry. At low mixing 
intensity the needle-shaped crystals were prone to forming dead zones while at high mixing 
intensities the needle-shaped crystals stabilized the formation of difficult-to-handle foam. 
Table 4.2. Kinetic parameters for the crystallization of cephalexin monohydrate with 95% confidence 
interval. Confidence interval values marked “ns” indicate parameters that were not significantly 
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different from a theoretically justified value, therefore they have been fixed at the theoretically 
predicted value 
Parameter name symbol [units] Value Lower bound Upper bound 
Primary nucleation prefactor kJ [min-1 L-1] 2.54 1.39 9.00 
Primary nucleation exponential Bo 1.79 1.28 2.88 
Secondary nucleation prefactor kB [min-1 L-1] 2.98 × 105 1.01 × 105 4.95 × 105 
Secondary nucleation exponent b 1.0 ns ns 
Suspension density exponent m 0.46 0.30 0.62 
Mixing power exponent p 0 ns ns 
Growth prefactor kG [μm min-1] 6.52 5.16 7.43 
growth exponent g 2.0 ns ns 
 
 The crystal growth rate was inhibited by both co-solutes, though 7-ADCA was a 
more potent inhibitor. 7-ADCA inhibited cephalexin crystal growth by adsorbing onto the 
growing faces and impeding the advancement of growth steps. These results in aggregate 





CHAPTER 5. AMPICILLIN CRYSTAL GROWTH RATES AND 
GROWTH RATE DISPERSION MEASURED BY IMAGE 
ANALYSIS4 
5.1 Introduction 
In the previous chapter the crystallization kinetics of cephalexin monohydrate were 
determined in conditions that simulated the expected conditions in the CM reactive 
crystallization process. Supersaturation of cephalexin was generated by manipulating the 
pH value of the solution, whereas in the CM process supersaturation will be generated by 
the PGA-catalyzed synthesis reaction. In this chapter, using ampicillin as a model 
compound, the crystal growth kinetics were examined when supersaturation was generated 
by the PGA reaction. The results from the previous chapter informed analysis of the data 
gathered for this study. 
The experimental techniques used in this chapter also differ significantly from those 
used in the previous chapter. Here, individual crystals are observed growing, whereas in 
the study on cephalexin, crystal growth was inferred from measured changes in solution 
composition. One of the benefits of observing each crystal growing individually is the large 
amount of data collected enables examination of the distribution of crystal growth rates, 
referred to as growth rate dispersion (GRD). Previously only the mean growth rate was 
calculable. It should be noted that the original motivation for the experiments in this chapter 
 
4 Adapted from “McDonald, M.A.; Bommarius, A.S.; Grover, M.A.; Rousseau, R.W. Direct Observation of 
Growth Rate Dispersion in the Enzymatic Reactive Crystallization of Ampicillin. Processes 2019, 7, 390.” 
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was to estimate the specific surface area of a sample of crystals, however, the observed 
GRD made that difficult. The implications of GRD for a continuous process are significant, 
with the potential to create a product size distribution skewed heavily towards large 
crystals. 
Growth rate dispersion is a deviation from McCabe’s ΔL law which states that 
“geometrically similar crystals of the same material suspended in the same solution grow 
at the same rate”.131 Past research has yielded a number of distinct mechanisms that can 
lead to or explain GRD.132 One explanation is size dependent growth (SDG), whereby 
larger crystals grow faster. SDG has been proven to be a manifestation of GRD. The 
crystals with the faster growth rates grow to become larger, as opposed to the notion that 
crystals that are larger now grow faster.133 Another model states that crystals undergo 
random fluctuations (RF) in growth rate but all have the same time-average growth rate.134 
The constant crystal growth model states that nuclei are created with an intrinsic growth 
effectiveness based on surface features.135 Still other models contend that different rates of 
attrition of different sized crystals136 and different crystal faces explains GRD,137 surface 
charge distributions can cause GRD,138 or the presence of additives or adsorbing species 
can enhance or inhibit growth, leading to growth oscillations and GRD.139 In this study it 
is shown that GRD observed in ampicillin trihydrate is most easily explained by the 
constant crystal growth model and that surface morphology and crystal imperfections (such 
as dislocations) are likely the cause, although the influence of additives, in this case the 
ampicillin precursors 6-aminopenicillanic acid (6-APA) and D-phenylglycine methyl ester 
(PGME), may have an important influence. 
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In this study, the growth rates of individual ampicillin trihydrate crystals were 
measured by optical microscopy as ampicillin was generated by the PGA-catalyzed 
condensation of 6-APA and PGME. The PGA-catalyzed generation of supersaturation 
enabled precise control over the supersaturation of ampicillin.41 The catalyst and reactants 
were homogenous and the reactants were initially present, eliminating mass transfer effects 
and inhomogeneity that complicate the analysis of reactive crystallizations and anti-solvent 
crystallizations involving the volumetric addition of different species.140, 141 The entire 
experiment was isothermal, eliminating the heat transfer and subsequent inhomogeneity 
that complicate analysis of cooling crystallization.111, 142 The control over supersaturation 
also obviated the need for complex flow apparatuses used to maintain a supersaturation set 
point in other single crystal growth experiments.135, 143 One recent study used simulation to 
look at GRD with these simplified conditions (homogeneous, isothermal, non-nucleating 
batch);144 here a unique experimental system enables probing GRD experimentally with 
these simplifications. Rather than reconstruct the growth rate distribution from crystal size 
distributions (CSDs), which requires assumptions about the form of the distribution,145, 146 
the growth rate distribution in the present work is observed directly, enabling simple 
determination of the mechanism of GRD. Up to ~100 crystals can be analyzed in a single 
small-volume experiment (<20 microliters) requiring only a microscope and camera. 
5.2 Materials and Methods  
Seed crystals were prepared as follows. Ampicillin trihydrate crystals were formed 
at room temperature by dissolving ampicillin sodium salt (>99%, Fischer Scientific, Geel, 
Belgium) and neutralized by adding concentrated hydrochloric acid. All seed crystals were 
grown in the same batch, which was unseeded. Crystals were sieved and the 212- to 300-
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μm fraction was used as seed crystals. Breakage occurred during sieving and most of the 
seed crystals were smaller than 212 μm, demonstrating the difficulty in sieving needle 
shaped crystals (their small cross section allows them to slip through the sieve despite 
having a long characteristic size). Seeding sometimes connotes addition of a small amount 
of crystals to breed a large population of crystals via secondary nucleation; since nucleation 
is suppressed in this study, the seed crystals are from here on referred to as initial crystals.  
Field emission scanning electron micrographs of the initial crystals (Figure 5.1) were 
obtained using a Zeiss Ultra-60 FE-SEM with an accelerating voltage of 3 kV using the 
high vacuum mode at room temperature. Samples were gold-sputtered for 30 seconds using 
















Figure 5.1. FE-SEM images of ampicillin trihydrate initial crystals. The scale bar is 30 μm in (a) and 
2 μm in (b)-(f). Image (a) shows uniformity of initial crystals, (b) shows a fracture and splinter of an 
initial crystal, (c) and (d) show epitaxial growth and possibly twinning, (e) and (f) show ends of initial 
crystals. In (e) the end has several visible growth hillocks stemming from screw dislocations, in (f) 
two ends are shown, one pristine pointed end with few growth steps, the other a clean break. 
Growth experiments were prepared as follows: 0.111 grams of 6-aminopenicillanic 
acid (6-APA, >98% purity, TCI America, Portland, OR, 200 mmol/L) was suspended in 
1766 μL of DI water. To dissolve the 6-APA, 634 μL of 1.0 M sodium hydroxide (>98%, 
Sigma Aldrich, St. Louis, MO, 250 mmol/L) was added to the 6-APA suspension. To the 
now clear 6-APA solution, 0.103 grams of phenylglycine methyl ester hydrochloride 
(PGME, >95%, Sigma Aldrich, St. Louis, MO, 200 mmol/L) was added. The PGME•HCl 
dissolved immediately. To this solution, 0.01 to 0.05 grams of ampicillin trihydrate initial 
crystals were added, and the suspension was then incubated at 25.0 °C for 15 minutes with 
agitation to allow the ampicillin to partially dissolve and saturate. The addition of these 
crystals saturates the solution and provides initial crystals for observation of growth, at 
0.01 g 57% of this initial charge dissolves, at 0.05 g only 11% of the initial charge 
dissolves. The suspension was divided into three aliquots of 665 μL allowing three repeats 
of each experiment. To a single aliquot, 35.0 μL of PGA stock solution (10.0 mg/mL, 
Assemblase®, DSM-SinoChem, Delft, Netherlands) was added. Once the PGA was added, 
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the suspension was mixed with a magnetic stir-bar, 15.0 μL of suspension was rapidly 
pipetted with a wide-bore pipette tip (to avoid classifying particles by size) onto a glass 
microscope slide, the droplet was covered with a glass cover slip, the cover slip was sealed 
with silicon oil, and the microscope began recording images; the entire process from 
addition of PGA to beginning of data collection took approximately one minute. Images 
were collected with a temperature-controlled microscope, set at 25.0 °C, at a rate of one 
frame every two minutes, totaling two hours. The initial conditions for each experiment, 
based on this procedure, are listed in Table 5.1. 
Table 5.1. Initial conditions for growth experiments. 
Experimental variable Value 
Volume (of one aliquot) 700 μL 
6-APA concentration 200 mmol/L 
PGME concentration 200 mmol/L 
Ampicillin concentration 18 mmol/L 
PGA concentration 5.0 μmol/L 
Ampicillin trihydrate initial loading 0.01 – 0.05 g 
pH value 6.50 
Temperature 25.0 °C 
 
 A Leica DM LM microscope with a temperature-controlled stage was used with 
incident lighting and 200x total magnification (20x Leica PL Fluotar objective lens and 
10x eyepiece magnification). A CoolSNAP-Pro CF camera with 36-bit color imaging was 
attached to the TV port; the field of view was 1040-by-1392 pixels, corresponding to 1100-
by-1480 microns. Images were collected with Image-Pro Plus and exported to MATLAB 
for analysis. 
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The images collected were analyzed with GT Fiber.147, 148 GT Fiber is a program 
designed to measure the lengths of fibers in images and has the advantage that it can 
distinguish when two fibers (or crystals) overlap or cross, an issue which has rendered 
image analysis of other needle-like crystals difficult.48, 51 As there was no convection 
during the experiment, individual crystals did not move substantially between frames and 
could be tracked over the course of the entire experiment. With the initial frame, individual 
crystals to be tracked were selected, by hand, and their length and width calculated with 
GT Fiber. Figure 5.2 (a) shows the initial frame from a single experiment; every additional 
frame was fit with GT Fiber, using the previous frame to identify the crystals of interest. 
Figure 5.2 (b-f) shows the same experiment over 2 hours of growth. The lengths and widths 
of each individual crystal over time were extracted, from which growth rates could be 
determined. While the length calculation is robust, the width measurement is more 
uncertain; the crystals are transparent (only their edges are visible, see Figure 5.2) so there 
is no obvious edge along which to measure the width. In total, 1,003 ampicillin trihydrate 
crystals were observed by this method. Occasionally, two crystals would grow end to end 
(confusing the image analysis) or out of the image frame (resulting in unobservable 
growth); these crystals were removed from the dataset, giving a working set of 887 crystals. 
To make inferences about the properties of the entire population of crystals, as well 
as the properties of ampicillin trihydrate itself, from this sample of 887 crystals required 
the use of several different statistical tools. A discussion of those tools is included here to 
enable the reader to quickly understand the coming results. The Lilliefors statistical test 
tests the null hypothesis that the data are sampled from a normally distributed population 
without specifying the mean or variance of the population. The test statistic is the maximum 
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distance between the sample cumulative distribution and the cumulative normal 
distribution with mean equal to the sample mean and variance equal to the sample variance. 
Tables of critical values have been computed by Monte Carlo methods and are widely 
available.149 The coefficient of determination, R2, is a measure of the amount of variance 
explained by the model. R2 will be close to unity when there is little noise (compared to 
signal) and the model has high predictive power; when there is significant noise (compared 
to signal) R2 will be close to zero regardless of the model. The root mean squared error, 
RMSE, measures the differences between estimated values and observed values, making it 
more robust against noise compared to R2. However, RMSE is scale dependent, and 
therefore is not used to compare an estimator’s predictions on different sets of observed 
values; rather it should be used to compare different estimator’s performance on a single 
set of observed values. A t-test can be used to assess if the means of two sets of data are 
significantly different, given that the means come from a normally distributed population. 
Spearman’s rho, ρS, is a rank correlation coefficient that assesses whether or not a 
monotonic (i.e. one-to-one) functional relationship exists between two variables. When ρS 
is zero there is no monotonic relationship between the variables and when ρS is unity there 
is a perfect monotonic relationship; a t-test can be used to determine if ρS is significantly 
different from zero, thus assessing the significance of the correlation between two 
variables. Finally, the results are reported as 95% confidence intervals, meaning that if the 
study was repeated multiple times on different sample crystals, 95% of the calculated 
confidence intervals would cover the true value. Higher confidence levels will give larger 
confidence interval widths, 95% confidence is common and was therefore chosen to be the 














Figure 5.2. Microscope images of ampicillin trihydrate, colorized to enhance contrast. The scale-bar 
is 100 μm: (a)-(f) images taken at 2, 20, 40, 60, 90, and 120 minutes, respectively. 
5.3 Results 
5.3.1 Growth rate dispersion at the population level 
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Previous studies on growth rate dispersion have predominately focused on changes 
in the crystal size distribution that could not be explained by nucleation or growth. The 
evolution of the CSD was examined in this study as well to enable simple comparison to 
past studies. Figure 5.3 (a) shows how the CSD widened over the course of 2 hours, in this 
case for the experiments with an initial loading of 0.03 grams. Lognormal fits to the initial 
and 2-hour CSD are included. A Lilliefors statistical test, which tests for normality without 
prior knowledge of the mean or standard deviation, failed to reject the null hypothesis that 
the log-transformed CSDs came from a normally distributed population at the 99% 
confidence level. Figure 5.3 (b) shows the cumulative distribution of growth rates from the 
same loading (0.03 grams, the combined results from 10 repetitions of the same 
experiment) and a normal distribution for reference. Here, a Lilliefors statistical test failed 
to reject the null hypothesis that the growth rate distribution came from a normally 
distributed population at the 99% confidence level. This is consistent with the central limit 
theorem which suggests the growth rates should be distributed normally, given that the 
growth rate is the combination of many distinct processes (such as bulk diffusion, surface 





Figure 5.3. (a) The CSD of initial crystals (green circles) and fit to lognormal distribution (solid green 
curve) and the CSD after 2 hours of growth (red squares) and fit to lognormal distribution (dashed 
red curve) for experiments with an initial loading of 0.03 g, the bin widths are the same for both 
CSDs; (b) Cumulative distribution of growth rates extracted from CSDs for experiments with an 
initial loading of 0.03 g (solid blue curve) and a normal distribution with a mean of 0.84 and standard 
deviation of 0.43 μm/min (dashed black curve) for reference. Note that the CSDs are lognormal while 
the growth rate distribution is normal. 
5.3.2 Growth rate dispersion at the individual level 
The growth of a single crystal was described by the piecewise equation below, 
where tcr is the time required for a critical supersaturation to be generated, Linit is the length 











  (5.1) 
Figure 5.4 (a) shows the result of fitting two crystals, both from the same 
experiment under the same conditions, to equation 5.1. At the same time, the widths of the 
crystals, also shown in Figure 5.4 (a), follow no obvious trend; the challenge of measuring 
the width is illustrated by ‘Crystal 2’ apparently widening and then thinning between 50 
and 110 minutes. For ‘Crystal 2,’ the aberrant widening appears to be the result of a change 
in the optical properties of the crystal surface. Initially the surface is rough and opaque, the 
surface smoothens and becomes transparent during growth, but surface healing is not 
uniform in time or space. Here, the transient optical behavior led to an apparent increase in 
crystal width which then appeared to thin as the optical properties became more uniform 
across the crystal. 
Equation 5.1 fits the data remarkably well; Figure 5.4 (b) shows an analysis of the 
goodness of fit for the entire data set in the form of a histogram of coefficient of 
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determination values (R2). Of the crystals examined (i.e. did not grow end-to-end or out of 
frame), 84% have fits with R2 > 0.95 (the five rightmost bins), but there is a significant 
population with low R2, indicated by the leftmost, red bin in Figure 5.4 (b). On the right-
hand axis of Figure 5.4 (b) the mean and one standard deviation of the growth rates for all 
the crystals in that R2 bin are shown, the slow mean growth rate for the poorly fit crystals 
explains why the R2 is small. R2 measures the amount of variance explained by the model; 
when the growth rate is zero none of the variance in length can be explained by growth, 
rather signal noise dominates, and R2 = 0. Other measures of goodness of fit, such as root-
mean-square error (RMSE), are not skewed by low growth rate, but RMSE is not scale 
invariant and will indicate a worse fit for a large crystal than a small crystal with the same 





Figure 5.4. (a) The length (left axis, closed symbols) and width (right axis, open symbols) of two 
individual crystals is plotted over time. Note the right axis scale is 5x the left axis scale. Both crystals 
are fit to equation 5.1. (b) Left axis, histogram of R2 values. Right axis, mean growth rate for each 
bar in the R2 histogram (with enough samples to compute a meaningful mean and standard 
deviation, n > 10) with error bars of one standard deviation. Note all bins for R2 less than 0.8 have 
been grouped into a single red bin 
Upon close inspection of Figure 5.4 (a) the model does not capture the transition 
from no growth to growth with perfect accuracy. In many crystals, an initial burst of growth 
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occurs when the ends of the initial crystals (which have been blunted by breakage during 
solids handling) grow into facets (the equilibrium shape); Figure 5.2 shows blunt-ended 
crystals initially, and pointed growing crystals later. The accelerated initial growth can be 
seen in Figure 5.4 (a), particularly for ‘Crystal 2’, which also shows that the initially smaller 
crystal grows faster. However, this trend is not found when all crystals are viewed in 
aggregate. The growth rate does not increase with time as might be expected in a system 
with size-dependent growth (SDG) or randomly fluctuate as would be expected with 
random fluctuations (RF). 
In considering all crystals, the growth rate shows a large amount of variation. Figure 
5.5 shows the growth rate of crystals versus the initial length for five different initial 
loadings, and a linear regression has an R2 = 0.07, indicating the initial length explains very 
little of the observed variation in growth rate. The slope of the linear correlation between 
Linit and G is positive, with a 95% confidence interval of 0.9 × 10-3 to 1.4 × 10-3, 
demonstrating that longer initial crystals do in fact grow faster, as is expected with the size 
dependent and constant crystal growth models. Breakage of the initial crystals can explain 
the weakness of the correlation between Linit and G, but it does not account for the large 
scatter of growth rates. Rather, in the constant crystal growth model the dispersion of 
growth rates is attributed to intrinsic properties of individual crystals, not any easily 
measured quality like length. 
The normalized empirical histogram of the growth rates is shown next to the y-axis 
and the normalized empirical histogram of the initial lengths is shown beneath the x-axis 
and. The distributions are divided between five initial loadings; it can be seen that the 
highest loading (shown in purple) has the largest population of small crystals initially and 
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lowest average growth rate while the smallest loading (shown in red) has a wider 
distribution of crystal lengths initially and the fastest average growth rate. 
 
Figure 5.5. A scatter plot of growth rates of individual crystals against the length of the initial crystal 
for different initial loadings, with a linear correlation and 95% prediction interval. Along the x-axis 
is the normalized number-based CSD histogram of the initial crystal lengths, colored by loading. 
Along the y-axis is the normalized growth rate distribution histogram of the initial crystals, colored 
by initial loading.   
5.4 Discussion 
Over the course of 2 hours, the mean crystal width increased from 18.9 μm to 21.5 
μm. This change in width corresponds to an increase of approximately two pixels. All 
measurements are discretized by the camera making it impossible to measure accurate 
width trends for individual crystals, but for the population the two-pixel change in width is 
significant at the 99% confidence level. Since the width change is so small it is assumed 
most of the growth occurs at the ends of the needles. Equation 5.2 characterizes the rate of 
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accumulation of dissolved ampicillin c as solute is generated by the reaction R and 





= −   (5.2) 
where ρ is the density of the crystal, A is cross-sectional area of the crystal, and G is growth 
rate of the crystal. 
Shortly after the critical time, tcr, the linear increase in length over time suggests 
that the concentration reaches a pseudo steady state such that the left-hand side of equation 
5.2 goes to zero. Since the reaction rate is constant across experiments, the product of area 
and growth rate must be constant. At higher loadings there is more area, therefore, one 
expects to observe a decrease in growth rate. The relationship between area and initial 
loading is not obvious. At a loading of 0.01 g, 57% of the initial crystal mass dissolved 
during the initial dissolution step to form a saturated solution (see Methods). Many small 
crystals may have dissolved entirely, leaving mostly large crystals, evidenced by the 
broader distribution of initial sizes in Figure 5.5. At a loading of 0.05 g, only 11% of the 
initial crystal mass dissolved. Less dissolution of each crystal was required to saturate the 
solution; many of the small crystals that would have entirely dissolved in the 0.01 g loading 
were observable in the growth phase of the 0.05 g loading experiments.  
Figure 5.6 (a) shows that the growth rate is negatively correlated with the initial 
loading, but that initial loading is a poor predictor for growth rate given the large scatter in 
the data and the low R2 = 0.10. The 95% prediction interval given by the dashed curves are 
correspondingly wide to capture the variance in the growth rate. It is also possible that the 
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Figure 5.6. (a) Growth rate of individual crystals versus the initial loading of the experiment in which 
the growth rate was measured, horizontal jitter is introduced to illustrate the density of data points; 
(b) Growth rate of individual crystals versus the critical time of the crystal. The solid lines are the 
linear best fits and the dashed curves are the 95% prediction intervals 
There also exists a weak but statistically significant (at the 95% confidence level) 
correlation between critical time and growth rate. Longer critical times are correlated with 
slower growth rates, independent of initial loading, as can be seen in Figure 5.6 (b) where 
the 95% confidence interval on the slope is -8.1 × 10-3 to -5.9 × 10-3. There is evidence that 
the presence of other species, in this case the reactants 6-APA and PGME, can inhibit the 
growth of ampicillin crystals,150, 151 which may lead to lack of growth below a critical 
supersaturation. The lack of growth is postulated to arise from the other species adsorbing 
to the edge of growth steps and preventing the step from advancing; halting the layer-by-
layer growth mechanism.99-101 The advance of edges along the length of the crystal is 
visible on some crystals in the videos provided with the Supplemental Material, although 
to be visible at this magnification they must be groups or bunches of growth steps. 
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Again, the scatter in the data is large, R2 = 0.15, making critical time only weakly 
predictive of growth rate, however both are affected by similar surface phenomena. An 
underlying property of the crystal surface could be affecting both growth rate and critical 
time but by different mechanisms, resulting in the observed correlation and providing 
evidence that the distribution of growth rates results from a distribution of crystal properties 
(the spacing of the adsorbed species on the edge of advancing growth steps determines the 
critical supersaturation required to overcome the impinging adsorbed molecule).100 The 
distance between adsorbed molecules on the edge should follow a geometric distribution 
(assuming each adsorption site is identical), as the length and number of edges increases 
the probability of gaps between adsorbed molecules large enough to support growth also 
increases, even with the same fractional coverage of sites. Therefore, in this experimental 
procedure, crystals with longer growth step edges are expected to have shorter critical times 
and higher growth rates. Different numbers and arrangements of dislocations in the crystal 
can lead to different lengths of growth step edges as well as different growth rates.113, 135 
Finally, given that the system is not mixed, it must be considered whether the 
distribution of growth rates could be attributed to the slight differences in local 
supersaturation due to the random scattering of crystals. For this analysis, it is still assumed 
that growth occurs predominately at the ends of the crystals (as is seen in Figure 5.4), such 
that only the ends of the crystals act as a sink for ampicillin generated in the bulk. It is also 
assumed that there is no bulk flow and that the height dimension is insignificant (sampled 
volumes measure 1290 × 967 × 43 microns L × W × H). With these assumptions, the 
images can be divided into areas such that each area contains a single growing crystal end 
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that is the only sink for dissolved ampicillin in that area. Figure 5.7 shows how one such 
image was divided. 
 
Figure 5.7. An image of growing crystals is divided into areas based on distance to nearest growing 
crystal end. The areas are colored based on the volume represented by the area and range from dark 
blue representing the smallest volume (0.1 nL) and yellow representing the largest volume (2 nL). 
The areas are overlaid on the grayscale image from which the data were generated. The white points 
are the crystal ends used in the analysis, and the white curves connecting them illustrate how the 
crystal is represented in the image analysis program GT Fiber. The red scale bar is 100 μm. 
Since the reaction rate is the same throughout the bulk and if GRD is the result of 
the random placement of crystals only, the growth rate of each crystal should be correlated 
with the area over which that crystal serves as the dissolved ampicillin sink (controlled for 
the growing area of the sink). Instead, no correlation was found between the area of 
influence and the growth rate; Figure 5.8 shows the expected growth rate (calculated from 
the known rate of ampicillin generation based on the PGA kinetics and the areas of 
influence) versus the measured growth rate for the experiment shown in Figure 5.7. The 
calculation under-predicts the growth rate, likely because the width is overestimated during 
the image analysis. It is visually obvious that the data are not correlated, with a 95% 
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confidence interval on the slope ranging from -0.50 to 0.99, indicating no linear 
relationship (Spearman’s rho indicates no one-to-one relationship, linear or otherwise). No 
correlation was found when the same analysis was applied to other experiments not shown 
in Figure 5.7. To describe the growth rate of an individual crystal requires knowledge of 
the collective system properties (i.e. supersaturation, temperature, etc.) and intrinsic crystal 
properties (dislocation frequency, surface features). While many correlations exist and can 
partly be explained by system properties, the large scatter in the data are in line with the 
constant crystal growth model where GRD is explained in terms of intrinsic crystal 
properties.  
 
Figure 5.8. The measured growth rate of the crystals in Figure 5.7 versus the calculated growth rate 
of the same crystals based on the division of the image in Figure 5.7. 
Previous studies have incorporated a distribution of growth rates into a population 
balance model to examine the effect of GRD on the CSD from a continuous crystallizer.145 
The population density function, n, from a mixed-suspension, mixed-product removal 
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  (5.3) 
where Bo is the nucleation rate, f(G) is the probability density function describing the 
growth rates of nuclei, and τ is the mean residence time of the MSMPR. To compare CSDs, 
it is assumed that the rate of generation of crystals, given by the suspension density MT 
divided by the residence time, is the same in systems following the ΔL law and systems 
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where kv is a volumetric shape factor. With equation 5.4 the nucleation rate could be 
adjusted to ensure the same rate of crystal generation in any crystallizer. It was shown in 
Figure 5.3 (b) that the growth rates of the crystals follow a normal distribution, with a mean 
μ = 0.84 μm/min and σ = 0.43 μm/min, and it is assumed that this distribution is appropriate 
for the nuclei in the MSMPR exhibiting GRD, f(G). Using these results, an MSMPR 
producing ampicillin by the PGA-catalyzed reactive crystallization was modeled. A 
residence time of 42 minutes has previously been shown to optimize yield while meeting 
purity constraints, therefore τ = 42 was used in the model.21 Figure 5.9 shows the population 
density function of the crystals produced by an MSMPR following the ΔL law (no GRD, σ 
= 0) and an MSMPR with GRD. With GRD, the population density function becomes 
skewed towards larger crystals compared to the ΔL law growth rate; there are an order of 
magnitude more crystals at 400 μm length with GRD than without GRD. Such a substantial 
increase in large crystals could require a further processing step, such as grinding, if the 
process were designed to meet product size specifications with the assumption that the 
growth rates of all crystals are the same. 
 109 
 
Figure 5.9. The CSD in an MSMPR producing ampicillin by PGA-catalyzed reactive crystallization. 
The dashed curve represents the case with no GRD and the solid blue curve shows the CSD when the 
growth rates follow a normal distribution as described in Figure 5.3 (b). 
5.5 Conclusions 
Growth rate dispersion of ampicillin trihydrate crystals was directly observed. The 
experimental design allowed many sources of potential differences in growth rate to be 
eliminated: isothermal conditions ruled out spatial differences in temperature and any 
Arrhenius dependence, homogeneous bulk phase ruled out mixing effects seen with anti-
solvent crystallization and precipitation, quiescent conditions ruled out breakage, 
agglomeration, and nucleation as sources of irregularity in the CSD. Image analysis of 
individual crystals over time showed that the growth rate was linear and steady, ruling out 
the possibility of random fluctuations and size dependent growth, two theories previously 
advanced to explain unexpected widening of CSDs. Direct observation of growing crystals 
led to insight regarding the mechanism of growth rate dispersion that would not be possible 
with population-level measurements such as size distribution. Analysis of the spatial 
orientation of the crystals, in an unmixed environment, revealed that the magnitude of 
growth rate dispersion could not be explained by the random scattering of crystals. 
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Therefore, the dispersion of growth rates observed in ampicillin trihydrate crystallized in 
the presence of the precursors, 6-APA and PGME, is almost certainly due to properties 
intrinsic to each individual crystal. The correlation of growth rates and critical times 
required for growth to begin suggests that the most important intrinsic property is total 
length of growth step edge, which will be influenced by number and arrangement of screw 
dislocations. 
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CHAPTER 6. DEVELOPMENT OF A MODEL FOR IN SILICO 
DESIGN OF AN OPTIMAL PROCESS FOR CONTINUOUS 
MANUFACTURING OF BETA-LACTAMS5 
6.1 Introduction 
The preceding chapters have created the knowledgebase needed for the 
development of a comprehensive model of the continuous reactive crystallization of beta-
lactams by penicillin G acylase. The model, to be complete, needs to consider the following 
kinetic phenomena: (1) the kinetics of the PGA-catalyzed reactions, (2) the kinetics of 
crystallization, both nucleation and growth, and (3) the kinetics of PGA deactivation. The 
conditions over which the kinetics need to be calculated is bounded by several factors, such 
as reactant solubility for concentration, enzyme activity profile for pH value, and product 
solubility and enzyme stability for temperature. 
The model is developed from first principles, introduced in previous chapters, and 
fit with experimental data, also collected in previous chapters. Simplifying assumptions are 
used to construct attainable regions with respect to reactant conversions and mean crystal 
size, and Levenspiel plots are used to evaluate reactors and reactor networks. Three process 
attributes—conversion (X), productivity (P), and fractional yield (Φ)—are presented as a 
Pareto-optimal surface, i.e. the set of attribute values such that no one attribute can be 
improved without negatively impacting any other attribute. Attainable regions for mean 
 
5 Adapted from “Computers & Chemical Engineering, 123, McDonald, M.A.; Bommarius, A.S.; Rousseau, 
R.W.; Grover, M.A. Continuous reactive crystallization of β-lactam antibiotics catalyzed by penicillin G 
acylase. Part I: Model development, 331-343.” Copyright (2019), with permission from Elsevier. 
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crystal size with a series of mixed suspension mixed product removal reactive crystallizers 
(MSMPRs) are discussed. The use of classified product removal as a technique for 
improving the mean crystal size over the MSMPR is demonstrated. Finally, manipulating 
the enzyme concentration is discussed as a means of further improving the process. 
6.2 Model Development 
A combined model of reaction and crystallization was constructed to track the 
amounts of all species.  Three conceptually distinct (if not physically separate) phases were 
considered: the crystalline phase with solid products or byproducts, the liquid phase with 
dissolved solutes, and the enzyme phase which could be either soluble, immobilized on a 
solid support, or encapsulated/recycled in some other manner. Two timescales are also 
considered: reaction, crystallization, and convection all occur on the single residence time 
timescale, while enzyme deactivation occurs over a much longer timescale. 
The reaction model is based on the mechanism and resulting kinetics of PGA, 
elucidated in CHAPTER 3, which have previously been studied.32, 63, 80 As a reminder to 
the reader, PGA catalyzes three reactions: the desirable synthesis reaction, as well as 
undesirable primary hydrolysis and secondary hydrolysis reactions. The mechanism of 
each of these reactions can be represented by the scheme in Figure 6.1.  
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Figure 6.1. The kinetic scheme for the mechanism of PGA.  E is free PGA, S is acyl-donor 
(HOPGME or PGME), Nu is 6-APA or 7-ADCA, B is the byproduct (HOPG or phenylglycine), P is 
the antibiotic, EAH is the activated acyl-enzyme complex, EA and EAH2 are dead-end complexes due 
to pH equilibria, ENu is PGA bound to 6-APA or 7-ADCA, ES is PGA bound to HOPGME or 
PGME, EANu is acyl-enzyme complex bound to 6-APA or 7-ADCA, and EP is PGA bound to 
antibiotic.32 
The rates of the synthesis and hydrolysis reactions are explained in detail in 
CHAPTER 3 and are listed here as equations 6.1-6.5. This system of equations defines the 
reaction rates of production and consumption (RP for antibiotic product, RB for byproduct, 
RS for substrate acyl-donor, and RNu for nucleophilic β-lactam core). The reaction rates are 
dependent on the concentration of substrate acyl-donor (cs), nucleophilic β-lactam core 
(cNu), and antibiotic product (cp), as well as the pH value and concentration of free active 
enzyme (cE), defined with respect to the total enzyme concentration (cE,0) in equation 6.5.  
The parameters in equations 6.1-6.5 are reported in Table 6.1.   
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Table 6.1. Values of the rate and association constants shown in Figure 6.1 and equations 6.1-6.5. 
Notes: a Youshko et al. 200263, b McDonald et al. 201732, c values calculated from published values of 
α, β0, and γ and invariants between mechanisms (e.g. ampicillin and amoxicillin have the same 
nucleophile, therefore they must have the same nucleophile association constant). Discussion of α, β0, 
and γ can be found in CHAPTER 3. 
Parameter Units Amoxicillin a,c Ampicillin b Cephalexin a,c 
k2 s-1 187 162 162 
k3 s-1 44 44 44 
k4 s-1 302 235 316 
k-4 s-1 217 217 217 
k5 s-1 39 9.0 6.3 
KN mol/L 0.043 0.043 0.019 
KS mol/L 0.38 0.38 0.38 
KP mol/L 0.095 0.095 0.057 
KA1 - 10-7.52 10-7.52 10-7.52 
KA2 - 10-8.19 10-8.19 10-8.19 
 
The driving force for crystallization and the equilibrium solute concentration 
depend strongly on the solubility of the species. The solubility of the crystallizing products 
amoxicillin, ampicillin, and cephalexin, as well as the byproducts which may crystallize 
and contaminate the product, HOPG and phenylglycine, are functions of pH value. The pH 
of the solution was solved with species and charge balances as described elsewhere.90, 152 
Figure 6.2 shows the solubility of the antibiotics, byproducts, β-lactam cores, and acyl-
donors. The solubility (c*j) was modeled according to equation 6.6, which captures the 
solubility behavior and depends on two parameters, the solubility at the isoelectric point 
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(c*pI,j), and the acid dissociation constant (pKa,j).153  These parameter values are given in 
Table 6.2. The dissociation constants are also corrected for ionic strength with equation 
6.7, where zj is the charge of the conjugate base; over the pH range of interest it has a value 
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In Figure 6.2.a it can be seen that amoxicillin (solid) is less soluble than ampicillin 
(dashed) which is less soluble than cephalexin (dash-dot) at all pH values, resulting in less 
antibiotic going unrecovered in the effluent stream from the amoxicillin process.  The 
solubility of HOPG, shown in Figure 6.2.b, is also approximately three-fold greater than 
that of phenylglycine and is only a weak function of pH. The solubility of the β-lactam 
core, presented in Figure 6.2.c, can also dictate operating conditions; the low solubility of 
7-ADCA compared to 6-APA indicates that 400 mM 7-ADCA cannot be used at a pH 
value of 7, which will result in slower synthesis of cephalexin compared to amoxicillin or 
ampicillin. The solubility of HOPGME, shown in Figure 6.2.d has the opposite pH 
dependence of the other species investigated, which requires that an HOPGME feed be 
slightly acidic, potentially neutralized by a slightly basic nucleophile feed. The large 
increase in HOPGME solubility at slightly acidic conditions motivated the two pH values 
(6.5 and 7.0) investigated in detail in this chapter. The solubility of PGME is greater than 
one molar at all investigated pH values; it is therefore not a constraint on the CM process 




Figure 6.2. The solubility of amoxicillin (solid), ampicillin (dash), and cephalexin (dash-dot) (a), 
HOPG (solid) and phenylglycine (dash) (b), 6-APA (solid) and 7-ADCA (dash-dot) (c), and 
HOPGME as a function of pH with experimental data from Bezerra et al. 2013155, Diender et al. 
1998156, Felix et al. 2016157, Santana et al. 201045, Youshko et al. 200077, McDonald et al. 201732, and 
Rudolph et al. 200122, as well as this work.  
The crystallization kinetics of amoxicillin trihydrate and ampicillin trihydrate have 
previously been reported.88, 89, 151  The crystal growth rate, G, was modeled as a power law 
with respect to relative supersaturation, ( )* *c c c = − , and was considered to follow 
McCabe’s ΔL rule that all crystals grow at the same rate,131 given in equation 6.8. After 
initial design, the known growth rate dispersion, being more computationally intensive to 
optimize for, was incorporated into the results (CHAPTER 5). The crystal nucleation rate, 
B, was modeled as the sum of the primary (B1) and secondary nucleation (B2) rates, shown 
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in equations 6.9-6.11. In addition to being a function of supersaturation, the secondary 
nucleation rate is also a function of the slurry density, MT, which will be defined later in 
equation 6.18. Table 6.3 contains the parameter values used for these equations. 
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B TB k M =   (6.10) 
 1 2B B B= +   (6.11) 
Table 6.2. Summary of the parameter values used to model the solubility of amoxicillin, ampicillin, 
cephalexin, their precursors, and their hydrolysis products. Notes: a Felix et al. 2016157, b Santana et 
al. 201045, c Bezerra et al. 2013156, d McDonald et al. 201732,  e This work.  
 Units Amox. Amp. Ceph. 6-APA 7-ADCA HOPG PG HOPGME 
pKa - 7.48 a 7.31 b 7.12 e 4.83 b 6.26 e 9.20 c 9.14 b 7.97 d 
c*pI  mol/L 0.0068 c 0.021 d 0.024 e 0.020 d 0.012 e 0.113 c 0.035 d 0.010 d 
 
Table 6.3. Summary of parameter values used to model the crystallization of amoxicillin and 
ampicillin. Notes: a Encarnación-Gómez et al. 201641 
Parameter Units Amoxicillin a 
kG μm/min 8.95 
g - 1.87 
kB1 1/kg/min 5×1010 
Bo - 1.27 
kB2 1/kg/min 2.2×109 
m - 0.60 e 
b - 1.37 e 
 
A reactive crystallizer network of independently sized well-mixed vessels in series 
was considered because a series of reactive crystallizers still requires less volume than a 
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single reactor and crystallizer, while potentially improving overall performance. While 
potentially more capital-intensive than a single reactive crystallizer, vessels in series could 
provide more operational freedom with reductions in operational costs that justify the 
increased capital expense. In this study, volume is used as a proxy for cost and a 
preliminary screen of process plausibility; the cost analysis required to design an optimally 
profitable plant is beyond the scope of this work.  
Figure 6.3 shows the flowsheet used for this model. No inter-stage feeds were 
included, both for simplicity and to approximate industrially relevant designs. It is assumed 
that the enzyme separator is ideal; this model does not make any assumptions as to the 
form of the enzyme, such as soluble or immobilized, so a more detailed separator 
configuration is not presented here. In the stirred tanks, the residence time of the solids, τs, 
is independent of that for the liquid and is crystal size dependent to model fines and 
classified product removal. Agglomeration and breakage were considered negligible, 
similar to previous crystallization models of β-lactams and in accordance with our 
experimental observations. 
 
Figure 6.3. Schematic representation of the system being modeled.  The product classifier allows the 
residence time of the crystals to be independent of the solution and vary as a function of crystal size.  
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The enzyme recycle is assumed to recycle a pure enzyme stream but does not affect the degradation 
of the enzyme.  
Based on these simplifications a system of equations for the crystal size distribution 
was formulated, utilizing a population balance model with reaction and given below as 
equations 6.12-6.15.  Equation 6.12 is the population balance, equation 6.13 is the solute 
balance, and equations 6.14 and 6.15 are boundary and initial conditions, respectively. 
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In the above equations nj,k and cj,k represent the crystal size distribution (CSD) and 
solute concentrations, respectively, of component j in the kth stirred tank where the 0th 
stirred tank is the feed. τs and τl are the solids and liquids residence times, respectively. kv 
and ρ are the volumetric crystal shape factor and crystal density. L and t represent the 
crystal length and time domains.   
The moments of the CSD are defined in equation 6.16; differentiating the moments 
with respect to time gives equation 6.17, which can be solved with a differential equation 
solver as described in the Methods section below. It is also convenient to define the slurry 
density, MT,j, with the third moment of the CSD, μ3, as shown in equation 6.18. 
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 , , 3,T j V j j jM k  =   (6.18) 
In CHAPTER 2 the deactivation kinetics of PGA were determined and those 
findings are applied here.158  Assemblase®, a commercial form of PGA used in this study, 
follows the Lumry-Eyring model of deactivation.  In the Lumry-Eyring model66 natively 
folded (active) enzyme, E, is in equilibrium with a reversibly unfolded conformation, U, 





E U D⎯⎯→ ⎯⎯→⎯⎯   (6.19) 
The decay (kd) and equilibrium (KU) constants are functions of temperature 
parameterized by the enthalpy and entropy of deactivation, enthalpy of reversible 
unfolding, and melting temperature of PGA. Equations 6.20 and 6.21 define kd and KU 
respectively (kb is the Boltzmann constant, h is Planck’s constant, and R is the gas constant).  
The enthalpy of deactivation (ΔHdeact) has a value 350 kJ/mol, the entropy of deactivation 
(ΔSdeact) has a value of 770 J/mol/K, the enthalpy of reversible unfolding (ΔHU) has a value 
of 236 kJ/mol, and the melting temperature of PGA (Tm) is 328.4 K.158  
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  (6.21) 
The stability of PGA diminishes rapidly above ~50 °C, however, at the conditions 
experienced in the reactive crystallizer the amount of active PGA is practically unchanging 
over the course of many residence times. Equation 6.22 is the differential equation form of 
equation 6.19 which, in conjunction with equations 6.20 and 6.21, can be used to determine 
the amount of active PGA in a process of arbitrary temperature.  Changing temperature is 
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beyond the scope of the present work, therefore equation 6.22 can be reduced to equation 
6.23, where the effective decay constant (kd,eff) has a value of 4.6 × 10-9 s-1 at 298 K (time 
















   (6.22) 
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6.3 Methods 
The model is formulated as a system of partial differential equations (PDEs) 
according to equation 6.12.  These PDEs are reduced to a system of ordinary differential 
equations (ODEs) by two methods; the method of lines and the method of moments.159, 160  
The two different methods have different qualities that make using both of them 
advantageous. The method of lines enables the CSD to be solved as a function of time, 
enabling modeling of selective removal of crystals based on size, but at a large 
computational cost. The method of moments uses the moments transformation to solve the 
PBEs with a limited number of ODEs, enabling fast solutions and large design spaces to 
be searched, but without the full CSD information provided by the method of lines.  
With the method of lines, the crystal length domain is discretized to give a system of 
ODEs in the time domain that are solved with the MATLAB ODE solver ode113, which 
is an efficient ODE solver when the ODE function is expensive to evaluate. In this work, 
the length domain was discretized at 0.20 μm intervals from 0 to 200 μm, giving a total of 
1,001 size bins. An error analysis, visualized in Figure 6.4, showed that a 1,000-bin 
discretization gave a smaller error than the method of moments, which only evaluates the 
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moments (μi) of the crystal size distribution, defined in equations 6.16 and 6.17, greatly 
reducing the number of ODEs compared to the method of lines and allowing for evaluation 
with the MATLAB ODE solver ode45. The method of moments was used to search for 
global optima by repeatedly running the optimization with different starting points, the 
method of lines was used to determine a finer-grained optimum and calculate the crystal 
size distribution (which the method of moments cannot do). 
 
Figure 6.4. The fractional error of several different solutions to the population balance to determine 
mean crystal length (L43) as a function of conversion.  At higher conversion the error increases, 
however it is never more than 3%, even with the coarsest model (PBE 250) or the method of 
moments.  In the legend, PBE indicates a complete solution of lines using the indicated number of 
bins to discretize the length domain.  MOM indicates the method of moments 
Determination of the maximum and minimum possible mean crystal sizes for 
reactive crystallizers in series was formulated as an optimization problem.  The 
optimization was performed with the MATLAB nonlinear constrained optimizer fmincon. 
Experimental solubility data, shown in Figure 6.2, were obtained by allowing a 
mixture with excess solids to equilibrate at constant temperature and pH before final optical 
rotation measurements were taken. The pH was adjusted with sodium hydroxide or 
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hydrochloric acid in an un-buffered solution. Ampicillin, cephalexin, 6-APA, and 7-ADCA 
were from TCI America, Portland OR. Phenylglycine came from Sigma-Aldrich, St. Louis 
MO. All chemicals were used as received. 
6.4 Results and Discussion 
In this section, results from the model are examined and discussed, focusing on the 
amoxicillin system as a case study.  The attainable region for continuous reactive 
crystallization is compared to that for distinct reaction and separation.  The attainable 
crystal size is determined for MSMPR units in series, and strategies for increasing crystal 
size are discussed.  The tradeoffs between productivity and conversion are examined for 
reactive crystallization and the properties of the system that give rise to unique behavior 
are discussed.  Tradeoffs between fractional yield and conversion are also discussed and 
used to construct a Pareto-optimal surface for all three attributes (conversion, productivity, 
and fractional yield).  Finally, after characterizing the model with mixed-product removal 
and a fixed enzyme concentration, the effects of changing the product withdrawal 
mechanism and enzyme concentration are explored to further enhance process attributes. 
6.4.1 Attainable regions 
Solving the method of lines becomes computationally expensive when attempting 
to optimize continuous reactive crystallization over several process variables (pH, 
residence times, 6-APA concentration, HOPGME concentration).  One method to reduce 
the size of this optimization problem is to construct an attainable region, a region that 
defines what steady state conversions of 6-APA and PGME can be achieved without 
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making assumptions about the underlying reactors, crystallizers, mixing and recycling, or 
process conditions.   
To construct an attainable region for the conversion of 6-APA to amoxicillin 
trihydrate crystals, the reaction is assumed to be rate limiting, eliminating the need to 
consider the crystallization kinetics in the PBE. Accumulation of amoxicillin is kinetically 
controlled while crystallization of amoxicillin trihydrate can be kinetically or equilibrium 
controlled, depending on the slurry density or enzyme concentration. For the purpose of 
constructing an attainable region, it is assumed that any amoxicillin supersaturation 
generated by PGA is immediately incorporated into the crystal phase. Therefore, only the 
reaction and the solubility (crystallization equilibrium) need to be considered when 
determining the attainable region in conversion space (where conversion is defined as
6-APA 1
feed
Nu NuX c c= − , HOPGME 1
feed
S SX c c= − ). Later, the impact of enzyme concentration 
will be explored, and it will be shown that these assumptions hold over a range of enzyme 
concentrations.  
The attainable region was determined based on the geometric criteria put forth by 
Glasser and coworkers.161 At each point in HOPGME 6-APA conversion space, a reaction 
vector is calculated based on the rate equations 6.3 and 6.4. Only the direction of the 
reaction vector is important and factors that affect both reaction rates equally—the vector 
magnitude—such as enzyme concentration do not affect the attainable region. The 
attainable region is then obtained by drawing a curve from the feed conversion (in this case 
the origin, zero conversion) to the final steady-state conversion such that no vectors on the 
attainable region boundary point out of the attainable region and no reversed vectors 
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outside the attainable region point into the attainable region. The attainable region is then 
shifted to lower 6-APA conversion to account for the amoxicillin that does not crystallize 
and is unrecovered. The shift gives a slightly modified definition of 6-APA conversion, but 
for the purpose of an attainable region the shift more accurately represents the amount of 
amoxicillin that can be produced by a reactive crystallization process.  This method is 
demonstrated in Figure 6.5. Figure 6.6.a shows the attainable region for a distinct reactor 
and separator, while Figure 6.6.b shows the same results for the reactive crystallizer.   
 
Figure 6.5. Demonstration of the geometric method for determination of the attainable region for the 
case of no crystallization, at pH 7 with 600 mM HOPGME and 400 mM 6-APA initially.  The 
reaction vectors show the direction the system moves at each point in conversion space, the length of 
the arrow is proportional to the rate at  which the system move in that direction (however the 
attainable region is agnostic of rate).  Only 3% of the calculated reaction vectors are shown for 
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readability. A line representing stoichiometric reaction of 6-APA and HOPGME is drawn to show 
how a perfectly selective enzyme would perform. 
 
Figure 6.6. The attainable region for production of amoxicillin with PGA (a) in a distinct reactor and 
separator scheme and (b) with a reactive crystallizer. The attainable region is expressed in terms of  
HOPGME conversion and a modified 6-APA conversion that better captures how much product can 
actually be recovered: 6-APA converted into amoxicillin trihydrate. The 800:400 mM, 600:400 mM, 
400:400 mM and 200:400 mM HOPGME:6-APA feed concentration ratios are shown in blue, red, 
green, and yellow, respectively.  The light-colored region represents the attainable region at pH 6.5 
and the dark color represents pH 7. The dashed lines represent stoichiometric conversion of 
HOPGME and 6-APA to amoxicillin. 
The attainable region for the reactive crystallizer is larger than that for the distinct 
reactor and separator. The attainable region was determined for four concentration ratios 
of HOPGME:6-APA (200:400, 400:400, 600:400, and 800:400 mM, yellow, green, red, 
and blue) and at two pH values (6.5 and 7, light and dark shaded).  The stoichiometric limit 
of 6-APA conversion is shown as a dashed line for each of the four different feed 
compositions; deviation below this line illustrates the imperfect selectivity of PGA.  
Complete conversion of HOPGME at a HOPGME: 6-APA ratio of unity is possible while 
complete conversion of 6-APA is not; HOPGME can hydrolyze while 6-APA can only 
react with HOPGME.  For this reason, increasing the HOPGME:6-APA concentration ratio 
also increases the size of the attainable region since 6-APA generated by amoxicillin 
hydrolysis can be resynthesized into amoxicillin. The crystallization equilibrium also 
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means that amoxicillin saturation must be reached before any amoxicillin trihydrate can be 
formed.  Therefore, at non-zero conversion of HOPGME it is possible to have zero 
conversion of 6-APA to amoxicillin trihydrate because amoxicillin saturation has not yet 
been achieved. The attainable region for the reactive crystallization process is larger 
because the crystallization isolates the product from the enzyme, reducing the rate of the 
secondary hydrolysis reaction and freeing enzyme to catalyze the desired reaction.   
The attainable mean crystal size region was determined with the optimization 
technique developed by Vetter et al.162 modified to vary residence time to reach a specified 
conversion, rather than vary saturation concentration to reach a specified residence time.  
The optimization, which attempts to maximize or minimize the volume-weighted mean 
crystal size 43 4 3L  = , is defined in equation 6.24 below. XNu,k , , , 11Nu k Nu k Nu kX c c −= −  
is the conversion in the kth reactive MSMPR, τk is the residence time in the kth reactive 
MSMPR, XNu is the overall conversion, and K is the total number of MSMPRs. The 
maximization does not include any aggregation, as aggregation was not observed 
experimentally.  The minimization does not include any milling or grinding, processes 
which could be implemented to further reduce the average crystal size. The optimization 
also does not consider the use of fines removal or classified product removal to further 
enhance product size, although this will be considered later in the paper. Figure 6.7.a shows 
the attainable volume-weighted mean crystal size for one, two, and three MSMPRs in series 
as a function of conversion for a feed composition of 800 mM HOPGME and 400 mM 6-
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Figure 6.7. (a) the bounds of attainable mean crystal sizes for one, two, and three MSMPRs in series 
(● – 1 MSMPR, ▲ – 2 MSMPRs, ▼ – 3 MSMPRs).  (b) the breakdown of the residence time of each 
MSMPR in a series of three MSMPRs (■ – 1st MSMPR, ♦ – 2nd MSMPR, ► – 3rd MSMPR) to reach 
the maximum mean crystal size. The feed concentrations are 800 mM HOPGME, 400 mM 6-APA, 
and steady state pH of 7.0. 
Initially, as the conversion increases, the range of crystal sizes shifts towards larger 
mean size, but at high conversion the attainable region rapidly narrows.  A single MSMPR 
has a defined mean crystal size at each conversion (shown by the blue circles in Figure 
6.7.a) because there is only a single residence time that can achieve that particular 
conversion (there are no degrees of freedom).  With two MSMPRs in series, the second 
residence time adds an additional degree of freedom.  Figure 6.7.b shows how the residence 
times are allocated to meet the specified conversion to maximize the mean crystal size with 
three MSMPRs in series. The maximum conversion examined is 97% the maximum 
possible conversion determined by the attainable region in Figure 6.6.b; higher conversion 
requires significantly more residence time. 
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The crystal size is maximized when the first MSMPR operates as a seed generator 
with high supersaturation and short residence time.  The second MSMPR operates at low 
supersaturation to grow the crystals and reach the desired conversion.  The minimum 
crystal size is achieved with the opposite heuristic, with a large seed generating MSMPR 
and small growth MSMPR, although both phenomena occur in all MSMPRs. The addition 
of a third MSMPR does not significantly increase the mean crystal size at low to moderate 
conversion and therefore has negligible residence time over that conversion range. At high 
conversion the optimal configuration adds a small vessel (<5% total residence time) with 
higher supersaturation than the second vessel to the end of the first two vessels in series to 
further boost mean size. In the case of the three MSMPR cascade, two optimal solutions 
exist in addition to the solution shown in Figure 6.7.b. Both additional solutions are 
degenerate forms of the solution shown in Figure 6.7.b.  In the regime where the third 
MSMPR has negligible volume, the three MSMPR cascade reduces to a two MSMPR 
cascade. The two other solutions result from the elimination of the first or second MSMPR, 
giving two MSMPR cascades equivalent to that shown in Figure 6.7.b. Where the third 
MSMPR has significant volume (conversion > 0.8) only the solution drawn in Figure 6.7.b 
is optimal.  
6.4.2 Pareto-optimal fronts 
To determine the bounds on productivity, selectivity, and conversion, Levenspiel 




, versus concentration or conversion) are 
drawn based on the reaction rate in equation 6.1.163 The Levenspiel plot is reactor design 
agnostic (including whether the process is continuous or batch) and useful for visualizing 
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reactor sizing because the area under the curve is related to the reactor size. In Figure 6.8.a 
both the distinct reaction and separation (dashed curves) and reactive crystallization (solid 
curves) are considered for the four feed concentration ratios at pH 7. Figure 6.8.b is a 
zoomed-in version of Figure 6.8.a for the 800:400 mM HOPGME:6-APA curve, with 
additional curves drawn to highlight different aspects of the enzymatic reactive 
crystallization system. 
    
Figure 6.8. (a) the Levenspiel plot for amoxicillin production at 800:400 mM, 600:400 mM, 400:400 
mM, 200:400 mM HOPGME:6-APA feed concentration ratios (blue, red, green, yellow, respectively) 
in a reactive crystallizer (solid curves) and a distinct reactor and separator (dashed curves). (b) 
Close-up of (a) for the 800:400 ratio; the dashed curve is the distinct reactor and separator, the 
dotted curve simulates a hypothetical variant of PGA without substrate inhibition by 6-APA, and 
dash-dot curve neither crystallizes nor has substrate inhibition, and the solid curve is reactive 
crystallization. 
The reactor and reactive crystallizer have markedly different reciprocal rate curves. 
The reactor (dashed curves in Figure 6.8.a) shows the expected approximately first-order 
reaction behavior with a convex monotonic increasing reciprocal rate curve; an asymptote, 
corresponding to the conversion at which amoxicillin degradation outpaces amoxicillin 
synthesis can be seen for each curve.  The reactive crystallizer has a more complex curve. 
At low conversion, the curves for the reactor and reactive crystallizer overlap; this 
beginning region represents conversion below that needed to generate amoxicillin 
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supersaturation and drive trihydrate crystallization.  The downward sloping curve beyond 
the saturation concentration is the result of a combination of relief of substrate inhibition 
by 6-APA and relatively constant amoxicillin concentration.  As 6-APA is consumed, the 
enzyme-nucleophile dead-end complex (see ENu in Figure 6.1) is less likely to form, 
increasing the concentration of free active enzyme.  Additionally, the concentration of 
amoxicillin that can be hydrolyzed by the enzyme remains constant at the saturation 
concentration, resulting in less enzyme-product complex (EP) and less drag on the 
synthesis reaction moving forward. Figure 6.8.b shows Levenspiel plots when the substrate 
inhibition is removed, showing both the reactor and reactive crystallizer behaving more 
like first-order reactions. Both the sequestration of product in the crystal phase and the 
alleviation of substrate inhibition are necessary to explain the decrease in reciprocal rate at 
conversions between 5% and 73%. Above 73% conversion, the nucleophile concentration 
has been depleted to the point that substrate inhibition by 6-APA starts becoming 
unimportant and the rate rapidly decreases with increasing nucleophile consumption. 
The results of the attainable mean crystal size region are also reflected in the 
Levenspiel plot results. Figure 6.9.a demonstrates how a Levenspiel plot can be used to 
size reactive MSMPRs (rectangles), plug flow reactors (dashed-line bounded area under 
the curve), and vessels in series. The vessels in series represent the reactive MSMPR series 
determined in Figure 6.7.b. The first reactor in the MSMPR cascade in Figure 6.7.b is 
small, and only handles the low conversion required to reach saturation and trigger 
nucleation. The second MSMPR, which is much larger, predominantly operates over the 
downward sloping section of the Levenspiel plot where mixing is advantageous. The third 
MSMPR makes use of the part of the plot where the slope switches back to being positive 
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and back-mixing no longer improves productivity. However, as discussed below, this 
arrangement of reactors does not give the optimal productivity or fractional yield, but only 
the maximum mean crystal size. 
 
Figure 6.9. (a): Sizing a series of reactive MSMPRs, rectangles, and a plug flow reactive crystallizer, 
dash-outlined area under the curve, to achieve a desired conversion using the Levenspiel plots from 
Figure 6.8, in this case the 800:400 HOPGME:6-APA feed concentration ratio. (b) The Pareto-
optimal front for productivity and conversion of 6-APA at 800:400 mM, 600:400 mM, 400:400 mM, 
200:400 mM HOPGME:6-APA feed concentration ratios (blue, red, green, yellow, respectively) in a 
reactive crystallizer (solid lines) and a distinct reactor and separator (dashed lines).  The data points 
are the result of solving the entire PBE for the 800:400 mM, pH 7.0 case. 
The consequences of the atypical Levenspiel plot (Figure 6.9.a) manifest 
themselves in the Pareto front for productivity and conversion (Figure 6.9.b). As mentioned 
above, the reactor size is related to the area under the curve in a Levenspiel plot. The 
residence time of a continuous stirred tank is equal to the area of the rectangle bounded by 
the feed conversion, outlet conversion, abscissa, and reciprocal reaction rate at the outlet 
conversion. The residence time of a plug flow reactor is equal to the area under the curve 
bounded by the feed and outlet conversions. Therefore, a continuous stirred tank has a 
smaller residence time than a plug flow reactor on decreasing Levenspiel curves while the 
opposite is true on increasing Levenspiel curves. The Levenspiel curve decreases for 
reactive crystallization but increases for distinct reaction and separation, therefore a well-
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mixed reactor is preferred for reactive crystallization while a plug flow reactor is more 
efficient when the product is not protected by crystallization. The red rectangle in Figure 
6.9.a demonstrates sizing a single reactive MSMPR to achieve 70% conversion and has a 
residence time of 32 minutes. The red area under the curve illustrates that the same 
residence time as the reactive MSMPR for the distinct reaction and separation, even with 
the optimal plug flow reactor geometry, only reaches 48% conversion. 
The minimum residence time to achieve a set conversion can be found by sizing a 
series of vessels (both well-mixed and plug flow) on a single Levenspiel plot and 
recognizing that stirred tanks are preferred on downward sloping sections and plug flow 
vessels are preferred on upward sloping regions. Somewhat unintuitive for an 
approximately first-order reaction, the well-mixed reactive crystallizer shows superior 
performance to that of a plug-flow reactor.  This is again the result of the enzyme turning 
over faster at lower 6-APA concentrations and of reactive crystallization.   
The Pareto front of productivity (P) and conversion (XNu) can be easily computed 
with the definition of productivity 
feed
Nu NuP c X =  and the minimum residence time (τ) 
determined geometrically with the Levenspiel plot as a function of conversion. In Figure 
6.9.b the productivity is low at low conversion, because the first 5% of 6-APA conversion 
goes towards saturating amoxicillin to produce amoxicillin trihydrate.  At higher 
conversion the productivity continues to increase, uncharacteristically for a first order 
reaction, due to the downward sloping Levenspiel plot. For the distinct reactor and 
separator, the productivity is highest at low conversion; no assumption has been made 
about the separator.  Therefore, losses to the mother liquor are not included as they are for 
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the reactive crystallizer (i.e. supersaturation does not need to be generated). At conversion 
greater than approximately 25%, even with a perfect separator, the benefits of reactive 
crystallization to productivity outweigh the losses of un-crystallized amoxicillin in the 
mother liquor.  
The markers in Figure 6.9.b show that the results for the full PBE solution with the 
method of lines corroborated with the method of moments follow the simplified trend well 
up until very high conversion. Due to the values of the kinetic constants and the feed 
concentrations, the boundary of the attainable region is approached asymptotically despite 
the fact that the reaction rate (and Levenspiel curve) is defined over the entire range of 
conversions. At high conversions the process begins to run up against the edge of the 
attainable region, which is not considered when constructing the Levenspiel plot which 
gives the appearance that all conversions are reachable. Solving the entire PBE with the 
method of lines and method of moments repeatedly for all process conditions and 
conversions is prohibited by the large computational cost, however the attainable region 
has been computed for all process conditions and similar behavior is expected close to the 
edge of each attainable region. 
Figure 6.8.a suggests that the optimal reactor for an equimolar feed or excess 6-
APA (green and yellow curves) is a single plug flow geometry because the Levenspiel 
curves are always increasing. In practice some degree of back-mixing or recycling would 
greatly improve the plug flow geometry to supply seed crystals once the conversion reaches 
amoxicillin saturation.  The optimal network of reactive crystallizers with excess 
HOPGME (Figure 6.8.a, blue and red curves) would consist of a MSMPR feeding a plug-
flow reactive crystallizer; however, based on the attainable region determined in Figure 
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6.6, the addition of the plug-flow reactive crystallizer could, at best, increase the conversion 
another 16%.  Additionally, operating MSMPRs in series would also result in sub-optimal 
productivity, the added volume would not be as well utilized as a plug flow reactive 
crystallizer based on the upward slope of the Levenspiel plot. However, the mean crystal 
size would increase approximately 10% with MSMPRs in series, according to Figure 6.7.a.   
  
Figure 6.10. (a) fractional yield as a function of conversion for reactive crystallizers (solid curves) 
and distinct reactor and separators (dashed curves) at four different feed concentration ratios: 
800:400 mM, 600:400 mM, 400:400 mM, 200:400 mM HOPGME:6-APA (blue, red, green, yellow, 
respectively). (b) reactor geometry considerations based on fractional yield of HOPGME. Solid 
curves are reactive crystallization, dashed curves are distinct reaction and separation. 
Fractional yield can be equally as important depending on the relative cost of the 
reactants.  If the excess reactant (HOPGME) and limiting reactant (6-APA) are costed 
similarly, then the fractional yield becomes an important design criterion. Even if the cost 
of 6-APA is much greater than HOPGME, fractional yield can play an important role in 
designing the process to avoid accumulation of impurities and byproducts. The overall 
fractional yield (Φ) is the amount of amoxicillin produced per amount of HOPGME 
consumed on a per mole basis.  Figure 6.10.a shows the fractional yield versus conversion 
for reactive crystallization (solid curve) and distinct reaction and separation (dashed curve) 
at an initial feed concentration ratio of 800:400 mM HOPGME:6-APA.  Figure 6.10.b also 
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demonstrates how reactor geometry considerations can be determined graphically; a 
reactive crystallizer with perfect back-mixing (blue rectangle) and plug-flow reactor 
without crystallization (red area under curve) are both sized to achieve an overall fractional 
yield Φ = 0.70. The overall fractional conversion of the well-mixed reactive crystallizer is 
determined by the output conversion on the fractional yield curve, while the overall 
fractional yield of the plug flow reactive crystallizer is the average of the fractional yield 
curve over the inlet to outlet conversion range.164 The plug flow geometry generally has 
superior overall fractional yield compared to a stirred tank when the fractional yield is 
monotonically decreasing with conversion, as is the case here.  However, the reactive 
crystallization scheme shows that an MSMPR system operating at 91% conversion has the 
same overall fractional yield as a non-crystallizing plug flow reactor operating at 67% 
conversion, despite the inherent superiority of the plug flow design. Figure 6.10.a shows 
the fractional yield Pareto-optimal front for the other feed concentration ratios. Figure 
6.10.a also shows that the results from solving the full PBE (data points) align well with 
the simplified calculations, only deviating at high conversion where the edge of the 
attainable region is not considered. 
A Pareto-optimal surface can be constructed by combining the graphical 
approaches presented for the determination of the Pareto-optimal fronts for productivity 
and conversion, together with fractional yield and conversion.  The blue region in Figure 
6.11 represents the attainable productivity and selectivity at different 6-APA conversions, 
shown by the white curves, for a concentration feed ratio of 800:400 mM HOPGME:6-
APA at pH 7.  As was shown in Figure 6.9, the highest productivity can be attained at a 6-
APA conversion between 0.7 and 0.75.  The surface shows that, at a conversion of 0.75, 
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approximately 20 g/L/h of productivity can be sacrificed to increase the fractional yield 
from 81% to 84%, demonstrated by following the white curve labeled 0.75 from right to 
left.  At high conversion (e.g. 0.875) the productivity and fractional yield can both be 
improved simultaneously, which is a result of requiring additional vessels in series or a 
plug flow reactive crystallizer to maximize productivity at high conversion (see Figure 
6.8). 
 
Figure 6.11. The Pareto-optimal surface for 6-APA conversion, productivity, and fractional yield for 
the reactive crystallization of amoxicillin.  The blue region represents the attainable fractional yield 
as a function of productivity.  The white curves represent constant conversion of 6-APA. 
6.4.3 Further improvements 
Two additional unexplored avenues to increase the mean crystal size are classified 
fines removal (CFR) and variable enzyme concentration. 
The crystal residence time dependence on crystal size can be used to implement 
classified fines removal. By preferentially removing small crystals or fines from the 
crystallizer, the mean crystal size is increased significantly.54, 165-167 At steady state, fines 
are the dominant crystal based on number fraction, however, they make up only a few 
percent of the total mass of the crystals.  Removing the crystals smaller than 10 μm at three 
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times the rate of crystals larger than 10 μm increases the mean crystal size in a single vessel 
by 33%, from 54.0 μm to 71.8 μm, while decreasing the yield 1.2% (this yield loss could 
be removed by introducing a fines dissolver and recycling the solute).  Figure 6.12 shows 
the volume-weighted crystal size distribution with and without fines removal.  A 
consequence of the fines removal is the broadening of the CSD, as can be seen in Figure 
6.12. A compromise between large mean crystal size and narrowness of the CSD must be 
reached. As discussed in CHAPTER 5, the broadening of the size distribution as a result 
of Growth Rate Dispersion must also be considered. 
 
Figure 6.12.  The CSD for a reactive MSMPR (red) and a reactive crystallizer with fines removal. 
All of the results presented above were determined with an enzyme concentration 
of 5 μM.  Changing the enzyme concentration could be a potential means of further 
improving process attributes such as fractional yield, mean crystal size, and productivity.  
Figure 6.13 shows that, relative to the 5 μM standard PGA concentration, increasing the 
enzyme concentration further increases the mean crystal size slightly and the productivity 
considerably while barely decreasing the fractional yield.  The increased size is a result of 
higher supersaturation in the reactive crystallizer (which also causes the negligible decrease 
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in fractional yield).  The large increase in productivity is not a surprising result; if presented 
on a per-gram-catalyst basis the productivity is the same at all four PGA concentrations 
investigated.  To maximize productivity on a per-liter basis the highest PGA concentration 
feasible should be used, however, unmodeled physical phenomena, such as enzyme 
separation and aggregated enzyme contamination that limit the active concentration. The 
enzyme is also costly, which limits how much enzyme should be used. 
 
Figure 6.13. The effects of changing the enzyme concentration on the fractional yield (Φ), mean 
crystal size ( 43L ), and productivity (P).  The values of these attributes are shown relative to the value 
found with an enzyme concentration of 5 μM and a conversion of 70%. 1.0 μM, 2.5 μM, and 10 μM 
are shown in lavender, teal, and navy, respectively. 
The concentration of active enzyme also changes with time as the enzyme decays.  
At the selected operating condition of 298 K the enzyme loses negligible activity over 
1,000 residence times at maximum productivity (201 g/L/h at 298 K).  At elevated 
temperatures the enzyme stability decreases but the activity increases. The half-life of the 
enzyme drops to only 4 days if the temperature is increased to 318 K, which could 
significantly increase operating costs despite the expected increase in activity. 
6.5 Conclusion 
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A model is developed for the simulation of continuous reactive crystallization of β-
lactam antibiotics catalyzed by penicillin G acylase. To the authors’ knowledge, this is the 
first model of continuous reactive crystallization with an enzymatic reaction. Attainable 
regions showed that a maximum conversion of 6-APA to amoxicillin of 98% was reachable 
with an excess of HOPGME of 400 mM and a reactive crystallizer, while only 72% 
conversion of 6-APA was possible under the same reaction conditions without 
crystallization.  Attainable crystal size regions showed that the use of MSMPR crystallizers 
in series could boost the mean size by 5 μm, but at the cost of increased residence time. 
Classical chemical engineering techniques for process design were used to develop 
a more detailed understanding of the continuous reactive crystallization system. Levenspiel 
plots showed that an MSMPR is desired to maximize productivity when the conversion of 
6-APA was between 10% and 73%, with an excess of HOPGME. The back-mixing 
increases productivity by two mechanisms: first by seeding the reactor so that 
crystallization is equilibrium controlled, and second by alleviating substrate inhibition by 
operating at lower 6-APA concentrations than in the feed. Interestingly, neither of these 
two mechanisms is substantive enough to favor a well-mixed system over a plug-flow 
system by themselves, but together a well-mixed reactive crystallizer becomes more 
productive. 
A Pareto optimal surface for productivity, fractional yield, and conversion was 
calculated. As the 6-APA conversion is increased up to 87%, both productivity and 
fractional yield decrease. However, at conversions greater than 87%, the productivity and 
fractional yield are maximized at the same operating conditions. The Pareto optimal fronts 
calculated with the simplifying assumptions regarding equilibrium control of 
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crystallization agree well with those calculated with the computationally expensive 
population balance equations.  The Pareto optimal surface will help inform design of an 




CHAPTER 7. IMPLICATIONS OF THE REACTIVE 
CRYSTALLIZER MODEL: A CASE STUDY ON PRODUCT 
PURITY6 
7.1 Introduction 
 In the previous chapter a detailed model was built for the continuous manufacturing 
process for the reactive crystallization of beta-lactams. The bounds on the achievable 
process metrics (conversion, productivity, and fractional yield) were given in the form of 
a Pareto-optimal surface. However, one of the most important design constraints is missing 
from the discussion in CHAPTER 6, product purity. In the case of amoxicillin this is not a 
significant issue because, as shown in Figure 6.2, HOPG is nearly three times as soluble as 
phenylglycine and optimizing for the three process metrics (conversion, selectivity, and 
productivity) alone prevents crystallization of HOPG. This is not the case for cephalexin 
or the favored model beta-lactam ampicillin.158 While the antibiotic could be separated 
from an insoluble contaminant with a downstream separation, a process design in which 
further purification is not required is more economical and robust. 
For cephalexin the purity of the product is more difficult to ensure when optimizing 
for the other three process metrics. In this chapter, the design for an optimal plant producing 
 
6 Adapted from “Computers & Chemical Engineering, 126, McDonald, M.A.; Bommarius, A.S.; Grover, 
M.A.; Rousseau, R.W. Continuous reactive crystallization of β-lactam antibiotics catalyzed by penicillin G 
acylase. Part II: Case study on ampicillin and product purity, 332-341.” Copyright (2019), with permission 
from Elsevier. 
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1,600 kg/day of cephalexin, roughly 10% of global demand, is developed (for reference, 
as of 2019 there are only three FDA-approved cephalexin manufacturers).168  
Continuous manufacturing is a design benefit for ensuring product quality, not a 
design hurdle that must be overcome. As of 2019, five drugs have received FDA approval 
to transition from batch to continuous manufacturing (among them, Orkambi® 
(lumacaftor/ivacaftor) and Symdeko® (tezacaftor/ivacaftor), both Vertex, 2015 and 2018,  
Prezista® (darunavir), Janssen Pharmaceuticals 2016, prexasertib and Verzenio® 
(abemaciclib), both Eli Lilly, 2017; improved reliability and quality were key factors in 
each decision.169 Cephalexin, and amoxicillin, could be the next drugs to transition to CM.  
The model used in this chapter is the same the previous chapter, but complemented 
with a second population balance to account of the crystallization of phenylglycine. The 
second population balance is solved with the moment transformation because, unlike for 
the antibiotic product, the details of the crystal size distribution (CSD) of the byproduct are 
not considered. Only the operating space where phenylglycine does not crystallize is 
suitable for antibiotic production. The moments of the phenylglycine population balance 
are solved simultaneously with the moments of the ampicillin population balance. It is 
assumed that the crystal phases of the two species do not interact (i.e. they do not 
agglomerate nor does the presence of one crystal promote or inhibit nucleation or growth 
of the other), although rigorous experimentation should be performed to confirm the non-
interaction. The crystallization parameters needed for both population balances are 
reported in Table 7.1 (note the ampicillin column is redundant from the previous chapter). 
Table 7.1. The parameter values used to model the crystallization of ampicillin and byproduct 
phenylglycine.89, 170 Notes: a values for phenylalanine anhydrate used in place of phenylglycine, the 
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crystallization kinetics of phenylglycine anhydrate have not been published but based on experiments 
during the course of this thesis they can be approximated satisfactorily with the similar molecule 
phenylalanine. 
Parameter Ampicillin trihydrate Phenylglycine Units 
c*pI 20.5 35.0 mmol L-1 
pKa0 7.35 8.70 - 
z 0 0 - 
kG 8.95 5.10 a μm min-1 
g 1.87 1.76 a - 
kB1 5.00 × 1010 7.0 × 1010 a L-1 min-1 
Bo 1.27 1.95 a - 
kB2 2.20 × 109 2.36 × 108 a L-1 min-1 
m 0.60 1.84 a - 
b 1.37 1.92 a - 
kV 0.03 0.10 - 
ρ 1.5 × 10-12 1.3 × 10-12 g μm-3 
 
7.2 Results and Discussion 
7.2.1 Well-mixed enzymatic reactive crystallizer 
Attainable regions for ampicillin trihydrate production were constructed to place 
bounds on the feasible conversion of 6-APA to antibiotic.  The same methodology was 
used in the previous chapter, but here an additional constraint on the attainable region was 
added to account for potential phenylglycine crystallizing and contaminating the product 
stream.  Briefly, a reaction vector is drawn at each point in conversion space, using 
equations 6.3 and 6.4, and the attainable region boundary is drawn from the feed point (in 
the present study, zero conversion of 6-APA or PGME) along the tangents of the rate 
vectors.  Ampicillin produced while ampicillin is under-saturated is removed from the 
attainable region because it does not contribute to the production of ampicillin trihydrate 
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crystals.  The ampicillin under-saturation region accounts for the first 5% of 6-APA 
conversion, therefore the entire region is then shifted 5% down in 6-APA conversion. 
Finally, the area where the amount of PGME converted is greater than the amount of 6-
APA converted less the saturation of phenylglycine (
*
,S Nu B S feedX X c c − ), is removed 
from the attainable region because it corresponds to the phenylglycine supersaturation 
region.  
 
Figure 7.1. The attainable regions, in the PGME 6-APA conversion space, for ampicillin produced 
without in situ crystallization (a) and ampicillin produced by reactive crystallization (b).  The blue, 
red, green, and yellow regions represent 800:400, 600:400, 400:400, and 200:400 mM PGME:6-APA 
initial/feed concentrations.  The light-colored regions are at pH 6.5 and the dark colored regions are 
at pH 7.0.  The dashed black lines represent stoichiometric conversion of PGME and 6-APA to 
ampicillin.  The white-washed (lightest colored) regions on the right represent the regime in which 
phenylglycine and ampicillin crystallize simultaneously, jeopardizing product purity. 
In Figure 7.1, the attainable region for ampicillin synthesis by PGA without in situ 
crystallization (left) is much larger than that for reactive crystallization (right), in contrast 
to the result for amoxicillin (CHAPTER 6).  The large size of the non-crystallizing 
attainable regions (compared to that for amoxicillin) can be attributed to the slower rate of 
hydrolysis of ampicillin compared to amoxicillin.  The small size of the reactive 
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crystallization attainable region is the result of the low solubility of phenylglycine (35 and 
36 mM at pH 6.5 and 7, respectively).  No assumption is made regarding the separation of 
ampicillin in the non-reactive-crystallizing system, therefore, the potential crystallization 
of phenylglycine is not considered a restriction on the non-crystallizing attainable region 
(e.g. phenylglycine crystallization may not effect membrane-based purification of 
ampicillin171).  As the maximum conversion of 6-APA is similar in both Figure 7.1.a and 
2.b (88% versus 93%), the advantages of reactive crystallization for ampicillin synthesis 
are rooted in productivity and simplicity of process design as opposed to improved 
conversion/yield, as was the case for amoxicillin (CHAPTER 6).  
Previously, it was shown that the productivity of amoxicillin is optimized with a 
single well-mixed reactive crystallizer tuned to a specific residence time and enzyme 
concentration.21  A similar setup can be sized for ampicillin, which due to small differences 
in the enzyme reaction kinetics, has a slightly different optimal residence time. In Figure 
7.2, a plot of productivity versus residence time of a single reactive MSMPR (at a fixed 
enzyme concentration) shows that a maximum productivity of 191 g/L/h is attained at a 
residence time of 42.0 minutes for a PGME:6-APA feed concentration ratio of 800:400 
mM. For comparison, amoxicillin productivity under the same conditions is 6% greater on 
a per mole basis at a residence time of 38.0 minutes. The dashed lines in Figure 7.2 denote 
the productivity of the distinct reactor and separator; no assumptions about the method of 
separation are made, perfect separation is assumed here. Therefore, no loss of ampicillin 
to the spent solvent (which results in the initial lack of productivity for reactive 
crystallization) is included in the distinct reactor and separator. 
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Figure 7.2. (a) the productivity of a reactive MSMPR (solid) and non-crystallizing well-mixed reactor 
(dashed) for different residence times and feed concentration ratios. (b) the conversion of 6-APA in a 
reactive MSMPR (solid) and non-crystallizing well-mixed reactor (dashed) for different residence 
times and feed concentration ratios (blue 800:400, red 600:400, green 400:400, yellow 200:400 mM 
PGME:6-APA). The black dotted line represents the maximum conversion, as shown in Figure 7.1. 
Figure 7.2.a shows that the productivity in a reactive MSMPR for the 800:400 mM 
ratio is 40% higher than the 600:400 feed ratio and 140% higher than the 400:400 feed 
ratio. Figure 7.2.b shows that, while both the 800:400 and 600:400 feed ratio reach the 
maximum conversion in a reactive MSMPR (dotted black line), the 800:400 feed ratio 
reaches maximum conversion appreciably faster. From this point forward only the highest 
feed concentration ratio of PGME to 6-APA, 800:400 mM, will be considered because it 
gives the highest productivity and yield in a reactive MSMPR.   
However, Figure 7.1.b showed that the attainable region for 800:400 PGME:6-APA 
only extends to 55% conversion of PGME.  Therefore, a significant amount of the feed 
PGME will go unreacted in favor of high conversion of 6-APA, good productivity, and 
>99.99% purity. A possible process improvement not considered in the present study 
would be to recycle the unreacted PGME. A PGME recycle would enable part of the 
unreacted 45% of PGME to be used to convert additional 6-APA. This would enable the 
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process to use a smaller excess of PGME while still maintaining the reactive crystallization 
benefits of an 800:400 PGME:6-APA ratio. While the means of PGME recycle has not 
been studied here, selective removal of the phenylglycine, possibly by crystallization, 
could enable reuse of the PGME-containing mother liquor, which would have the added 
benefit of recovering additional antibiotic from the mother liquor as well. Both the 
productivity and conversion (Figure 7.2.a and 3.b) should be considered in the final design 
of a continuous process, which metric is more important depends on specific economics. 
The optimal conditions are also sensitive to variations in operating conditions. 
Tight process control, particularly on temperature and residence time, which have an 
outsized impact on the process metrics, is recommended to maintain optimal steady state 
performance. For instance, at elevated temperature, the reaction rate increases, increasing 
the optimal productivity, however the solubility also increases, decreasing the optimal 
conversion. Purity, which is the most important process metric, can take on multiple steady 
states if the process is not adequately controlled.  
7.2.2 Steady state multiplicity in reactive MSMPRs 
In many cases, a supersaturated solution of phenylglycine exits the reactive 
MSMPR, and the relationship between that supersaturation and phenylglycine nucleation 
kinetics determines the state of the system.  If the phenylglycine suspension density is 
negligible (say < 0.03 g/L), new crystals will be formed predominantly by primary 
nucleation and removed from the crystallizer without the formation of substantial crystal 
mass. On the other hand, a significant phenylglycine suspension density increases the rate 
of secondary nucleation, which will generate phenylglycine crystals to accommodate the 
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rate at which they are removed. In the latter of these two cases, an impure product stream 
will ensue.  While both steady states are stable, it is possible for a disruption to trigger the 
process to transition from the favorable to the unfavorable steady state. Reverting from the 
unfavorable back to the favorable steady state is difficult because a large mass of 
phenylglycine crystals must be washed out of the crystallizer. External disturbances, as 
well as uncertainty in parameter estimation, require the design of a robust process for pure 
ampicillin production. 
 
Figure 7.3. (a) The coexistence of two steady states over the range of residence times from 41.5 to 43 
minutes, demonstrated by the hysteresis of the phenylglycine suspension density, MT (top) and 
supersaturation, σ (bottom).  The solid curves were generated by reaching steady state from a low 
suspension density initial state, and the dashed curves are from a high suspension density initial 
state. (b) A perturbation in the residence time of 5%, lasting 58 minutes and 60 minutes, leading the 
process to slowly decay back to the high-purity steady state and jump to the low-purity steady state, 
respectively. The noise at the second steady state in (b) stems from how the differential equation 
solver handles stiffness; solving for the steady state explicitly (by finding the roots of the equation) 
shows that the steady state is exactly 0.9856. 
Figure 7.3.a demonstrates how two stable steady states exist for an ampicillin-
producing reactive MSMPR with a feed concentration ratio of 800:400 mM PGME:6-APA.  
The solid and dashed curves represent the two different steady states; a hysteresis occurs 
where the low suspension density (solid curve) steady state prevails when increasing the 
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residence time while the high suspension density (dashed curve) steady state is dominant 
when decreasing the residence time.  The coexistence of two steady states depends on both 
supersaturation as well as residence time; therefore, at some shorter residence times, one 
value of supersaturation results in a pure effluent while the same supersaturation at a longer 
residence time results in an impure effluent (physical mixture of ampicillin and 
phenylglycine crystals). Tavare and Garside developed a concentration criterion for an 
MSMPR, which has been adapted here for a reactive MSMPR, to determine whether a 
steady state is unique.172 Defined in equation 7.1, this criterion limits the steady-state 
concentration of a crystallizing solute and informs further process design (the derivation of 
this criterion is given in section 7.4). In the example in Figure 7.3.b (τ = 42, cs,0 = 800 mM, 
cNu,0 = 400 mM, pH = 7.0) the criterion has a value of 45.9 mM and the steady state 
concentration is 47.1 mM for phenylglycine. 
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  (7.1) 
This criterion only considers secondary nucleation because of the stochastic nature 
of primary nucleation. Assuming that primary nucleation occurs at a deterministic rate 
governed by classical nucleation theory, a modified stability criterion can be developed, 
however a simple analytical representation similar to that given in equation 7.1 is not 
obtainable. Including primary nucleation does not noticeably change the value of the 
criterion in equation 7.1 because secondary nucleation is responsible for the formation of 
the overwhelming majority of crystals (see Figure 7.9). Inclusion of primary nucleation 
does shift the “pure” steady state (SS1 in Figure 7.3.b) to a negligibly lower purity (from 
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100% to >99.99%), but the stochastic nature of primary nucleation indicates that this is the 
expected value over many perturbations. 
Figure 7.3.b demonstrates how a perturbation can take the reactive crystallizer to 
the second steady state where the amount of solid phenylglycine in the effluent results in 
the purity of ampicillin decreasing from >99.99% to 98.56%. In Figure 7.3.b, the residence 
time of the reactive crystallizer is increased 5% (from 42 minutes to 44 minutes) for 
approximately one hour.  Disturbances lasting less than an hour do not result in a change 
of steady state, while those lasting an hour or longer trigger the system to switch to the 
impure steady state. The transition to the new steady state, or the return to the original 
steady state, is gradual, taking tens of residence times, making the transition hard to 
observe. It is therefore important to build a process where the risk of an impure steady state 
is negligible. 
7.2.3 Reactive crystallizers in series for robust purity 
The purity constraint elevates the importance of the fractional yield (Φ). Fractional 
yield, defined as the amount of ampicillin produced over the amount of ampicillin and 
phenylglycine produced, as a function of conversion, determines the maximum conversion 
possible while maintaining purity.  The light gray shaded region in Figure 7.4 indicates the 
region where a reactive MSMPR producing ampicillin has multiple steady states, at least 
one with purity > 99.99% and one with untenable phenylglycine impurity greater than 
1.0%.  The dark shaded region in Figure 7.4 shows the region where only a single impure 
steady state exists and phenylglycine will crystallize and contaminate the ampicillin 
trihydrate product.   
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Figure 7.4. The operating curves in fractional yield versus conversion space for a plug-flow reactive 
crystallizer (top solid curve, ×) and a well-mixed reactive crystallizer (bottom solid curve, +) with 
feed concentration of 800 mM PGME and 400 mM 6-APA. The dashed curve represents a well-
mixed reactor (no crystallization).  The light shaded area is the region where reactive MSMPRs 
exhibit steady-state multiplicity and the dark shaded area is the region where primary nucleation 
results in impure ampicillin product regardless of reactor design.  The labeled markers represent the 
residence time needed to reach the specified conversion and fractional yield in a plug flow (×) and 
well-mixed reactive crystallizer (+).  The blue, red, and yellow curves are plug- flow reactive 
crystallizer operating curves that are fed by reactive MSMPRS with residence times of 10, 25, and 35 
minutes, respectively.  
In section 6.4.1 of this thesis, well-mixed vessels in series were considered for a β-
lactam antibiotic producing process; in this section the plug-flow reactive crystallizer 
(PFRC) is introduced because it can achieve superior fractional yields.  However, the PFRC 
requires seed crystals during steady state operation to function effectively because 
nucleation predominantly occurs via primary nucleation173, which is orders of magnitude 
slower than secondary nucleation. To address the seeding issue, a reactive MSMPR, which 
at steady state is self-seeding, can generate nuclei, predominantly via secondary nucleation, 
and feed the PFRC. The population balance equation for the plug flow reactive crystallizer 
is expressed as 
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where y is the axial coordinate of the PFR and uy is the velocity in the axial direction. The 
nucleation boundary condition is ( ) 10,j j jn z B G= , note that only primary nucleation is 
considered because diminished mixing in plug flow decreases the secondary nucleation 
rate.174, 175  The inlet boundary condition, ( ),0jn L , is the outlet from a reactive MSMPR, 
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where the boundary condition is again the outlet from a reactive MSMPR, as described in 
the previous chapter equation 6.13. 
In Figure 7.4, the PFRC and MSMPR operating curves form the upper and lower 
bounds on the achievable fractional yield as a function of conversion (the solid black curves 
marked with × and +, respectively).  The lack of back-mixing in the PFRC means that only 
a single steady state is possible, and therefore a PFRC can operate up to the dark shaded 
region and maintain less than 1.0% phenylglycine impurity.  On the other hand, the 
MSMPR can only operate up to the lightly shaded region before the risk of the process 
being perturbed to an impure steady state arises.   
The blue, red, and yellow curves represent PFRC operating curves fed by reactive 
MSMPRs with residence times of 10, 25, and 35 minutes in the MSMPR, respectively. 
These three operating curves, together with the MSMPR operating curve up to the feed 
point, will be referred to as Designs 1, 2 and 3, respectively. The number labels on the 
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PFRC and MSMPR operating curves are the residence times (in minutes) required for a 
PFRC or MSMPR to reach that conversion and fractional yield. As can be seen, the 
MSMPR reaches higher conversions with shorter residence times than the PFRC, as was 
expected based on the results for amoxicillin in the previous chapter. Design 1 achieves 
18% conversion in the MSMPR, Design 2 achieves 44% conversion in the MSMPR, and 
Design 3 achieves 67% conversion in the MSMPR. Figure 7.5 shows the reaction rate in 
the MSMPR for each design, as well as the reaction rate along the length of the PFRC. The 
size of the MSMPR markers is proportional to the volume needed to achieve that 
conversion. It also shows that with crystallization (solid), the reaction rate is always higher 
than without crystallization (dashed), due to lower hydrolysable antibiotic concentration, 
as ampicillin is sequestered in the trihydrate crystal (discussed in detail in CHAPTER 6). 
 
Figure 7.5. The solid curve shows the reaction rate with in situ crystallization while the dashed line 
shows the reaction rate without crystallization. The colored squares are the reactive MSMPRs 
operating at the specified conversion with size proportional to the MSMPR volume.  The bolded solid 
line represents the range of conversion that occurs over the length of the PFRC, fed by each of the 
MSMPRs. 
It has already been shown for amoxicillin that the reaction kinetics favor 
implementation of a reactive MSMPR over a PFRC to maximize productivity from 5% to 
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73% conversion, but the benefit of an MSMPR over a PFRC decreases above 73% 
conversion.21 Applying the same findings to ampicillin production suggests that the nuclei-
generating MSMPR should be operated up to the largest conversion possible such that the 
maximum yield of the PFRC is not significantly impacted.  The yellow curve in Figure 7.4 
shows that as long as the MSMPR does not go beyond 70% conversion, the maximum 
possible conversion still reaches 98% of the theoretical maximum before contamination 
greater than 0.5% becomes certain—in the dark shaded region. Whether a disturbance can 
cause MSMPR operation to enter the light shaded region, or PFRC operation to enter the 
dark shaded region, needs to be considered for a robust process. 
The spatial distribution of productivity throughout the reactor network is shown in 
Figure 7.6. In Figure 7.6, the size of the square is proportional to the residence time of the 
reactive MSMPR and the length of the rectangle is proportional to the residence time of 
the plug flow reactive crystallizer. The color indicates the space time yield, which is the 
productivity of the vessel distributed across its volume (reactive MSMPRs, being well 
mixed, are uniformly colored). The last 5–10 minutes of the plug flow reactive crystallizer 
is not very productive but is necessary to reach high conversion.  The plug flow reactive 
crystallizers can be shortened to further improve productivity if single pass conversion is 
not as important (e.g. if unused reactants can be efficiently recycled). 
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Figure 7.6. The productivity of the reactive MSMPR fed plug flow reactive crystallizer is shown by 
the degree of shading (lighter hues indicating greater productivity) in the well-mixed vessel (square) 
and the plug flow vessel (rectangle).  The area of the square and rectangle are proportional to the 
volume of each vessel.  The residence time of the reactive MSMPR is labeled in the square, the 
residence time of each plug flow reactive crystallizer is shown on the abscissa. The top, middle, and 
bottom reactors represent Designs 3, 2, and 1, the yellow, red, and blue operating curves in Figure 
7.4. 
The CSD from each of these reactor configurations also differs significantly.  Plug 
flow crystallizers produce desirable narrow size distributions because all crystals have the 
same residence time, and therefore grow by the same amount. MSMPRs produce wide 
CSDs because of their exponential residence time distribution. Additionally, secondary 
nucleation is not considered in plug flow crystallizers because mixing is weakened. Figure 
7.7 shows the volume-weighted size distributions from Designs 1, 2, and 3. The area under 
each CSD is the same, confirming that each design gives the same conversion of 6-APA. 
Design 1 has the narrowest size distribution and a volume-weighted mean crystal size 4,3L  
of 54.5 μm. Designs 2 and 3 have very similar, but wider, size distributions and volume 
weighted mean sizes of 50.5 and 51.5 μm, respectively, suggesting that most of the growth 
is occurring in the MSMPR. Depending on the form factor of the final product (powder for 
suspension, capsule, etc.), the CSD shape may be as important as or even more important 
than economic criteria such as conversion and productivity.  
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Figure 7.7. The volume weighted CSD of ampicillin trihydrate resulting from the blue, red, and 
yellow operating lines in Figure 7.4. 
7.2.4 Evaluation of process robustness 
The most favorable process will be one that is robust despite uncertainty. In the 
present study two sources of uncertainty are considered: uncertainty in parameter values 
and variability of operating conditions.  The first could be the result of poor model 
calibration, but it is equally plausible that slight impurities in the feed could change the 
values of the kinetics parameters used in the model.  The second source of uncertainty 
accounts for environmental fluctuations that cannot be controlled.  To demonstrate this 
uncertainty, and the robustness of the MSMPR-fed PFRCs compared to a single optimized 
reactive MSMPR, we simulate a 10% decrease in the solubility of phenylglycine at the 
isoelectric point (c*) as well as a 2 °C increase in temperature from 25 °C to 27 °C. 
The decrease in solubility was selected as the source of “parameter uncertainty” 
because a change in solubility effects the driving force of crystallization, impacting growth 
and nucleation kinetics, combining for a larger purity deviation than an aberration in 
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growth or nucleation alone. The change in temperature was chosen to illustrate how a 
source of “operational uncertainty” affects the optimized process because as the scale is 
increased temperature control becomes increasingly difficult, and the solubility and 
reaction rates are strongly temperature dependent. While one can imagine other possible 
operational deviations, such as a change in flow rate, maintaining a uniform temperature 
in a scaled-up process poses one of the biggest challenges. 
Figure 7.8.a demonstrates the robustness of the purity of the effluent from the 
MSMPR-fed PFRCs.  A single reactive MSMPR generates a 98.8% pure ampicillin 
trihydrate effluent when the solubility of the primary byproduct, phenylglycine, decreases 
10% compared to the value used in the above analysis (see Table 7.1). Under the same 
conditions, the purity of Designs 1, 2, and 3 remains at >99.99%.  When the temperature 
of the reactive crystallizer is increased by 2 °C, the single reactive MSMPR purity drops 
to 95.9%.  The purity of Design 3 also decreases to 98.8%, but the two smaller MSMPR 
designs continue to yield >99.99% pure ampicillin trihydrate. In fact, Design 1 never 
reaches phenylglycine supersaturation, all but guaranteeing purity, even with the 
possibility that phenylglycine crystallization could be catalyzed by the presence of the 




Figure 7.8. (a) The purity of the effluent crystals from the different reactive crystallizer designs with 
a 10% decrease in phenylglycine solubility (darker shades) and 2 °C increase in temperature (light 
shades). (b) The productivity of the different reactive crystallizer configurations as well as a non-
crystallizing well-mixed reactor at the same final 6-APA conversion of 90%. 
To design the optimal process for the continuous synthesis of ampicillin trihydrate, 
robust purity needs to be weighed against economic factors such as yield and productivity, 
which are proxies for materials and capital costs.  Figure 7.8.a and 9.b taken together can 
help inform design. Based on the purity robustness and good productivity, Design 2 is 
recommended.  Confidence in tight process control could, however, make a single reactive 
MSMPR the favored design.   
As stated previously, ampicillin is a favorite model β-lactam, therefore, parameters 
used in the present study can be sourced from the literature for ampicillin but are not 
available for the far more important β-lactam cephalexin.  Because of the similarity of 
ampicillin and cephalexin—they both have phenylglycine as a primary byproduct and are 
synthesized with PGA—the results for ampicillin trihydrate are generalized here to 
cephalexin for the purpose of sizing a production plant. It is likely that the kinetics for 
cephalexin will differ from those for ampicillin, and therefore the calculations may need to 
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be rerun with updated kinetic constants to predict exact values of process metrics such as 
productivity and conversion for cephalexin. However, for the purposes of purity, both 
medicines have similar solubility and the same risk of phenylglycine contamination and 
are therefore suitable analogs for an illustrative sizing for production of a clinically vital 
drug; cephalexin.  
The global demand for cephalexin is approximately 6,000 tons per annum.  To meet 
10% of this demand using the proposed continuous enzymatic reactive crystallizer system, 
assuming 10% annual downtime, a 430-L total-volume reactive crystallizer would be 
needed. While 10% downtime is assumed, the actual time required for startup and 
shutdown has not been calculated. According to Design 2, the reactive crystallizer should 
consist of a 205-L reactive MSMPR and a 225-L plug flow reactive crystallizer in series 
and should be fed with 800 mM PGME and 400 mM 6-APA at a rate of 5.8 L min-1. Sizing 
a reactive plug flow crystallizer is non-trivial, the diameter must be small enough for 
turbulent flow to keep the crystals from settling but large enough to prevent the crystals 
from clogging. A computational fluid dynamics simulation could assist in the design of 
such an apparatus; a rough calculation indicates that the plug flow tube would have to be 
on the order of 100 meters long and several centimeters in diameter, static mixers could 
help maintain the suspension. 
7.3 Conclusions 
Using the model developed in CHAPTER 6, a process for the production of 
ampicillin was designed.21 Combined reaction and crystallization is shown to increase 
conversion and productivity of β-lactams, as well as reduce the risk of β-lactam 
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contamination in other drugs. Given the goal increased efficiency by process 
intensification, an additional purification step is undesired; therefore, purity of the effluent 
crystals is a paramount consideration in designing the process.  The single well-mixed 
reactive crystallizer design that had been employed for amoxicillin in CHAPTER 6 is not 
effective for ampicillin (or cephalexin) because phenylglycine, the byproduct of ampicillin 
(or cephalexin), is only slightly soluble, and its potential crystallization can contaminate 
the product. With ampicillin, the single reactive MSMPR has at least two steady-state 
conditions, one of which produces low-purity ampicillin trihydrate. Perturbations in the 
process can cause the system to change from one steady state to the other.  A plug-flow 
reactive crystallizer has higher fractional yield, leading to less accumulation of 
phenylglycine and reduced risk of the product being contaminated. However, a PFRC has 
lower productivity and detrimentally slow crystal nucleation kinetics compared to a 
reactive MSMPR. A reactive MSMPR-fed PFRC can combine the strengths of both 
reactor/crystallizer types. 
Three different MSMPR-fed PFRCs were considered: a reactive MSMPR with 10 
minutes, 25 minutes, or 35 minutes residence time followed by a plug flow reactive 
crystallizer with enough volume to reach 98% of the maximum possible conversion (as 
determined from the attainable regions, and equivalent to the conversion in a single 
optimized reactive MSMPR).  Designs 1, 2, and 3 are 94%, 95%, and 96% as productive 
as and 30%, 27%, and 26% larger than the MSMPR alone. All proposed designs have 
productivity 50% greater than a non-crystallizing reactor. The MSMPR-fed PFRC 
demonstrates much better robustness in the face of parameter uncertainty and operational 
variability than the MSMPR alone.  Designs 1 and 2 produce >99.99% pure ampicillin with 
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a 10% error in modeled phenylglycine solubility and 2 °C increase in process temperature.  
Additionally, Design 1 never generates any phenylglycine supersaturation, ensuring purity 
if phenomena not captured by the model cause phenylglycine crystallization (e.g. 
nucleation catalyzed by the presence of ampicillin crystals). Adapting Design 2 to meet 
10% of the annual demand for cephalexin yielded a realistic blueprint for a new continuous 
β-lactam producing plant. 
7.4 Derivation of steady state uniqueness criterion in a reactive MSMPR 
Steady state multiplicity in well-mixed continuous crystallizers was studied by 
Tavare and Garside in 1985.172 The framework they established is modified here to 
determine steady state multiplicity in reactive crystallizers. A solute balance for the 
reaction product in a well-mixed reactive crystallizer (assuming no solute in the feed) is 
given by: 
 TM R c= −   (7.4) 
where MT is the suspension density, R is the reaction rate, τ is the mean residence time, and 
c is the solute concentration. Crystal growth rate (G) and nucleation rate (B) are represented 
by a power laws; growth is independent of crystal size, and nucleation occurs 
predominantly through secondary nucleation, as shown in equations 7.5 and 7.6: 
 ( )1
g
GG k S= −    (7.5) 
 ( )1
bm
B TB k M S= −   (7.6) 
with rate coefficients kG and kB, exponents g and b, and supersaturation ratio *S c c= . The 
assumption that primary nucleation is unimportant for this analysis is justified by the fact 
that secondary nucleation is orders of magnitude faster in the presence of any other crystals; 
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Figure 7.9 shows the primary and secondary nucleation rates with a very low suspension 
density of MT = 0.01 g/L.  
 
Figure 7.9. The primary (blue) and secondary (red) nucleation rates of phenylglycine with a 
suspension density of 0.01 g/L. 
At steady state, the method of moments can be used to show that the suspension 
density is proportional to the residence time, growth rate, and nucleation rate, according to 
equation 7.7. 
 4 36T VM k G B=   (7.7) 
where kV is the volumetric shape factor and ρ is the crystal density.  Equations 7.5-7.7 can 
be made dimensionless with a dimensionless concentration, x c R= , and dimensionless 
saturation concentration, *c R = . Substituting equations 7.5-7.7 into the solute balance 
7.4 gives: 







− − =   (7.8) 
where 
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 3q g b= +   (7.9) 
and 
 ( ) ( )
14 36 *
q m q
V G Bk k k R c  
+ − −
=   (7.10) 
On the physically relevant interval of ξ < x < 1 (i.e. between 100% and 0% 
consumption of supersaturation), whether equation 7.8 has one or more additional roots 
determines whether there are multiple steady states. The mean value theorem states that for 
a continuous function to have two roots, the derivative of the function must equal zero 
somewhere on the interval between the roots. The system bifurcates when the parameters 
result in the derivative of equation 7.8 with respect to the dimensionless concentration (x), 
shown in equation 7.11, being equal to zero.  A unique steady state is guaranteed when the 
derivative is greater than zero, and multiple steady states arise when the derivative takes 
on values less than zero. 
 ( ) ( ) ( )( ) ( )
1 1 2
1 1 1 0
m q m q
q x x m x x 
− − −
− − − − − −    (7.11) 










  (7.12) 
An analytical uniqueness criterion for the ampicillin continuous reactive 
crystallization system does not exist because the rate of make, R, and solute concentration, 
c, depend on the residence time (the saturation concentration, c*, is also weakly dependent 
on the residence time because changes in residence time affect the steady state pH value, 
which affects the saturation concentration). In the example given in Figure 7.3, the 
uniqueness criterion, 7.12, has a value of 0.975 and the dimensionless concentration, x, is 
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0.999.  Since x ≈ 1 (and cannot be greater than 1), it is prudent to design a process where 
the criterion is always greater than unity. Figure 7.10 shows the value of the uniqueness 
criterion versus the residence time of a single well-mixed reactive crystallizer. Using the 
same analysis as above for ampicillin showed gives a uniqueness criterion greater than 
unity for all relevant process conditions (conditions that give appreciable yield and 
productivity), indicating a unique steady state for ampicillin suspension density always 
exists. 
 
Figure 7.10. The uniqueness criterion defined in equation (9) versus the residence time in a well-
mixed reactive crystallizer with four different feed compositions (blue- 800:400 mM PGME:6-APA, 
red- 600:400 mM PGME:6-APA, green- 400:400 mM PGME:6-APA, and yellow- 200:400 mM 
PGME:6-APA). The points represent the residence time that gives the maximum productivity and 
are labeled with that productivity. Below the black dashed line is the region where steady state 
multiplicity can arise. 
Casting the dimensionless uniqueness criterion 7.12 back into dimensional terms 
gives equation 7.1. 
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CHAPTER 8. PROCESS ANALYTICAL TECHNOLOGY FOR 
CONTINUOUS MANUFACTURE OF BETA-LACTAMS 
8.1  Introduction 
Quality by Design (QbD) is one of the main pillars of the FDA’s current 
manufacturing best practices. The crux of QbD is that medicines and the process used to 
manufacture them should be designed to minimize risk, and where risk is identified 
measures are taken to mitigate it.176 Testing cannot make up for poor process design. QbD 
therefore requires a detailed understanding of the properties of the product as well as of the 
manufacturing process.177, 178 These properties are termed Critical Quality Attributes 
(CQAs) and Critical Process Parameters (CPPs) in FDA parlance.179 The goal of PAT is to 
guarantee that CQAs are met upon completion of processing. Ideal PAT can be 
implemented in an online configuration, such that sampling is not required. PAT enables 
real time monitoring and control of CPPs and is key to mitigating known risks.17 Validation 
is a key part of QbD, both for the manufacturing process, which must have validated 
performance, and for the PAT, which must be reliable and give useful information.16, 180 
 For the CM enzymatic reactive crystallization of beta-lactams several different 
PATs have been tested, including polarimetry, attenuated total reflectance Fourier 
transformed infrared spectroscopy (ATR-FTIR), focused beam reflectance measurement 
(FBRM), and in situ microscopy. Polarimetry measures solution concentrations but is 
easily confounded by the presence of solids, which obscure the path of the polarized light. 
ATR-FTIR also measures solution concentrations, with less sensitivity than polarimetry 
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but robustness against suspended solids. FBRM measures the chord length distribution 
(CLD) of a crystal population, which can be used as a proxy for the crystal population 
density function. In situ microscopy uses nanosecond laser pulses to capture still images 
of crystals in suspension; paired with image analysis, information regarding the crystal 
population can be extracted. 
 In this chapter each of these PAT is discussed in the context of the CM beta-lactam 
process. While most of these tools have been mentioned in the preceding chapters, the work 
required to monitor a CM process is still underway. Large strides have been made towards 
using each of these PAT in the final pilot plant. Validation, including construction of 
calibration curves, and quantification of the limits of detection (LoD), limits of 
quantification (LoQ), bias, and root-mean-square error of prediction (RMSEP), is also 
necessary for a QbD process. The LoD is defined as three standard deviations of the blank 
sample, the LoQ is ten standard deviations. The bias is the average amount by which the 
concentration derived from the calibration model deviates from the true concentration. The 














where N is the number of tests, xi is the measured value, and xi,prediction is the predicted value 
from the calibration model.15 
8.2 Polarimetry 
 Polarimetry works by measuring the rotation of polar light by chiral molecules in 
solution. The optical rotation of a solution is the linear combination of the optical rotations 
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of the dissolved species weighted by their concentrations.89 Figure 8.1 demonstrates how 
the polarimeter works; a polarizer at one end allows only plane polarized light into the 
cuvette, at the other end a second polarizer is rotated to allow the maximum amount of 
light through, the angle between the polarizers is the polarimeter output. As the antibiotics, 
their precursors, and byproducts are all chiral, do not undergo any racemizing reactions, 
and have distinct specific optical rotations, the measured optical rotation, along with the 
known reaction stoichiometry and starting concentrations, can be used to determine the 
solution concentration. This was the basis for measuring enzyme deactivation in 
CHAPTER 2, using an Anton Paar MCP 500 polarimeter. In Figure 8.2 the calibration 
curves for the ampicillin system are shown, demonstrating how each species has a unique 
specific optical rotation, enabling determination of conversion. 
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Figure 8.1. A polarimeter measures the optical rotation of a solution caused by chiral solutes by 
measuring the angle between two polarizers such that the maximum amount of light is allowed 
through. 
 
Figure 8.2. The calibration curves for determination of the specific optical rotation of the species 
involved in ampicillin synthesis. The optical rotation was measured in water at 20 °C, at 589 nm, and 
in a 100 mm cuvette. 
 A linear model of the form i ic a= , where ci is the concentration, ai is the specific 
rotation of species i, and ϑ is the measured rotation, was found to be sufficient. The model 
was evaluated, and the relevant parameters and validation metrics are given in Table 8.1. 
The calibration data were randomly divided into two subsets, one for calibration model 
fitting, and the other for calibration model validation. 
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Table 8.1. Evaluation of the simple linear model of optical rotation dependence on concentration. 
Specific rotation for a 10 cm cuvette at 20 °C at a wavelength of 589 nm,  ±95% confidence interval. 
Compound Ampicillin 6-APA Phenylglycine PGME 
Specific Rotation (°/mol/L) 96.8 ± 1.8 61.6 ± 1.7 -14.2 ± 0.7 -22.1 ± 2.3 
LoD (mol/L) × 10-6 31 49 211 136 
LoQ (mol/L) × 10-6 103 162 704 452 
Bias (mol/L) × 10-3 -0.77 -0.45 1.2 1.5 
RMSEP 0.0053 0.0013 0.0020 0.0039 
 
Polarimetry is by far the simplest of the PAT evaluated in this thesis. The 
polarimeter reports a scalar quantity, the optical rotation at a fixed wavelength, which when 
combined with process knowledge, such as stoichiometry and initial conditions, can be 
used to determine concentrations. It is also incapable of monitoring slurries as the solids 
immediately obstruct the very long path length needed for accurate measurements. Going 
forward, each additional PAT requires more effort to extract useful low-dimensional 
process information (such as concentrations) from instruments that generate high-
dimensional data (such as spectra). 
8.3 Attenuated total reflectance Fourier transform infrared spectroscopy 
Extracting the maximum amount of actionable information possible from ATR-
FTIR and other spectra collected in situ has been the subject of many papers, including 
those by Griffin55, 103, 181, 182 and Kocevska et al.183 The principle of ATR-FTIR is a simple 
variation on standard Fourier transform infrared spectroscopy, shown in Figure 8.3. The 
IR laser is reflected within an ATR crystal (diamond), with each reflection producing an 
evanescent wave reaching only two micrometers outside the ATR crystal. By contacting 
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the ATR crystal with the slurry, one can take advantage of hydrodynamics hindering 
crystals from entering the sampled region, thereby producing a signal predominantly from 




Figure 8.3. In ATR-FTIR evanescent waves are generated during the internal total reflection of the 
IR laser (red) in the ATR crystal (green). The evanescent waves only penetrate a few micrometers 
into the solution, such that hydrodynamics prevent crystals from being ‘seen’ by the laser. 
In CHAPTER 4 ATR-FTIR was used to measure concentration of cephalexin. A 
linear calibration model of the form ( )1369 1305c a h h b= − +  was used, where hN represents 
the height of the peak at wavenumber N. The peak at 1369 cm-1 was chosen because it 
proved to be most robust against the presence of other species, 1305 cm-1 was used to 
baseline the peak height. Figure 8.4 shows the IR spectrum of cephalexin and the 
calibration curve used in CHAPTER 4. In Table 8.2 the parameters for the calibration 
model for cephalexin and other single species are presented, with different wavenumbers 
used for different compounds. Cephalexin was calibrated from zero to 100 mM while 7-
ADCA and PGME were both calibrated through 200 mM, reflecting the expected ranges 
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of concentrations in the final process. The instruments used were Mettler-Toledo’s ReactIR 
iC10 and ReactIR 702L. 
 
Figure 8.4. The IR spectrum of cephalexin (left) and the linear calibration model used to convert the 
1369 cm-1 peak height to concentration (right). Error bars represent standard deviation of n = 38 
samples. 
Table 8.2. Summary of IR calibration models and validation for single species. *Data collected on 
ReactIR iC10 with 30 second scan time, all others collected on ReactIR 702L with 60 second scan 
time. 
Compound 
(peak – trough) 
Cephalexin* 
(1369 – 1305) 
7-ADCA 
(1744 – 1820) 
PGME 
(1252 – 1212) 
a (mol/L/cm-1) 6.021 ± 0.031 2.474 ± 0.012 4.524 ± 0.046 
b (mol/L) 0.0513 ± 0.0002 -0.1873 ± 0.0015 -1.155 ± 0.013 
LoD (mol/L) × 10-3 1.51 1.21 0.67 
LoQ (mol/L) × 10-3 5.04 4.05 2.22 
Bias (mol/L) × 10-3 0.54 -1.84 3.61 
RMSEP 0.0012 0.0014 0.0028 
 
 For single compounds the linear models of concentration are sufficient. Baselining 
can be used to remove the spectrum of second (or more) dissolved species, provided the 
concentration of the additional species is constant. However, once the concentration of 
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multiple species begins changing in tandem, the simple models used thus far are no longer 
accurate. To monitor the changes in concentration of several species more advanced 
methods are required. One group of methods involves reducing the dimensionality of the 
data to give only one dimension for each independent concentration (dependent 
concentrations would be, for example, the concentrations of A and B in the reaction A + B 
makes C; A and B decrease in concentration at equal rates). This approach was implicitly 
used in the single species models, as only a single wavenumber was chosen to represent 
the species. Since spectra of the acyl-donors, by products, beta-lactam cores, and 
antibiotics overlap considerably the reduced dimensions may not be individual 
wavenumbers but some combination of them instead. This remains an active area of work 
for the CM process. 
 While tracking changes in the concentration of many different species with ATR-
FTIR may be difficult for the beta-lactam chemistry, CM simplifies monitoring immensely. 
In a CM process at steady state, the concentrations of each species are by definition not 
changing; therefore, to monitor the process by IR, all one needs is a spectrum representing 
the desired steady state. Deviations in the measured spectrum from the desired spectrum 
indicate a change in the process and could be turned into actionable information with 
empirical correlations. For example, if a decrease in signal in a certain range of spectrum 
can be correlated to a decrease in purity, then an excursion in that range would signal to 
the operator or controller that action must be taken to segregate material flowing out of the 
reactive crystallizer at that time, so as not to contaminate the pure product with impure 
product. In this manner the ATR-FTIR produces actionable information without intricate 
models for deconvolution of complex signals. The most conservative approach, applying 
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statistical process control,184 would be to divert the product line upon any deviation from 
the desired spectrum, as potentially measured by Pearson correlation coefficient.185 More 
nuanced approaches, which should be pursued once steady state operation has been 
achieved and intentional perturbations studied, could use principle components analysis 
(PCA) to correlate specific changes in the principle components of the spectrum to changes 
in the CQAs. With a known correlation, designer and operator insight could enable 
corrective action to avoid wasted product. 
 The main challenges with further developing ATR-FTIR for use in the CM reactive 
crystallization of beta-lactam antibiotics are: (1) complex non-linear phenomena, (2) low 
concentrations and therefore signals, (3) probe fouling, and (4) probe variability. The first 
challenge cannot be changed as crystal nucleation is a non-linear phenomenon. 
Linearization of the process model around the steady state set point can simplify control, 
and design choices can be made to make sure that no actions are taken that result in 
significant system changes faster than the ATR-FTIR sampling rate (order one sample per 
minute). The second challenge is also inherent to the system and will require large amounts 
of calibration data such that small changes in signal can be quantifiably related to changes 
in the solution. The signal to noise ratio can also be improved by increasing the sampling 
time and averaging over more scans. The third challenge is addressable by process design 
and operation. Rapid generation of supersaturation and free PGA have been shown to foul 
the probe. Figure 8.5 shows the apparent concentration of amoxicillin increasing 
indefinitely during a pH-swing crystallization (left) with high supersaturation and an 
enzymatic crystallization (right) with soluble PGA. QbD requires that the process be 
designed to maximize real time process analysis, therefore immobilized PGA should be 
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used with a large enough reactor residence time to keep the supersaturation to a minimum. 
The fourth challenge relates to smaller but significant differences in the optical properties 
of different probes or even the same probe in different positions. Griffin et al. previously 
addressed this issue;103 in addition to implementing their solution based on preferentially 
weighting stable parts of the spectrum, the position of the probe can also be stabilized as 




Figure 8.5. The FTIR signal from a continuous amoxicillin crystallization experiment with spectrum 
trace (red) and progression trace (black), highlighted in the insets to the right, showing an increasing 
signal as amoxicillin crystallizes over the probe window. At approximately 14000 seconds the probe 
was removed, cleaned, and reinserted into the crystallizer, resulting in the drop in peak height visible 
in the black progression trace. 
8.4 Focused Beam Reflectance Measurement 
 Focused beam reflectance measurement gives a signature of the crystal population 
which measured over time can be indicative of certain underlying processes. The 
instrument used is a Mettler-Toledo G400. The apparatus works by spinning a focused 
laser through a crystal slurry at 2.0 m/s (significantly less than the impeller tip speed, 
approximately 1.0 m/s). The focus of the laser is several micrometers into the slurry such 
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that the probe can ‘see’ the particles in front of it, unlike for ATR-FTIR, but not particles 
far from the probe window. When the laser scans over a crystal, which is standing relatively 
still compared to the laser speed of 2.0 m/s, the beam is reflected back into the probe, where 
the duration of the backscattering event is recorded. Based off the laser speed the 
reflectance durations are transformed into lengths, and the lengths are binned into a size 
histogram. The working principles are illustrated in Figure 8.6. 
The histogram, or chord length distribution (CLD), is representative of the crystal 
population, but is not the same as the CSD (which is an important CQA). Larger crystals 
are more likely to be scanned by the laser, but they may not give longer chords if they are 
needle-shaped, as with amoxicillin and cephalexin. The CLD is often weighted by the 
square of the bin size to transform from a number-based distribution to a volume or mass-
based distribution. The FBRM can also miss larger particles due to what has been termed 
the snowstorm effect, observed with cephalexin experimentally in Figure 8.7, whereby a 
great number of small crystals (snowflakes) obscure the larger crystals.186 Other factors 
that increase variability include probe orientation relative to the flow, mixing intensity, 
small differences in the optics between different probes, and properties affecting crystal 
reflectivity (refractive index, surface roughness, etc.).187 
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Figure 8.6. The working principle of FBRM is illustrated. Large crystals are more likely to be ‘seen’ 
by the probe, but even large crystals can produce short chords, especially if they are high aspect ratio 
crystals like those of amoxicillin and cephalexin. 
 
Figure 8.7. The snowstorm effect observed during the crystallization of cephalexin. Beginning with a 
small number of seed crystals (red), the initial population grows and breeds new crystals (yellow) 
until a maximum appears for chords 100 μm in length (green). Continued crystallization creates 
many fines, obscuring the large (~100 μm) chords and shifting the mode of the distribution down to 
~25 μm (blue and purple). 
Reconstructing the CSD from the CLD has been the topic of several studies and 
been approached with several methods. Ruf et al. rigorously modeled the CLDs of 
ellipsoids and cuboids of different sizes and experimented with spheres precisely 
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positioned in front of the probe to understand exactly what aspects of the crystal are 
captured in the CLD.188 Barthe et al. moved more towards empirical experimental 
characterization of FBRM by observing paracetamol crystallization and modeling of the 
FBRM mechanism by simplifying the crystals as two dimensional projections of octahedra 
and using PCA to reconstruct the population.189, 190 Li et al. moved to complete empiricism, 
also for modeling paracetamol crystallization, by taking well specified crystal populations 
and measuring their CLDs (termed fingerprints), then reconstructing complex populations 
by fitting their CLDs to linear combinations of the fingerprints.109, 110 There are many 
frameworks within which to utilize FBRM, but as was the case with ATR-FTIR, but each 
of them requires significant effort and may not be helpful in quantifying CQAs. 
 In a CM process at steady state the CLD should not change with time, similar to 
how the ATR-FTIR spectra should not change with time. Therefore, the greatest strength 
of FBRM may be ensuring steady operation rather than determining crystal size 
distributions. A CLD representing the desired steady state can be determined, and then 
deviations from that CLD can be used to indicate excursions from the operating point. An 
even simpler approach is to add all bins, or certain subsets of bins, together and observe 
the change in total counts over time. It may also be possible to correlate certain types of 
excursions, such as a proportional increase in number of chords in all bins, to pilot plant 
issues, such as clogging. However, a significant effort will have to be invested to turn CLDs 
into actionable data for more complex operations such as manipulating the CSD. 
 A possible application of FBRM specific to the cephalexin system is the detection 
of phenylglycine crystallization. To maximize process metrics (conversion, yield, and 
productivity) the concentration of the phenylglycine byproduct must approach its solubility 
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limit. A perturbation causing phenylglycine crystallization would contaminate the solid 
cephalexin product, therefore detecting phenylglycine solids is of paramount importance. 
Measuring the concentration of phenylglycine with ATR-FTIR and ensuring that it remains 
below the solubility limit could guarantee purity, but the precision of such measurements 
is (presently) insufficient as the solubility of phenylglycine is approximately 30 mmol/L. 
Likewise, detecting the decrease in phenylglycine concentration upon crystallization with 
ATR-FTIR is also impractical. Ongoing work is investigating the efficacy of FBRM in this 
role. If a model that successfully identifies phenylglycine is constructed it will be validated 
in the same manner as the IR and optical rotation concentration models, i.e. the LoD, LoQ, 
bias, and RMSEP will be evaluated, with particular emphasis on LoD as any amount of 
solid phenylglycine is considered unacceptable. An alternative approach would be to 
measure the phenylglycine concentration with ATR-FTIR and ensure that it remains below 
the solubility limit, but so far it has not   
8.5 Particle Vision and Measurement 
 The final PAT planned for use in the CM pilot plant is in situ microscopy with 
particle vision and measurement (PVM). The instrument used is a Mettler-Toledo 
EasyViewer 100. PVM allows one to see phenomena (such as growth, nucleation, 
agglomeration, etc.) as they occur in the crystallizer while with FBRM one has to infer the 
occurrence of such phenomena from CLD trends, which is not a trivial exercise. Figure 8.8 
shows PVM images of amoxicillin, cephalexin, and phenylglycine; it is immediately 
obvious that each crystal is distinct with very different optical properties. An advantage of 
FBRM over PVM is that confirming steady state operation is more difficult with a series 
of images than a series of CLDs. One technique to overcome this disadvantage is to use 
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computer vision to extract size distributions, or even CLDs, from the images to compare 
over time. Simpler yet, the turbidity can be computed from the average pixel intensity, 




Figure 8.8. Top left: Amoxicillin trihydrate. Top right: Cephalexin monohydrate. Bottom left: 
Phenylglycine. Bottom right: Cephalexin and phenylglycine, both produced curing a batch enzymatic 
reactive crystallization. Each image is 1.0 mm × 1.0 mm. 
 The rage of applications of computer vision, and the resulting tools available for 
analyzing large sets of images, means that PVM may be better suited to directly measuring 
certain CQAs than FBRM. Measuring the crystal size distribution for needle-shaped 
crystals has been demonstrated for other systems, and may be plausible here as well.48, 191-
193 There is also of interest in training a computer to recognize phenylglycine crystals in a 
slurry of cephalexin crystals, which may be a powerful application of machine learning 
and big data for the successful operation of the CM pilot plant. Convolutional neural 
networks have proven adept at image classification and could be trained on large data sets 
collected with PVM.194 The challenges associated with such an approach include the 
typical challenges of preventing probe fouling and properly sampling the slurry, as well as 
the challenges of running computationally expensive image analysis in real time. 
8.6 Other Process Analytical Technology 
 It is worth noting that many other PAT were considered for this project; many have 
been implemented but are common analytical techniques not requiring further elaboration, 
e.g. HPLC and pH measurement, while others are powerful tools but were deemed 
unsuitable for this project.17 For completeness, it should be mentioned that refractometry, 
UV-vis spectroscopy, and Raman spectroscopy were all investigated as additional online 
PATs. Refractometry gives additional information about the total amount of dissolved 
content in the solution, which is valuable information when measuring crystallization 
extent. However, the refractometer (Anton Paar Abbemat 500) is very sensitive to changes 
in flow rate, which are inevitable as peristaltic pumps produce pulsating flow (see next 
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chapter). UV-vis spectroscopy was not sensitive to changes in relative amounts of reactants 
and products while keeping the total concentration constant, which would serve to measure 
reaction conversion. Use of a chromophore derivatizing agent, namely p-dimethyl amino-
benzaldehyde, enabled quantification of 7-ADCA by UV-vis spectroscopy, but online 
implementation is not feasible.195 Raman spectroscopy was promising as it probes the 
composition of both the solution and crystalline phases, however the signal-to-noise ratio 
for the Raman spectrometer (Mettler-Toledo ReactRaman 785) in an antibiotic slurry was 
very low and not quantifiable. 
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CHAPTER 9. THE PILOT PLANT: PROGRESS TOWARDS 
OPERATION OF A CONTINUOUS PROCESS FOR THE 
MANUFACTURE OF AMOXICILLIN AND CEPHALEXIN 
9.1 Introduction 
Demonstration of the continuous manufacture of beta-lactam antibiotics by 
enzymatic reactive crystallization in a lab scale pilot plant is the primary goal of this work. 
Recently, academic and industrial labs have published numerous examples of pilot plants 
for specific CM processes. The motivations for utilizing CM in pilot plants have varied, 
including containing potent materials,9, 10 providing a variety of drugs on demand,12, 19, 97 
and simplifying operation and control of crystallizers compared to batch.14, 196, 197 Each of 
the motivations cited above are also reasons to construct a pilot plant for the CM of beta-
lactams. Beta-lactams are known to be highly allergenic, requiring hospitalization upon 
exposure in 0.1-0.5% of the population, and the FDA now requires that they be produced 
in standalone facilities; CM would provide an additional layer of containment.6, 8, 198 Beta-
lactams, particularly amoxicillin and cephalexin, are produced on a huge scale, 
approximately 20,000 and 6,000 tons per year, respectively,1 and are often subject to 
shortages, especially when disruptions in highly optimized supply lines, dependent on 
single nations, are caused by unforeseeable events. Continuous manufacturing could abate 
the cost of operating new plants with the flexibility to shore up delicate supply networks.3, 
199-201 Control of the batch process is also a concern for reactive crystallization; maintaining 
a low but productive level of supersaturation is critical to produce quality crystals, 
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particularly for cephalexin, and is comparatively easier in an MSMPR crystallizer where a 
population of crystals exists to consume the generated supersaturation.99, 202 
In this chapter the various parts of the pilot plant are discussed individually, the 
results of extensive modeling of the pilot plant with the models built in CHAPTER 6 are 
shown, and the future directions for the pilot plant are explored in depth, as there is still 
much to be done in the coming years. The pilot plant is planned to be built in two iterative 
phases; the first phase, termed the basic pilot plant, has been assembled and undergone 
some testing while the second phase, termed the optimized pilot plant, will be built around 
the skeleton of the basic pilot plant. The differences between the two phases is shown in 
Figure 9.1, where additional elements in the optimized pilot plant are shown in green in 
the simplified schematic of the plant. 
 
Figure 9.1. Basic pilot plant elements in blue/black, optimal design elements shown in green. 
9.2 Reaction and Crystallization 
The modeling conducted in CHAPTER 6 suggested that a mixed suspension mixed 
product removal reactive crystallizer (MSMPR), leftmost vessel in Figure 9.1, followed by 
a plug flow reactive crystallizer (PFRC), center vessel, would optimize the three process 
metrics (conversion, selectivity, and productivity). The benefits of this reactor combination 
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are: self-seeding, low substrate concentrations, and ease of PAT implementation.203 In the 
basic pilot plant phase only the MSMPR-RC will be included, the PFRC is one of the add-
ons for the optimized pilot plant. 
9.2.1 Mixed-suspension Mixed-product-removal Reactive Crystallizer 
The MSMPR-RC is the equivalent of the continuous stirred tank reactor for 
crystallizers, the effluent slurry is representative of the reactor contents. MSMPR-RCs have 
been used extensively in the chemical industry,126, 137, 143, 204, 205 and are now making their 
way to pharmaceuticals as continuous manufacturing gains traction in the industry.9, 206-210 
The setup is simple, a jacketed glass vessel with ports for PAT probes and feed and effluent 
streams. On overhead stirrer keeps the slurry suspended while PGA, immobilized on high 
surface area beads, is also mixed and generates supersaturation. The simple design allows 
representative sampling of the entire crystal population by FBRM and PVM and accurate 
concentration measurements by ATR-FTIR in the MSMPR-RC. In this section, relevant 
research on the MSMPR-RC is introduced, the predicted behavior of the enzymatic 
MSMPR-RC from the models built in CHAPTER 6 is discussed, and the challenges 
anticipated with the MSMPR-RC, along with potential solutions, are enumerated. 
In the 1970s and 80s the fundamental behaviors of the MSMPR was an active area 
for researchers combining vast experimental data sets with newfound computational 
resources. Topics included hydrodynamics,123 secondary nucleation,211 sustained 
oscillatory behaviors,212, 213 growth rate dispersion,133, 143, 214 but perhaps the most relevant 
here is steady state multiplicity, and so it is revisited. Like the CSTR, a multiplicity of 
temperature steady states may exist based on the heat of crystallization and temperature 
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dependent crystal growth rates.215 The enzymatic reactive crystallization process is planned 
to be isothermal (25 °C) and has very low heats of crystallization and reaction, which 
should eliminate the possibility of temperature steady state multiplicity, however steady 
state multiplicity may arise from size distributions alone.172 Furthermore, when coupled to 
reaction kinetics that depend on product concentrations, the possibility of multiple steady 
states increases further.216 Figure 9.2 shows how multiple steady state arise. Secondary 
nucleation (the dominant nucleation pathway in MSMPRs)204 and crystal withdrawal are 
both functions of suspension density; if they have different orders in the power laws used 
to describe them, then a multiplicity of steady states may arise. In designing the pilot plant, 
the reaction rate should be selected such that a stable population of cephalexin crystals 
exists but any population of phenylglycine crystals wash out, otherwise the concentration 
of phenylglycine must be kept below the solubility limit.  
 
Figure 9.2. A diagram depicting how a multiplicity of steady states arise in an MSMPR-RC, based on 
the nucleation rate (solid curve) and crystal removal rate (dashed curve) dependence on suspension 
density. For a slow reaction (red curves) the removal rate is greater than the nucleation rate at all 
suspension densities; the reaction is not fast enough to sustain a crystal population, a condition 
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known as wash out. For a medium speed reaction (yellow curves) two stable steady states exist, one 
with a stable crystal population (yellow square) and one with no crystal population. Systems to the 
left of the circle eventually converge to the wash out condition while systems to the right of the circle 
converge to the stable population. For the fast reaction (green curves) the behavior is the same as the 
medium speed reaction, except there is no wash out condition as the fast reaction generates enough 
supersaturation to sustain a population of primary nucleated crystals, hence the significant 
nucleation rate at low suspension density. This plot was created with the model from CHAPTER 7. 
The MSMPR has recently gained traction in numerous industries, with publications 
describing myriad improvements and alterations. In the pharmaceutical industry in 
particular the MSMPR has been improved by cascading multiple vessels together to reduce 
supersaturation,105, 106, 202, 217 incorporating membranes to remove impurities,218-220 and 
combining different modes of crystallization (e.g. cooling and antisolvent) to enhance 
yield.221 There has also been work taking advantage of the well-defined residence time of 
MSMPRs for producing metastable crystal forms or polymorphs.106, 222-224 The MSMPR 
has also found use for deracemizing conglomerate forming enantiomers.225-227 That so 
many improvements have been made to, and so many difficult processes been achieved 
with, the MSMPR speaks volumes to its important role in continuous manufacturing. 
The expected behavior of the pilot plant MSMPR-RC has been modeled in 
CHAPTER 6 and CHAPTER 7.  The MSMPR-RC will be operated with the inputs 
summarized in Table 9.1 for the two different antibiotics. These parameters were chosen 
to give optimal performance in terms of conversion, selectivity, and productivity. The 
expected performance of the MSMPR-RC in the basic pilot plant is given in  
Table 9.2 for both antibiotics, operating under the conditions set out in Table 9.1. 
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Table 9.1. Summary of design conditions for reactor sizing, feed concentrations, and flow rates. 
Residence time (min), Volume (mL) Amoxicillin Cephalexin 
MSMPR-RC 120 min, 600 mL 70 min, 350 mL 
PFRC 20 min, 105 mL 30 min, 160 mL 
Feed (flow rate, concentration, pH)   
Feed 1 (4-HPGME/PGME) 3 mL/min, 0.5 M, pH 4 1.5 mL/min, 1.1 M, pH 4 
Feed 2 (6-APA/7-ADCA) 2 mL/min, 0.6 M, pH 7 3.5 mL/min, 0.37 M, pH 7 
pH value, temperature, PGA conc. pH 6.5, 25 °C, 5 μM pH 6.5, 25 °C, 5 μM 
 
Table 9.2. Summary of expected performance of the basic pilot plant based on modeling and the 
values in Table 9.1. 
Basic pilot plant Conversion w.r.t. 





Amoxicillin 80% 3.73 23.2 
Cephalexin 65% 5.15 15.7 
 
There are several aspects of the design, implied in Figure 9.1 and Table 9.1 that are 
worth pointing out. First is the separation of the precursors into two separate feeds with 
different conditions. For amoxicillin, the solubility of HPGME is less than 100 mM at 
MSMPR-RC conditions (pH value of 6.5) but increases rapidly at lower pH values, while 
the solubility of 6-APA decreases rapidly at lower pH values. There is no single feed 
condition that results in completely dissolved reactants, necessitating two feeds. Upon 
dilution into the MSMPR-RC the HPGME remains dissolved. The same is true of 7-ADCA 
for cephalexin: it requires a neutral pH value (basic conditions result in degradation) but 
remains in solution upon dilution in the MSMPR-RC. This could pose an additional 
challenge during startup, it is recommended that the reactor be initially charged with a 
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solution saturated with beta-lactam nucleophile, acyl donor, and antibiotic, then seeded 
with antibiotic crystals before adding PGA, after which feeding can begin. 
The second point is that the volume of the MSMPR-RC is different between the 
two antibiotics. This stems from cephalexin requiring greater selectivity than amoxicillin 
because the byproduct from cephalexin hydrolysis is much less soluble than the byproduct 
of amoxicillin hydrolysis. Selectivity decreases with residence time in the MSMPR-RC, so 
cephalexin achieves proportionally more conversion in the PFRC compared to amoxicillin. 
The volumes are close enough that the same vessel will be used for both antibiotics. 
The MSMPR-RC, while easier to implement than the PFRC, is not without its own 
challenges. Fouling remains a significant concern in the MSMPR-RC. As discussed in 
CHAPTER 8 the PAT probes are subject to fouling, making process control difficult. The 
simplest solution is to decrease the supersaturation of the system. The supersaturation can 
be decreased by increasing the MSMPR-RC volume while holding all other design 
variables constant (feed rate, concentration, enzyme concentration); the rate of antibiotic 
formation is the same but the crystal population surface area is greater enabling faster 
depletion of any accumulated supersaturation. Another source of potential fouling comes 
from the tendency for amoxicillin and cephalexin crystals to form spherulites, shown in 
Figure 9.3. Spherulites clog tubing, often forming log jams at the crystallizer outlet port. 
Solutions again include decreased supersaturation, as well as milling to break up large 
particles, and periodic back pumping to clear clogged inlet. Decreasing supersaturation has 
the added benefit of making cephalexin crystals less needle-like,228 the impact of 
supersaturation on amoxicillin has not been studied. 
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Figure 9.3. PVM images of amoxicillin (left) and cephalexin (right) spherulites. Both images are 1.0 
mm2. 
9.2.2 Plug Flow Reactive Crystallizer 
The plug flow reactive crystallizer is equivalent to a batch crystallizer in that the 
residence time distribution is, ideally, a delta function. Some non-ideal dispersion and 
mixing ultimately result in a narrow residence time distribution. Less research has been 
conducted on the PFRC than the MSMPR-RC, however there have still been several 
important studies on controlling crystal size in a PFRC,162, 167, 229 preventing particle 
settling due to insufficient mixing in a PFRC,173, 230 and monitoring crystals in a PFRC.231, 
232 There has also been a large amount of work with continuous oscillatory baffle 
crystallizers (COBCs) which seek to mimic the performance of the PFRC with a long series 
of very small compartments separated by baffles and agitated by oscillatory flow.206, 233-236 
Some work with modeling COBCs has even involved reactive crystallization (of 
paracetamol)236 which is highly relevant to the current process.  
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The PFRC in this process will receive a feed directly from the MSMPR-RC 
effluent, avoiding the difficulties associated with seeding and primary nucleation.230, 232 
The PFRC will operate according to the parameters in Table 9.1 with expected performance 
outlined in Table 9.3. The design of the PFRC is not as straight forward as for the MSMPR-
RC, the length and diameter of the tubing have to be considered. To avoid clogging the 
diameter must be large enough to accommodate the largest crystals, the particles need to 
remain suspended, the length must short enough to avoid large pressure drops, and the 
volumetric throughput must be equal to (or greater than, with recycling of the PFRC 
products) that of the MSMPR-RC. The tubing must have an inner diameter of at least 1.5 
mm as the largest crystals can reach lengths of almost 1.0 mm. The critical velocity (vc) 
required to keep the particles suspended can be estimated with the equation below and is 
found to be 1.96 cm/s.237 
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where g is the acceleration due to gravity, d is the average particle diameter, s is the ratio 
of the solid to liquid densities, C is the volume fraction of particles in the slurry, n 
determines the order of the dependence of the hindered settling velocity on particle 
concentration and ranges from 4.5 at low Reynolds number to 2.5 at high Reynolds number, 
x is the fraction of eddies with velocity greater than the hindered settling velocity and 
typically takes a value between 0.95-1.0, D is the diameter of the tubing, ρl is the liquid 
density, and μ is the viscosity. Putting all the design requirements together, and searching 
through available inner diameters for pharmaceutical compatible tubing, one determines 
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that the PFRC should consist of Tygon E-3606 I.D. 2.0 mm with a length of 32 m for 
amoxicillin and 50 m for cephalexin with a velocity v = 2.67 cm/s. While v > vc it is possible 
that some settling may occur, in which case pulsed flow, with an average velocity of v but 
an instantaneous velocity vi > v may enable steady flow. The pulsation could also improve 
the performance of the MSMPR-RC by ensuring true mixed product removal.  
Table 9.3. Summary of expected performance of the optimized pilot plant based on extensive 
modeling and the inputs from Table 9.1. 
Optimal pilot plant Conversion w.r.t. 





Amoxicillin 89% 3.60 27.0 
Cephalexin 80% 5.07 18.0 
 
9.3 Enzyme crystal separation 
 In Figure 9.1 the enzyme crystal separator is shown after the reactor(s) with two 
outlets, an enzyme rich retentate and enzyme free permeate. The terms retentate and 
permeate are borrowed from membrane literature as one of the means of retaining the 
enzyme is by using an ultrafiltration membrane and soluble PGA, however, initial tests 
showed low throughput with high fouling potential; not suitable for a continuous process. 
Rather the separation is conducted based on differences in the properties of the crystals and 
enzyme carrier. While the design is far from finalized, a promising candidate is the use of 
a magnetic carrier particle upon which PGA is immobilized and subsequently recovered 
by application of a magnetic field. 
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Immobilization of enzymes on magnetic particles is not new, however, so far there 
have not been any published studies demonstrating continuous recovery of a magnetic 
biocatalyst, only batch recovery.238-240 Additionally, those examples are limited to liquid 
phase reactions, magnetic biocatalysts have not been used to recover the catalyst from a 
product slurry. The inspiration for a continuous magnetic biocatalyst recovery system 
comes from continuous cell sorting, where antibodies conjugated to magnetic particles bind 
specific cells. The cells are then sorted by magnetophoresis, or the movement 
perpendicular to the flow of the medium due to the application of a magnetic field.241 Figure 
9.4 shows the basic layout, a rectangular compartment with an inlet on the left from the 
reactor (green) and two outlets on the right, one for the permeate (purple) and a second for 
the retentate (yellow). A sweeping solution may be optionally included (blue) to improve 
the separation efficiency. Magnetic particles accumulate above the magnet before being 
swept into the retentate whereas nonmagnetic particles are free to enter either outlet. It does 
not matter if there is a significant population of crystals in the retentate as they will be 
recycled back into the reactor with the biocatalyst. In fact, recycling of crystals increases 
the suspension density in the crystallizer and may have benefits similar to those found in 
double draw off crystallizers, namely increased capacity to consume low levels of 
supersaturation.165, 242 
 
Figure 9.4. Schematic of magnetic separation device. Green arrow, crystallizer effluent containing 
crystals and biocatalyst. Blue arrow, sweep solution. Purple arrow, permeate, to filtration units. 
Yellow arrow, retentate, recycled back to reactor. Magnetic particles accumulate above the bar 
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magnet before being swept into the retentate stream. The scale of the device is <1 cm wide and <15 
cm long. 
 Computational fluid dynamics are used to model the separation factor for magnetic 
beads before testing in the lab. The magnetic separation system is an ideal application of 
rapid prototyping by 3-D printing. The initial device, refined from Figure 9.4, is modeled 
in Figure 9.5. Simulations have shown that laminar flow is key to good separation, but not 
necessary for high biocatalyst recovery, i.e. to avoid dispersion of the crystals smooth flow 
is required, otherwise the concentration of crystals is approximately equal in both outlets. 
Figure 9.5 shows the development of laminar flow with a gentle velocity gradient in the 
initial section of the device, viewed from the top down (a) and at two slices, one just after 
the inlets and one near the outlets (b). Experiments with the initial prototype, where 
retention >95% was achieved at all flow rates (2-5 cm/s) and inert magnetic beads 212-250 
μm in diameter, informed the second iteration of the device. 
 
Figure 9.5. Computational fluid dynamics analysis of a continuous magnetic particle separating 







and two outlets at the other. A magnet is placed parallel to the length of the separator body, pulling 
magnetic particles to that side. Two slices of the flow field are shown in (b), with velocity scale in (c). 
  The next steps in the development of the crystal enzyme separator involve scaling 
the device to work with smaller (2-5 μm) functionalized magnetic beads, conjugated to 
PGA. Smaller beads are required to achieve a practical enzyme loading per gram of catalyst 
as the beads are non-porous. A Buckingham Pi analysis, whereby the relevant dimensions 
are used to infer relevant criteria for good separation, will help to ensure reproducibility 
with scaled down particles. The relevant dimensionless groups deal with flow rate, 
magnetic field strength, and solids concentrations; it is expected that particle shape and 
size should not have too great an impact as long as the flow regime and drag regime are 
the same across scales. 
9.4 Filtration and washing 
The final operation in the pilot plant is the combined washing and filtration step. 
The product will be continuously collected from the permeate stream of the enzyme crystal 
separator and fed to one of two (or more) batch filtration units. While one filter is collecting 
material, the material in the other filter is re-suspended with washing solvent and re-
filtered, by application of pressure, to give a pure product. When the collection filter is 
filled, the two filters’ roles are switched. Drying is considered beyond the scope of this 
thesis, being complicated by the product taking the form of a hydrated crystal. However, it 
can be noted now that too much drying will dehydrate the crystal, compromising product 
quality.  
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Filtration is a significant bottleneck in many solids-handling processes.243, 244 




=   where k is 
the cake permeability, A is the filter area, μ is the solution viscosity, h is the filter cake 
height, and Δp is the pressure differential across the filter. The cake permeability k is highly 
sensitive to particle attributes such as shape, size distribution, and suspension density. It 
has been shown that more needle-like particles and smaller particles filter more slowly, 
having greater filter cake resistances.245 The same trend was observed for cephalexin at 
small scale, the solution containing a slurry of very high aspect ratio cephalexin crystals 
filtered at a rate of about 10 mL/min while that containing low aspect ratio cephalexin 
crystals filtered at nearly 100 mL/min. Figure 9.6 shows the filtration of the two different 
samples of cephalexin at a suspension density of 100 g/L with vacuum pressure pulling 
solution through the filter cake.  
   
Figure 9.6. The filtration rate of low (left) and high (right) aspect ratio (AR) cephalexin crystals, as 
measured by the time required to collect the solution in which the crystals were suspended. IN the 
case of the low AR crystals, complete filtration took less than two minutes, the sharp decrease in 
mass of collected solution is a result of deliquoring the filter cake. 
The pilot plant requires a filtration rate of 5 mL/min, which both samples achieved 
in this small scale test, however, extrapolating the decreasing rate of filtration seen for the 
high aspect ratio sample to several hours indicates that these filtration conditions (filter 
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area, pressure, crystal size and shape) will not suffice. The filter to be used in the pilot plant 
has approximately twice as much surface area and the capacity for three times as much 
pressure to drive fluid flow. Still, optimizing the MSMPR-RC and PFRC to grow low 
aspect ratio crystals will further reduce the risk of a filtration bottleneck. It has been shown 
that producing cephalexin with a large amount of seed crystals (as would be present in an 
MSMPR) and at a very low supersaturation, which has previously been advocated for 
several reasons, can reduce the aspect ratio.228 
Similar filtration experiments were conducted with amoxicillin. A mixture of 
amoxicillin trihydrate crystals produced under different conditions, to simulate the product 
from an MSMPR-RC, were suspended and filtered in the same filter to be used in the pilot 
plant. Complete filtration of 750 mL of suspension took less than four minutes with the 
application of 15 psi of air pressure pushing solution through the filter cake. While it is 
possible to model filter performance, based on preliminary results it is not clear that 
modeling is needed at this time. 
Washing, which entails resuspending the filter cake in a non- or poor-solvent, is 
necessary to both remove entrained reaction solution and reduce adsorbed contaminants 
from the crystal surface. At present cold water is the intended washing solvent, however, 
preliminary studies of alcohols and glycols also show promise. A good washing solvent is 
non-toxic/benign, environmentally friendly, miscible with the aqueous reaction solution, a 
poor solvent for the antibiotics, a good solvent for the reactants and byproducts, and has 
high enough water activity to avoid dehydrating the product crystals. The amount of 
washing solvent, duration of washing, and temperature of washing also need to be 
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determined. Washing with water would simplify waste treatment and raise the possibility 
of wash recycling, assuming the primary contaminants are in fact reactants. 
9.5 Control 
The performance of the process plant is measured in terms of conversion, selectivity, 
and productivity, while maintaining that purity is more important than any of the 
performance metrics. Process control should therefore work to keep conversion, 
selectivity, and productivity at their optimal values without compromising purity, or taking 
prompt action to uphold high product purity. The process has been designed such that the 
optimal state is stable, however, large perturbations can cause a very slow return to the 
controlled state or worse, in the case of the MSMPR-RC, settling into a new steady state, 
see Figure 9.2. The desired steady state results in pure antibiotic product, but the undesired 
steady states may not. A process control system that helps keep the system at steady state 
is therefore highly desirable. It should also be mentioned that additional product 
specifications, e.g. crystal size, are not yet defined for this process, but some form of active 
control could enable those specifications to be met as well. 
For the dependent variables of purity, conversion, selectivity, and productivity, there 
are independent variables of flow rates of both the feeds (see Figure 9.1), pH value in the 
MSMPR-RC, total residence time, and wet-milling intensity. The first four independent 
variables have well quantified impacts on the dependent variables; their effects are 
captured by the model developed in CHAPTER 6. Wet-milling, however, is still an area of 
active research, it has been shown to increase nucleation rates and to significantly decrease 
crystal length and aspect ratio, enabling control of particle size.246-249 The simplest 
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implementation for control would be to linearize the models around the desired steady state 
and use PID control based on just one of the independent variables. Complexity could be 
added by manipulating multiple independent variables. Crystal size control by wet-milling 
is possible but not a primary aim of the initial pilot plant.248  
An important consideration for process control is the ability of PAT to accurately 
measure the process metrics. In the previous chapter the relevant PAT were evaluated and 
validated. Concentration measurements from ATR-FTIR, paired with knowledge of the 
feed concentrations and MSMPR-RC pH value, can be used to determine conversion, 
selectivity, and productivity for the basic pilot plant. Estimating crystal size and purity is 
more difficult. The FBRM signature of the desired crystal size distribution and suspension 
density could be measured and an empirical relation to wet-milling intensity developed. 
The presence of phenylglycine crystals should be detectable with PVM, but the controller 
action will be difficult, as the phenylglycine crystal population would be washed out of the 
reactor. The difficulty of process monitoring complicates process control and is an 
additional consideration for estimated controller performance. 
9.6 Conclusion 
Figure 9.7 shows the progress to date on the basic pilot plant. The entire plant is 
housed in a fume hood, with temperature control of the feeds, reactor(s), and filters, shown 
as blue, yellow, and orange jacketed vessels in Figure 9.7. Figure 9.7 has a schematic 
overlay to make the pilot plant parts recognizable, but what is clear even without labeling 
is the compactness of the plant, with ample room for upgrading to the optimized pilot plant 
all within a footprint of less than 20 square feet. 
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Figure 9.7. Basic pilot plant as of July 2020, with schematic overlay. Prepared for first rounds of 
testing imminent. Ample space for expansion to the optimal pilot plant can be seen on the right side 
of the fume hood. The Chillers are color coded to their respective unit operation. PAT are shown in 
gray 
Before attempting the continuous enzymatic reactive crystallization, the pilot plant 
will be run through a series of tests to ensure successful continuous operation and validity 
of results. The planned tests are listed below, with the aspects of the plant being tested 
briefly described. Robust testing is vital to successful implementation of the entire process 
but is not often discussed 
1. Water only: identify leaks, unsteady behavior, verify pump performance, temperature 
control 
2. Reactants (no enzyme): Solution PAT, pH control, stability 
3. Non-reacting slurry: slurry transfer, clogging, mixing, particle PAT, filtration 
4. Reactive crystallization no separator: verify performance, reclaim catalyst by dissolving 
product, evaluate catalyst fouling 
5. Separator efficacy > 99.9%: continued development alongside reactor testing 
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In the coming year it is planned to produce kilogram quantities of amoxicillin 
trihydrate and cephalexin monohydrate in a biocatalytic CM reactive crystallization 




CHAPTER 10. FUTURE DIRECTIONS AND PAST 
REFLECTIONS 
In this chapter, the preceding studies are summarized from the perspective of how 
they add to the scientific knowledgebase. Additional work that could further develop the 
knowledge generated during these studies is discussed as well. 
The first chapter was spent motivating this thesis. While the motivation provides 
the necessary background to understand the results discussed in the later chapters, there are 
still facets of the background that are worth mentioning or expanding on here.  
First is the issue of antibiotic resistance. CM for beta-lactam antibiotics could 
potentially contribute to antibiotic resistance if not implemented properly; if done 
correctly, CM could lead to decreased antibiotic resistance even with a corresponding 
increase in antibiotic production. It has been shown that many pathogens develop resistance 
in pharmaceutical wastewater treatment facilities.250  A very recent metagenomics study of 
16 European wastewater treatment plants found that the concentration of antibiotic 
resistance genes downstream of the plant discharge was significantly greater than the 
concentration in the water upstream of the plant, with beta-lactamase genes (providing 
bacterial defense against beta-lactams) being some of the most prevalent.251 The story is 
worse in China, where >20% of bacteria isolated from a penicillin producing factory’s 
wastewater treatment plant were resistant to eight beta-lactams at concentrations greater 
than 1 g/L, significantly higher than the therapeutic concentration in a patient’s blood.252 
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The effluent is discharged to a river, where its spread and exposure to downstream 
populations is easily conceivable.  
By using CM, the production of wastewater associated with antibiotic manufacture 
can be decreased. The productivity per liter is significantly higher for the CM process 
compared to batch, decreasing the amount of solvent needed. Furthermore, by using 
biocatalysis, fewer steps are needed and no solvent changes are required, reducing the 
amount of solvent requiring treatment.20 A potential pilot plant improvement is to recycle 
the mother liquor; it is conceivable that the solvent could be recycled more or less 
indefinitely, producing no wastewater. For this to happen the following adjustments must 
be made: (1) powder feeding of reactants, (2) removal of built-up sodium and chloride, 
possibly by ion exchange, (3) removal of methanol, possibly by evaporation, and (4) 
removal of (4-hydroxy-) phenylglycine, ideally by crystallization. The last point, 
phenylglycine crystallization has already been investigated within this thesis. It has been 
repeatedly observed that phenylglycine crystals adhere to air-water interfaces, see Figure 
10.1, and it may be possible to separate the phenylglycine crystals by taking advantage of 
their hydrophobicity.253 Doing so continuously would be novel and allow conversion (w.r.t 
6-APA or 7-ADCA) to reach nearly 100%, without regard for the selectivity, and at double 
the productivity. A process producing no liquid waste (that had contacted antibiotics) 
would halt the spread of resistance in industrial and urban environments, especially since 
the industrially practiced method of treatment for amoxicillin manufacturing discharge 
(alkaline degradation, also practiced in this study) has been shown to be insufficient.254 
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Figure 10.1. PVM images of phenylglycine crystals adhered to bubbles. Left phenylglycine as 
received, middle pure phenylglycine during recrystallization, right phenylglycine crystallized during 
cephalexin synthesis (needle shaped crystals are cephalexin). All images are 1.0 mm2. 
It is beyond the scope of this thesis to address the spread of resistance in other 
settings, such as hospitals and farms, but it is encouraging to see that use is trending 
downwards in developed countries. This project could help equalize access to medicines 
in all countries, but it is up to doctors and veterinarians to dampen the spread of resistance 
in medical and pastoral settings. 
The second background point is related to safety and drug availability. Penicillins, 
such as amoxicillin, are notoriously potent allergens. The FDA requirement that penicillins 
be produced in stand-alone facilities (a practice also recommended for cephalosporins) has 
concentrated production in only a handful of plants worldwide. This concentration of 
production can and has led to supply chain issues and drug shortages. With this project, the 
potential exists to create a small, scalable, hypothetically portable, process to provide local 
access to key drugs on demand.  
Moving on to CHAPTER 2, the stability of the biocatalyst was examined. In the 
frame of the CM process, the exact stability numbers for PGA are most important. However 
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from a wider lens the scientifically novel contribution here is a method with which to 
rapidly evaluate biocatalysts. The thermal deactivation properties of almost any enzyme 
can be modeled and computed within a few hours; orders of magnitude less time than 
would traditionally be needed. The assay could be further developed by subjecting a variety 
of enzymes to the temperature profiles used to create a model of PGA deactivation. It would 
be particularly interesting to manipulate pH value rather than temperature. The same 
principles, but implemented with adjustable rates of feeding reactants in different pH 
buffers, could lead to pH specific deactivation models in only hours, again applicable to a 
wide range of enzymes. The requirement that the reaction produce a change in optical 
rotation is also unnecessary, different sensors, such as flow ATR-FTIR, flow Raman 
spectroscopy, flow UV-vis, flow refractometry, or any other online PAT could be used. 
In CHAPTER 3 the kinetics of PGA were determined for ampicillin and cephalexin. 
The feasibility of crystallizing ampicillin by the action of PGA alone, without simultaneous 
precipitation of phenylglycine was shown for the first time. The activity dependence on pH 
value was also captured and modeled, expanding on a model published for similar reactions 
and applied to PGA.255 One key assumption required for fitting the model parameters was 
that the equilibrium constant for binding the nucleophile (6-APA or 7-ADCA) to the free 
enzyme and the acyl-enzyme complex was the same. Few report that the nucleophile binds 
the free enzyme, but the inhibitory effects of excess nucleophile indicates such binding is 
significant. Since the inhibition is relatively weak this assumption has not impacted any 
pilot plant models discussed and no results have disproved this assumption. Still, it would 
further strengthen the expanded model if both constants were quantified independently, to 
confirm the assumption. A simple experiment would be to measure the inhibition of 
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cephalexin hydrolysis by 6-APA and the inhibition of ampicillin hydrolysis by 7-ADCA. 
For example, with cephalexin, phenylglycine, 7-ADCA, and ampicillin would be produced 
while cephalexin and 6-APA are consumed, as shown in Figure 10.2. Measuring the 
concentrations of all five species would add significant confidence to the models developed 
for each antibiotic system alone. 
 
Figure 10.2. Scheme depicting the reaction of ampicillin to cephalexin, and the possible conformation 
change induced by the acyl-donor. 
While the kinetics of enzyme-catalyzed reactions can be very complex, the kinetics 
of crystallization may be even more so. In CHAPTER 4 it was found that growth is 
inhibited by the presence of other species, however nucleation is unaffected, only limited 
to the extent that secondary nucleation depends on suspension density which in turn is 
determined by total crystal growth. The exact mechanism of inhibition was shown to be 
adsorption of impurities onto the growing surface, preventing the spread of new growth 
layers by the inhibition concentration dependence following a Langmuir isotherm. The 
specific inhibitory effect was stronger for 7-ADCA than PGME, but exactly why is 
uncertain. A crystal structure of cephalexin could elucidate how each co-solute binds the 
growing crystals, however no crystal structure of cephalexin monohydrate has been 
published. Determination of the crystal structure of cephalexin monohydrate presents an 
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additional opportunity to add to the scientific literature surrounding beta-lactam antibiotics. 
In any case, knowledge of the impact of the reactants on the crystallization kinetics of 
cephalexin will decrease the unknowns faced when starting the pilot plant. 
The modification of cephalexin crystal shape could also be studied further; it has 
been reported and observed during this thesis that lower aspect ratio cephalexin is produced 
at low supersaturation.228 It might also be possible to modify the shape with additives that 
either affect supersaturation or inhibit specific faces from growing.256-259 It may be possible 
to take advantage of the difference in binding to cephalexin crystals between 7-ADCA and 
PGME to create crystals of a more desirable. Cephalexin is also known to form low-
solubility complexes with several compounds, including parabens, which are already used 
as preservatives in pharmaceutical formulations.260 Adding a complexing agent could 
improve crystal shape while increasing yield by sequestering more of the antibiotic in the 
complex than would otherwise be sequestered by crystallization, preventing undue 
secondary hydrolysis. 
CHAPTER 5 was a slight departure from the main goals of this thesis. The insights 
into growth rate dispersion are certainly useful and will help to interpret the crystal size 
distributions measured in the pilot plant. However, as a target size distribution has not yet 
been determined, knowing fine details such as the degree of growth rate dispersion in a 
population of ampicillin crystals does not have a tremendous impact on how the pilot plant 
will be operated. In the future this will not be the case when a size distribution CQA is 
determined. 
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Instead the growth rate dispersion study has the most value as a new tool for 
measuring difficult-to-measure properties of crystal populations. With only a microscope, 
the differences in growth rates between individual crystals can be quantified without 
concerns of mass and heat transfer limitations or nucleation. Repeating this study with 
cephalexin and amoxicillin could increase understanding of growth rate dispersion, which 
presently is best explained as nebulous differences in surface structure and crystal 
perfection. An improved experiment would be able to measure the rates of surface repair, 
the growth rates of each end of the needle independently, and how fast non-equilibrium 
faces (i.e. those that are only exposed by crystal breakage) grow. Broken crystals grew 
faster to return to their unbroken shape, and this repair has been interpreted as a cause of 
growth rate dispersion in other studies.261, 262 This finding is consistent with observations 
of face specific growth rates and even solubilities,263, 264 but the implications and 
applications of confirming this phenomenon, e.g. enhanced crystallization rate by grinding, 
have not been explored.  
There are very few experimental examples of reactive crystallization models with 
defined reaction kinetics (i.e. reactions that are not modeled as instantaneous)265 despite 
the thorough theoretical groundwork laid by Kelkar and Ng.266 In this respect, the modeling 
in CHAPTER 6 stands out as unique but could easily be applied to many other systems 
with similar features, particularly in the realm of biocatalytic reactions. By undertaking 
such detailed modeling of the reaction, crystallization, and catalyst deactivation kinetics, 
bounds have been placed on the performance of the system, with guidance on how to reach 
those bounds. The model is being further improved to consider mass transfer resistances 
and immobilized biocatalysts.267 Applying the models to simulate other systems could 
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assist in evaluating the feasibility of using biocatalysis in other applications typically 
conducted with more traditional and environmentally taxing chemistry. One could also 
continue to expand on the present models to include phenomena such as breakage, face 
specific growth rates, and crystal habit modification. Such upgrades to the model may 
uncover additional operational modes not accessible with the present model but physically 
realizable and possibly more desirable. CHAPTER 7 was a natural continuation of 
CHAPTER 6, addressing the more challenging aspects of the pilot plant design for high 
conversion, selectivity, and productivity while maintaining purity. 
In CHAPTER 8 the value of PAT was discussed in the context of building a pilot 
plant within the quality-by-design framework. With advanced PAT the pilot plant could, 
in theory, achieve conversion, selectivity, and productivity beyond the bounds set in 
CHAPTER 6. In that chapter, the pilot plant was evaluated only at steady state; with PAT 
and the necessary control, one can imagine operating at an unsteady state or periodic steady 
state that gives even higher yields.213, 268 The work required to examine the infinite design 
space of unsteady operation is daunting and beyond this thesis, however some observations 
motivate further investigation. When modeling reactor startup the concentration goes 
through oscillations, which is a result of the feedback between reactant concentration, 
reaction rate, crystal nucleation rate, and crystal growth rate. During startup, transient 
peaks in phenylglycine concentration cause the formation of a sustained phenylglycine 
crystal population. However, the appearance of the phenylglycine crystal population is 
delayed (relative to the peak phenylglycine concentration) due to the kinetics of nucleation 
and growth. It is possible that there is a periodic operating regime where the phenylglycine 
peak concentration becomes very high but is corrected for before the phenylglycine crystal 
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population appears; a process only needs to be in a well-controlled state, not a steady state. 
The increased ceiling on phenylglycine concentration would loosen the selectivity 
constraint and enable higher conversion and productivity. However, running a pilot plant 
under these conditions would require more accurate concentration measurements and the 
ability to pick out phenylglycine crystals from a cephalexin slurry in the ppm range. For 
that, improved IR concentration measurements and PVM/FBRM solids characterization is 
needed. 
Finally, in CHAPTER 9, the completed pilot plant is discussed. Producing kilogram 
quantities of amoxicillin and cephalexin in days long continuous campaigns, as well as the 
challenges, knowledge, and experience that is sure to come from such an undertaking, will 
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